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ABSTRACT 
 
 
COMPUTATIONAL SIMULATION OF PLATELET TRANSPORT, ACTIVATION, AND 
DEPOSITION 
 
Erik Nathaniel Sorensen, Ph.D. 
 
University of Pittsburgh, 2002 
 
 
 Platelet-mediated thrombosis is a significant source of morbidity and mortality in 
cardiovascular device patients. Although Virchow elucidated the mechanisms governing 
thrombus formation over 100 years ago, the underlying processes have proven difficult to 
describe mathematically. A reliable, predictive thrombosis model would be a valuable aid to 
designers of artificial organs.  
 A comprehensive model of platelet-mediated thrombogenesis should simulate red-cell-
enhanced platelet transport, platelet activation, kinetics and mechanics of platelet deposition and 
aggregation, flow disturbances due to thrombus growth, thrombus disruption by fluid forces, and 
interactions between platelets and the coagulation cascades. Most models focus on these 
components individually; a unified approach is lacking. 
 The contribution of this thesis is a computational model of platelet thrombosis which 
incorporates many, though not all, of these essential components. This two-dimensional 
continuum model, based on prior work, is comprised of seven coupled species conservation 
equations, which model shear-enhanced platelet transport, platelet-platelet and platelet-surface 
adhesion, agonist-induced platelet activation, platelet-phospholipid-dependent thrombin 
generation, and heparin-catalyzed thrombin inhibition.  
 
 
 
 
 iv
 The model is first validated for Poiseuille flow of whole human blood over collagen. 
Very good agreement between predicted and experimentally measured platelet deposition is 
obtained for wall shear rates ranging from 100 to 1000 s-1. At 1500 s-1, however, the model fails 
to predict the shape of the experimental curve. This may be due to the higher shear rate, or to 
unmodeled effects of the chelating agent used as the anticoagulant in this study. 
 Next, two-dimensional flow over collagen is considered. For a tubular expansion with no 
agonists, good agreement with experiments can be obtained in the recirculation zone, but 
deposition in the fully-developed downstream region is greatly under-predicted. Surprisingly, 
deviation from experiments is worse at 0% than at 20% hematocrit. Similarly, for an 
axisymmetric stenosis with agonists present, the model does most poorly at predicting deposition 
in the downstream regions.  
 These discrepancies are attributed to the approximation of blood as a single continuum, 
rather than as a suspension. In a preliminary step toward correcting these deficiencies, an attempt 
is made to use existing two-phase flow models to predict platelet and red blood cell 
concentrations in fully-developed tube flow. 
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1.0 BACKGROUND 
“The average Ph.D. thesis is nothing but a transference of bones from one graveyard to 
another.” 
  -J. Frank Dobie 
1.1 Introduction 
 When damage to a blood vessel occurs, the body’s hemostatic mechanisms are called into 
action to create a clot (thrombus) at the site of injury, thereby preventing unnecessary bleeding. 
However, in certain abnormal situations, these mechanisms fail to work as intended. Simply put 
if they do too little, the result is a hemorrhage; if they do too much, the result is pathologically 
overactive clotting, or thrombosis.  
 Thrombosis is a serious medical complication because excessive clot formation can lead 
to obstruction of blood vessels, resulting in tissue ischemia or death. In addition to occluding the 
blood vessel where it was formed, it is also possible for a thrombus to break free (embolize) and 
lodge somewhere downstream in the microcirculation, the most deleterious possibility being a 
brain infarction if it finds its way into a cerebral artery.  
 Thrombosis and thromboembolism are important from an engineering perspective 
because they are significant sources of morbidity and mortality in cardiovascular device patients 
(1). For example, thrombotic complications afflict approximately 1-2% of coronary artery stent 
recipients (2-4), from 4-5% (5) to > 20% (6) of those receiving prosthetic heart valves, and 
anywhere from approximately 5% (7) to 45% (8) of ventricular assist device patients. 
Thrombosis is also the primary reason for early failure of small-diameter (≤ 6 mm) synthetic 
vascular grafts (9, 10), which are essentially unusable due to their low patency rates. An 
important objective in designing the next generation of these devices is to minimize their 
thrombotic complication rates. As in any engineering analysis, this requires a mathematical 
model which can predict the failure mode(s) one wishes to avoid. At present, there is no such 
model for thrombosis or thromboembolism. The specific aims of this thesis are to develop and to 
validate a computational model of thrombosis relevant to the conditions prevalent in 
cardiovascular devices. It is hoped that this will one day lead to improved computational design 
strategies for these devices. 
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1.2 Virchow’s Triad 
 Although unraveling the many complex and intertwined chemical and biological 
processes that lead to thrombus formation is a continuing challenge for modern medical research, 
the primary factors governing thrombosis were identified nearly 150 years ago by the German 
pathologist Rudolf Virchow (11). He described three participating elements – the well-known 
“Virchow’s triad” of blood, surface, and flow. The contributions of each “leg” of the triad to the 
thrombotic process are described below. 
1.2.1 Blood 
 To maintain normal hemostasis, it is necessary to have the appropriate balance between 
pro- and anti-coagulant constituents in the blood. The blood elements primarily responsible for 
coagulation are the coagulation factors, typically identified by Roman numerals I – XIII, and 
platelets. Clotting can be achieved via either of two coagulation factor cascades, or via platelet 
aggregation and deposition. However, all three feed into and depend upon one another, meaning 
none usually occurs independent of the others. What follows is a brief overview of these 
complex processes. More detail can be obtained from any basic physiology text, e.g. Guyton & 
Hall (12), and the references therein. 
 Figure 1 illustrates the coagulation cascades. In the figure and the ensuing text, the 
lowercase suffix “a” after the Roman numeral representing a coagulation factor refers to the 
activated form of that factor. In the intrinsic cascade, all factors necessary for coagulation are 
present in the blood. Factor XII adsorbs to a foreign surface, which may be the subendothelium 
of an injured blood vessel or the man-made material in an implanted device. Prekallikrein (PKn) 
and high-molecular-weight kininogen (HMWK) contact the surface-bound factor XII, activating 
it and transforming PKn to kallikrein, which dissociates from HMWK. The free HMWK can 
now bind to factor XI, and this complex adsorbs to the same surface as XIIa, resulting in 
activation of factor XI. Next, XIa activates factor IX. Ionic calcium (Ca++) facilitates the binding 
of IXa, X, and VIII to a negatively charged phospholipid bilayer surface, such as the membrane 
of a procoagulant platelet. Once the factor VIII in this complex is activated by thrombin (factor 
IIa), activation of factor X ensues.  
 The extrinsic cascade, on the other hand, requires the exposure of tissue factor (TF), 
typically on an injury site or on the membranes of inflammatory cells such as monocytes. In the 
presence of Ca++ and a phospholipid bilayer, TF activates factor VII. The TF-VIIa complex then 
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activates factor X. Both cascades terminate in the common pathway, which begins when Xa 
combines with membrane-bound factor V. Factor Xa alone can activate prothrombin (factor II), 
but its action is greatly accelerated once thrombin begins to activate factor V to create the factor 
Va-Xa complex. Thrombin then cleaves fibrinogen (factor I) into fibrin monomer (IaM). In the 
presence of Ca++, thrombin also activates factor XIII. XIIIa facilitates creation of cross-links 
between the IaM molecules, thereby forming a much stronger fibrin polymer (IaP), which 
comprises the hemostatic “plug”.  
 Figure 2 illustrates platelet-mediated coagulation. This process begins when platelets 
(PLTs) are activated by stimuli (agonists) such as adenosine diphosphate (ADP), thromboxane 
A2 (TxA2), serotonin, or thrombin. These stimuli cause platelets to: 1) change shape, from 
discoid to spherical; 2) extrude pseudopodial filaments from their outer surfaces; 3) “flip-flop” 
their phospholipid bilayer membranes so that procoagulant phosphatidylserine is exposed; 4) 
express adhesive receptors (glycoproteins IIbIIIa and Ib, GpIIbIIIa and GpIb, respectively) on 
their outer membranes; and 5) release serotonin and ADP from their storage granules, as well as 
synthesize TxA2. The exposed receptors allow activated platelets to adhere to proteins on a 
foreign surface (e.g., man-made biomaterial) or to the subendothelium exposed by an injury; 
once adherent, the pseudopodia allow them to spread out and become firmly anchored. The 
released agonists combine with those already present to activate any resting platelets in the 
vicinity. Then, using fibrinogen as a bridge between GpIIbIIIa receptors, these activated 
platelets, with the aid of Ca++, can adhere to those already on the surface, forming an aggregate 
which stems the flow of blood. More detailed reviews of these mechanisms are available (13-15). 
 As mentioned above, the three hemostatic mechanisms interact. TF-VIIa from the 
extrinsic cascade can activate factor IX, starting the intrinsic cascade without the factor XII- and 
XI-dependent steps shown in Figure 1. Also, thrombin from the coagulation cascades is a potent 
activator of platelets, and, in a feedback loop, phosphatidylserine on the outer membrane of 
activated platelets provides the phospholipid bilayer surface needed by the coagulation cascades 
to generate additional thrombin. This thrombin generation not only results in activation of more 
resting platelets, but also induces formation of a fibrin mesh on top of the platelet aggregate, 
forming an even stronger clot. Finally, activated platelets release factors I, V, and XIII, thereby 
further contributing to the common pathway of coagulation and to further platelet aggregation 
and fibrin mesh stabilization. 
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Figure 1. Coagulation cascades 
Inhibitory and feedback pathways omitted. See text for abbreviations. 
 
 
 
Figure 2. Platelet-mediated hemostasis 
See text for abbreviations. 
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 The effect of red blood cells (RBCs) on coagulation is exerted primarily through flow-
induced physical effects on platelets, which will be described later. However, red cells should be 
also be discussed in the context of blood composition because their physical effects are 
hematocrit-dependent, so that the relative amount of them in blood is clearly important. Also, 
there is evidence that the membranes of a small percentage (~0.5%) of RBCs express 
phosphatidylserine and can support significant thrombin generation (16). Additionally, red cells 
contain ADP, which, if released, can enhance platelet activation (17).  
 Thus far, the discussion has focused only on the pro-coagulant aspects of blood clotting. 
Clearly, some mechanism is needed to keep the positive feedback loops of hemostasis in check 
so that thrombus formation is restricted to the site of an injury. There are many anticoagulants in 
both clinical and laboratory use, so what follows is a brief and selective overview. Table 1 is a 
summary of common anticoagulants, the blood elements they exert their inhibitory effects on, 
and whether they are commonly used clinically (in vivo) and/or in the laboratory (in vitro).  
 
Table 1. Selected anticoagulants 
 
Inhibitor Acts on: in vivo? in vitro? 
Antithrombin III ± Heparin IIa, IXa, Xa, XIIa  Y Y 
Coumadin, Coumarin, Warfarin II, VII, IX, X Y N 
Hirudin, PPACK IIa Y (Hirudin) Y 
Aspirin TxA2 Y N 
CP/CPK, PK/PEP, Apyrase ADP N Y 
Clopidogrel, Ticlopidine ADP Y N 
Dipyridamole Platelet activation Y Y 
GpIIbIIIa inhibitors Platelet adhesion/aggregation Y Y 
Ca++ chelators (EDTA, sodium citrate) Ca++ N Y 
 
 
 The first three entries in Table 1 are inhibitors of coagulation factors. Of these substances 
(and of all the others listed), only antithrombin III (ATIII) and heparin are naturally present in 
blood. ATIII acts on the common pathway of the coagulation cascades, combining with thrombin 
to produce thrombin-antithrombin III complex, which has no procoagulant effect (12). The 
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action of ATIII is catalyzed by heparin, which increases its rate of action by two to three orders 
of magnitude. The heparin-ATIII combination also inactivates factors IXa, Xa, and XIIa (18). To 
increase the anticoagulant effect of heparin beyond that due to its naturally occurring 
concentration in the blood, it is administered intravenously in the clinical setting.  
 Factors II, VII, IX, and X are synthesized by the liver, in a process requiring vitamin K. 
Coumadin, coumarin, and warfarin disrupt the vitamin K-dependent steps in the formation of 
these factors, so that the liver produces much smaller amounts of them (19). Because these 
anticoagulants disrupt the production, rather than the action, of clotting factors, they are not 
suitable for in vitro use. However, clinically they have the advantage of being administered 
orally. 
 Hirudin (20),which in its natural form is derived from the saliva of medicinal leeches, and 
PPACK (21), a synthetic compound, are direct thrombin inhibitors, binding to thrombin and 
preventing its further action in the coagulation cascades.  
 The next three entries in the table describe inhibitors of platelet-released platelet-
activating factors. Aspirin disrupts the cyclo-oxygenase pathway that culminates in the synthesis 
of TxA2 by activated platelets (22). While a widespread clinically administered oral 
anticoagulant, it is not commonly used in the laboratory. CP/CPK, PK/PEP and apyrase all 
prevent ADP from activating platelets by transforming it into another adenine nucleotide, either 
phosphorylating it to adenosine triphosphate (CP/CPK and PK/PEP) (23) or dephosphorylating it 
to adenosine monophosphate (apyrase) (24). While none of the three is used clinically, 
ticlopidine and clopidogrel are ADP inhibitors which are orally administered and which are used 
in vivo. Both work by binding to and inactivating the site on platelets where ADP binds to induce 
platelet activation (25, 26). However, because both must be metabolized to have an anticoagulant 
effect, they are of little use in vitro.  
 The following two entries also list anti-platelet agents. Dipyridamole acts by preventing 
uptake and breakdown of adenosine, a substance which inhibits platelet activation, but which is 
quickly removed from the blood by tissue and red blood cells (27). GpIIbIIIa inhibitors prevent 
platelet aggregation and adhesion by binding to the GpIIbIIIa receptor sites on platelets, 
preventing those receptors from binding to fibrinogen (28). Both these anticoagulants can be 
used in vitro or in vivo. 
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 Finally, it is apparent from Figures 1 and 2 that many of the steps necessary for both 
cascade- and platelet-mediated thrombus formation depend heavily on Ca++. Chelating agents 
such as EDTA and sodium citrate bind to Ca++ and prevent it from acting as it does when it is a 
free ion. Since many life-sustaining processes besides coagulation depend on Ca++, however, this 
is not a suitable method of clinical anticoagulation.  
1.2.2 Surface 
 Blood vessels are lined with endothelial cells which, in their normal state, express 
anticoagulant activity and do not support platelet adhesion (29). Exposure of the subendothelial 
surface by injury, however, initiates coagulation. This is due both to exposure of tissue factor, 
which activates the extrinsic cascade (Figure 1), and to the presence of collagen, which not only 
activates platelets, but also avidly supports their adhesion (30).  
 When the blood-contacting surface is a foreign material, the interactions are mediated by 
blood proteins. Within seconds of blood contact, proteins begin to adsorb to the foreign surface 
(31). Initial adsorption is dominated by proteins which are present at higher concentrations in the 
blood, such as albumin, with later displacement occurring if a less-concentrated protein with a 
higher affinity for the surface arrives (32). Once adsorbed, the proteins can change their 
conformations to interact more strongly (or in some cases, weakly) with cells and platelets than 
their bulk counterparts do (33). In terms of thrombosis, adsorption of HMWK can lead to 
initiation of the intrinsic coagulation cascade (Figure 1), while adsorption of fibrinogen or von 
Willebrand factor (vWf) will support platelet adhesion via the GpIIbIIIa and GpIb receptors, 
respectively, with aggregation and thrombus formation following thereafter. 
 Clearly, one way of controlling the thrombogenicity of a device is by controlling the 
interactions of blood with its surface. By and large, the materials used in blood-contacting 
devices are based on off-the-shelf industrial polymers and metals which possess the necessary 
physical properties (strength, elasticity, corrosion resistance, etc.) for the device being 
manufactured (34). While these substrates are not designed to prevent thromboembolism, one 
might suspect that perhaps they could be modified to be more blood-friendly. This seemingly 
intuitive conjecture has motivated the great majority of biomaterials research to date.  
 A relatively simple approach is to change the surface topography, with the expectation 
that a smoother surface will accumulate less protein and fewer cells and a rougher one more. 
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Although the latter approach seems counterintuitive when the objective is reduced 
thrombogenesis, both have met with some success. For example, some investigators have found 
reduced thrombus formation with polished metallic stents which are smoother than their 
standard-issue counterparts (35). On the other hand, the Thoratec Heartmate ventricular-assist 
device, whose pump sac is made from a textured polyurethane which is (deliberately) much 
rougher than competitors’ designs, has a very low thromboembolic complication rate even with 
minimal anticoagulation (36). This surface appears to support the formation of a stable pseudo-
intimal lining, which, though comprised at least in part of thrombotic material, is held tightly 
enough not to embolize and does not appear to support enough ongoing procoagulant activity to 
activate the blood passing over it (37).  
 Another way of improving biocompatibility is by modifying the material’s surface 
chemistry to alter its interactions with blood proteins. The enormous variety of both modification 
techniques and materials modified precludes a review here; see Lee et al. (38) for a general 
description of medical polymers and currently used surface modifications. The reason for the 
great heterogeneity in approaches to this problem is that no one has yet determined conclusively 
which surface properties correlate with different levels of protein adsorption. Some attributes 
believed to be important are degree of hydrophobicity, surface charge, surface energy, 
crystallinity, and homogeneity (33, 39). As with surface texture, approaches using surface 
modifications at both ends of the spectrum have performed well; these contrasting examples will 
be discussed briefly. The first, more conventional approach takes the view that the best way to 
keep thrombogenic phenomena from occurring at the surface is by preventing as much protein 
deposition as possible. The most successful modification based on this philosophy is 
immobilization of poly(ethylene glycol) (PEG) hydrogel. PEG’s properties exemplify the current 
conventional wisdom on what makes a “good” biomaterial: it is a hydrophilic (at the blood 
interface), non-ionic, non-crystalline, inhomogeneous polymer (39). It can, among other 
methods, be incorporated into a surface as a copolymer (40) or delivered to injured 
subendothelium or to an artificial surface pre-adsorbed with protein (41). With either method, 
platelet adhesion and surface aggregation from flowing platelet suspensions can be reduced by > 
90% on the modified substrates relative to unmodified controls (40, 42). Nearly the opposite 
approach would be to bind proteins rapidly, indiscriminately, and very tightly, which is 
exemplified by the behavior of pyrolytic-carbon-coated surfaces. Akin to the surface-roughening 
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philosophy discussed above, this material displays relatively good biocompatibility despite its 
having properties not thought to be conducive to thromboresistance: it is hydrophobic, 
crystalline, and electrically conductive (33). And, as expected based on these properties, it does 
adsorb large amounts of protein. However, it absorbs them non-specifically, almost irreversibly, 
and, in the case of albumin and fibrinogen, with equal affinity (33). This means that albumin, a 
relatively inert protein which does not participate in either cascade- or platelet-mediated 
coagulation, will be prevalent on the surface due to its high plasma concentration. And, in 
contrast to its typical behavior on polymers, it will be resistant to displacement by more 
thrombogenic proteins. Additionally, it is believed that fibrinogen, typical of pro-adhesive 
proteins, is so strongly held and heavily denatured that most of it which adsorbs is held in a 
conformation that prevents it from binding to activated platelets (33). 
 The next logical step beyond making surfaces passively un-thrombogenic by altering 
their affinity for proteins would be to make them actively anti-thrombogenic by endowing them 
with anticoagulant functions. An example of this strategy which is now in widespread clinical 
use is the immobilization of heparin onto biomaterials, mostly commonly the tubing and 
oxygenator surfaces of cardiopulmonary bypass circuits. The heparin is typically immobilized by 
covalent or ionic bonding, with some type of spacer molecule used to attach it to the device 
surface while allowing its active site enough room to interact with ATIII (43). Ideally, using a 
heparin-coated surface should deliver anticoagulation only where it is needed, allowing reduced 
use of systemic heparinization and thereby reducing the risk of bleeding complications. 
However, despite over a decade of clinical use of heparin-coated circuits, it is still not clear 
whether this theoretical benefit is actually realized (43). 
 In addition to heparin, immobilization of anti-thrombin anticoagulants hirudin (44) and 
thrombomodulin (45), an endothelial-cell-expressed factor which reverses the action of thrombin 
from pro- to anti-coagulant, has also been reported. An advantage of immobilized hirudin over 
heparin is that it is a direct thrombin inhibitor, rather than merely a catalyst, as heparin is for the 
action of ATIII. However, this also works to its disadvantage, since, unlike heparin which can 
turn over and continually inactivate additional thrombin, it is possible for all the surface-bound 
hirudin to become saturated with bound thrombin, after which no anticoagulant activity remains.  
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This behavior was observed at high thrombin loadings in the work of Phaneuf et al. (46). 
Additionally, in the event of bleeding, heparin can be rapidly reversed with protamine sulfate 
(18), while hirudin is irreversible. 
 Like heparin, thrombomodulin both requires cofactors, proteins C and S, to have 
significant anticoagulant activity (a disadvantage), and acts enzymatically, so that its 
anticoagulant activity will not become saturated by excess thrombin (an advantage) (47). 
 Obviously, the ultimate blood-contacting surface for an implant would be one identical to 
that already in the body – endothelial cells. Creating such cellularized biomaterials and even 
whole replacement organs is the lofty goal of the emerging field of tissue engineering. The initial 
cardiovascular-related efforts in this area were concentrated on developing a biocompatible 
small-diameter vascular graft by seeding endothelial cells onto commonly used biomaterials, an 
approach which has met with spotty success due to the difficulty of retaining the cells once the 
grafts are implanted in the circulation (48). While these efforts continue, a more forward-looking 
approach would be to recreate not just the surface of the native organ, but the entire organ itself. 
One would expect this to eliminate the cell-adhesion problem seen in hybrid biomaterial/cell 
vascular grafts, because the surface cells would be in their native milieu, rather than being forced 
to interact with an artificial surface. Some current frontiers in cardiovascular tissue engineering 
involve efforts to grow blood vessels, heart valves, and heart muscle (9, 48). While this work is 
far from clinical application, it has the potential to one day revolutionize organ replacement 
therapy.  
 In spite of all this work, however, the goal of developing a truly biocompatible implant 
material has yet to be reached. In part, the lack of success of these endeavors is due to the 
absence of even a straightforward, consensus definition of their ultimate aim, i.e. blood 
compatibility (49). As Haycox and Ratner (50) point out, whether or not a material is deemed 
blood-compatible may depend on what measure is used to make the assessment. Their argument 
is forcefully made by their test results for four polymers, each of which exhibits a distinct mode 
of interaction with platelets. In order from least to most platelet-compatible, the materials and 
their responses are (50): 1) Biomer, which supports continuous platelet adhesion and activation; 
2) poly(vinyl alcohol), which supports little adhesion but appears to fragment and activate 
platelets that contact it; 3) polyethylene, which develops a relatively passive, non-thrombogenic 
covering of spread platelets after an initial transient of adhesion and activation; and 4) a custom-
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made polyurethane with octadecyl pendant groups that supports neither adhesion nor activation. 
These studies illustrate the importance of considering all salient variables in making a 
determination of whether or not a surface is blood compatible. In this case, not only endpoint 
platelet deposition (the most common single measure of blood compatibility used in the 
literature), but also bulk platelet activation and changes in the properties of the deposited platelet 
layer over time must be considered (50). Furthermore, these considerations apply only to platelet 
compatibility; as Ratner (49) discusses, other measures may be needed to determine a 
biomaterial’s effect on the coagulation cascades, inflammatory pathways, etc., and some 
materials compatible with one of these systems may not be compatible with the others. The take-
home message here is that the blood-artificial surface interaction problem is a multifactorial one, 
and this leg is perhaps the most complex part of Virchow’s triad to address when attempting to 
model thrombogenesis. 
1.2.3 Flow 
 The last leg of the triad is the one that ties everything together. Clearly, in order for 
platelets and coagulation factors to reach an artificial surface or the site of an injury, they must 
be transported there. The effects of local flow patterns on the coagulation reactions and on 
platelet aggregation and deposition play a substantial role in determining not only where a 
thrombus will form, but also what its composition will be, how large it will grow, and whether or 
not it will remain at its nidus or embolize.  
 The composition of blood itself determines how it flows and can thereby aid thrombus 
formation. The rheological behavior of normal whole blood is dominated by RBCs, which 
typically account for about 40% of the total blood volume and 99% of the volume of particulate 
matter (51). Largely due to their deformability (51), an excess of RBCs develops in the central 
core of a steady tube flow, while an RBC-depleted layer develops near the wall; this is the well-
known “Fahraeus effect” (52). Due to the crowding of RBCs in the center of the tube, platelets 
are expelled to the near-wall region, where an excess which has been observed to be as high as 
nine times the bulk concentration can develop (53). RBC collisions and rotational motions also 
enhance mixing and transport of platelets. 
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 The shear-rate-dependent effective platelet dispersion coefficient due to this RBC-
enhanced transport has been calculated as approximately two to three orders of magnitude 
greater than the Brownian value (54, 55). Having platelets transported rapidly to and located near 
the surface in this way obviously enhances their ability to either initiate thrombus formation or to 
attach to an already growing aggregate. 
 A thrombus’s composition is largely determined by its location in the vasculature. It is 
generally accepted that thrombi formed in the arterial circulation are primarily comprised of 
platelets (“white thrombi”), while those formed in the venous circulation mainly contain fibrin, 
which then entraps platelets and RBCs to create “red thrombi” (56). This is due to the relatively 
high shear rates and fluid velocities in the arterial tree versus the relatively slower flow on the 
venous side (57). As Figure 1 shows, the coagulation cascades which lead to fibrin formation 
require several consecutive reactions, each of which needs some finite amount of time to 
complete. Rapid arterial flow will tend to convect the reactants away before they have time to 
assemble in the appropriate configurations. The platelet cascade, on the other hand, requires only 
that platelets have an adhesion site available on the surface; the only kinetic step other than 
adhesion itself is the activation of other platelets by agonists, thus allowing this process to 
complete in a relatively short time.  
 However, the aforementioned considerations assume undisturbed tube flow. Geometrical 
features that create flow disturbances, such as atherosclerotic stenoses, vessel bifurcations, and 
venous valves may create low-shear recirculation regions where increased fibrin formation will 
be likely on either the venous or arterial side (57). Furthermore, these disturbed flow patterns 
will enhance the transport of both platelets and coagulation factors to the vessel wall or device 
surface, making such regions “hot zones” for thrombus formation (58, 59).  
 Additionally, as recently reviewed by Kroll et al. (60), pathologically high fluid shear 
stresses (> ~50 dynes/cm2), as might be found, for example, in an atherosclerotically narrowed 
artery, in the jets produced at closure of mechanical heart valves, or in the impeller of a rotary 
blood pump, can directly induce platelet activation and aggregation via a mechanism that 
requires vWF and both the GpIb and GPIIbIIIa receptors. This shear-induced activation is 
enhanced by ADP released both from platelets due to activation or lysis (61) and from RBCs due 
to what is believed to be stress-induced leakage (62). However, it is not only the level of shear 
stress, but also the length of time a platelet is exposed to it that determines whether or not 
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activation takes place. In general, it is observed that the higher the shear stress level, the shorter 
the threshold exposure time for observable prothrombotic events to ensue (63); the exact 
relationship between exposure time and shear stress has yet to be formally quantified.  
 The level of fluid shear stress also modulates platelet-surface interaction. At lower shear 
rates (e.g, < 600 – 900 s-1), GpIIbIIIa binding to fibrinogen typically is sufficient to fully arrest 
platelets (64). At higher shear rates, though, vWF-GPIb binding is the initial event, its function 
apparently being to slow the passing platelet sufficiently for GpIIbIIIa binding to occur and bring 
it to a halt (65). Thus, fluid shear stress is, in effect, an additional platelet agonist, acting not only 
in the bulk flow but also at the fluid-surface interface and enhancing thrombus formation at 
arterial (and higher) shear rates. 
 Finally, a growing wall-bound thrombus will create its own upstream and downstream 
flow disturbances, further promoting localization of hemostatic factors. It will also be subjected 
to increased pressure due to the restriction it creates on upstream flow. If the fluid dynamic 
forces on the thrombus are greater than the tensile strength of the bonds holding the aggregate 
together, some or all of the clot will break off, creating a possibly deadly embolus. Although 
such an event is the thrombotic complication one would most like to avoid, it is also the least 
studied. Apart from some preliminary theoretical work by Basmadjian (66-68) and Wilson et al. 
(69) and in vitro experimental investigations by Goodman et al. (70), almost no studies 
characterizing the critical thrombus size and strength for embolization have been done. This is 
likely due to the complexity of the problem, both from an experimental standpoint (an 
unpredictable, three-dimensional, time-dependent event must be observed in a dense suspension) 
and a mathematical one (fluid-structure interaction and fracture mechanics must be modeled).  
1.3 Thrombosis Modeling1 
 The majority of internal cardiovascular devices, such as prosthetic heart valves, synthetic 
vascular grafts, and ventricular-assist devices, are placed in the arterial circulation and generally 
harbor high hemodynamic shear rates. The thrombotic deposition encountered in these devices is 
thus composed primarily of platelets, with less fibrin involvement than one would encounter in 
low-shear venous thrombosis (56). Despite Virchow’s prescient elucidation of his triad of blood, 
surface, and flow over 100 years ago, the underlying chemical, physical, and biological 
                                                 
1 The majority of the text in this section and its subsection were adapted with permission from Sorensen et al., Ann. 
Biomed. Eng., 1999;27(4):436-448 (71). Copyright 1999, Biomedical Engineering Society.  
 14 
processes which culminate in thrombus formation have proven difficult to model in a systematic, 
quantitative fashion. If a model were available which could reliably predict regions of platelet 
activation and deposition within a cardiovascular device, engineers could potentially optimize 
the design of the device flow path after appropriately considering the thrombogenicity of the 
blood-contacting materials and the status of the patient’s hemostatic system. 
 A truly comprehensive model of platelet-mediated thrombogenesis requires components 
which describe all the phenomena discussed in the previous section: platelet activation (via shear 
and agonists); effects of disturbed flow and RBCs on platelet transport; effects of artificial 
surfaces (if present) on protein adsorption; kinetics and mechanics of platelet-platelet and 
platelet-surface adhesion; flow alteration by a growing thrombus and thrombus disruption by 
fluid dynamic forces (embolization); and interplay between platelet- and cascade-mediated 
hemostatic mechanisms. To date, most models in the literature have focused on these 
components individually without attempting to integrate them into a single, comprehensive 
approach. Furthermore, we are not aware of any attempts to model the distinct types of platelet-
biomaterial interactions that occur on materials of differing chemical composition, as 
investigated by Haycox and Ratner (50) (see section 1.2.2). 
1.3.1 Prior Work 
 Numerous studies have analyzed platelet transport and deposition in unidirectional tube 
or channel flow in the context of the convection-diffusion equation (72-76). While the equations 
derived by these authors are often quite complex, the following simplifying assumptions are 
commonly made to them to allow analytical solutions: 1) negligible axial diffusion; 2) diffusion-
limited platelet-surface adhesion, i.e. rate of reaction at the surface >> rate of transport to the 
surface ; 3) linearly varying near-surface velocity fields; 4) steady-state behavior; 5) no decrease 
in adhesion rate due to surface site occupation, i.e. 100% surface availability at all times; and 6) 
constant platelet diffusivity. Basmadjian (72) presents several such solutions and discusses their 
applicability for different surface reaction conditions and vessel sizes. Stubley et al. (75) also 
review the early efforts to model platelet deposition and compare their results to those of the 
authors’ own more complex model. They conclude that, for platelet adhesion onto glass, 
assumptions 1-3 typically have little effect on predicted platelet adhesion. They argue that the 
most crucial element to include is a surface saturation term of the type proposed by Grabowski et 
al. (73). When this term is neglected (assumption 5 above), poor agreement with experiments at 
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long perfusion times is obtained, since observed adhesion tends to a constant asymptote, while 
the 100% availability model predicts continuous adhesion at a constant rate. The authors also 
state that neglecting time-dependent behavior (assumption 4) can lead to inaccurate predictions 
at low shear rates, due to the longer initial transients for those cases. Assumption 6 was not 
examined.  
 While limited in scope, the results of such modeling have proven helpful in describing 
the relative effects of convection, diffusion, and surface reaction on platelet deposition. They 
have also helped elucidate the effects of RBCs in augmenting platelet transport, as platelet 
diffusivities used to fit the experimental results simulated in these studies were found to be both 
dependent on shear rate and two to three orders of magnitude greater than the Brownian value 
(73, 74, 76). However, these models have not seen wide application for predicting experimental 
results, since they cannot be extended to real-world situations such as two- and three-
dimensional flows. Furthermore, these studies consider the transport of platelets as a single 
species, neglecting the different adhesive properties of activated and resting platelets. They also 
assume the only relevant surface phenomenon is platelet adhesion, thereby neglecting platelet-
platelet aggregation and its flow-modifying effects. Additionally, they neglect the effects of 
agonist production and transport in creating “hot spots” for increased platelet activation, as well 
as ignoring the effects of the coagulation cascades in producing platelet-activating thrombin. 
 In the studies just discussed, effective RBC-enhanced platelet diffusivities were merely 
adjusted so that the solutions obtained for the convection-diffusion equation would best fit 
experimental platelet deposition results. Rather than treating platelet diffusivity as a parameter to 
be estimated, it may be preferable to have a model to account for the effects of shear-induced 
RBC motion on platelet transport. However, developing such a model is an onerous task because 
the exact mechanisms which lead to shear-enhanced particle migration are not fully understood. 
As explained by Zydney and Colton (77) in their thorough review of such modeling efforts, most 
models assume that the driving force for lateral platelet transport is fluid motion due to shear-
induced red cell rotation. The prototype of such models would be that of Keller (78), who uses 
an analogy to the Prandtl mixing length analysis used to calculate turbulent diffusivities to obtain 
an enhancement factor that depends on fluid shear rate and particle diameter. The next level of 
sophistication is typified by the model of Antonini et al. (55), who extended Keller’s analysis to 
obtain an enhancement factor with a different functional form and a dependence on particle 
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volume fraction (hematocrit) in addition to shear rate and particle diameter. In contrast, Zydney 
and Colton (77) ignore the effects of shear-induced RBC rotation and focus instead on RBC 
migration due to deformation and collisions, which they argue will be the dominant effect in a 
concentrated suspension such as blood. The diffusion enhancement factor they derive also 
depends on shear rate, particle diameter, and hematocrit. Because they fit their function to 
experimental results for a wide range of hematocrits and for both rigid and deformable particles, 
however, agreement with experimental results is better than for previous work, which rested 
mostly on purely theoretical analysis.  
 Another alternative approach is the one taken by Eckstein and Belgacem (79), who add a 
convection-like “drift flux” term to the traditional convection diffusion equation. This term acts 
as a source which drives the platelet concentration profile to a predetermined fully-developed 
profile. The obvious drawback of this model is that knowledge of that fully-developed profile is 
necessary a priori. While experimentally measured platelet concentration profiles are available 
for tube flow (53, 80), no such results exist for more complex flows. Nevertheless, Buchanan and 
Kleinstreuer (81) applied the Eckstein and Belgacem model to platelet transport in a stenotic 
tube, adding a shear-rate-dependent term to the drift flux to account for the effect of geometric 
variations. The computed results they present were not compared to any experimental studies, so 
the validity of their modeling approach remains to be seen. 
 Modeling the coagulation cascades is also a daunting prospect due to their complexity 
and their interactions with each other and the platelet system (see Figures 1 and 2). Rather than 
tackling the entire problem at once, most researchers have chosen to model parts of the cascades 
while assuming that sufficient products from upstream reactions are available to start the 
reactions being modeled. Additionally, so that the equations to be solved can remain ordinary, 
rather than partial, differential equations, the reactions are often assumed to take place in well-
mixed vessels, so that spatial variations in concentrations can be ignored. For the intrinsic 
cascade, examples of such spatially invariant models are: those which attempt to cover the entire 
cascade and the common pathway (82, 83); those which ignore the common pathway (84); and 
those which consider only the initial “contact activation” of XII by HMWK and PKn (85). For 
the extrinsic cascade, most models focus on everything from VIIa-TF through the common 
pathway (86-89); however, a partial differential equation model which considers only the 
intrinsic cascade but which takes into account spatial variations due to fully-developed tube flow 
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was developed by Gir et al. (90). Some models ignore the upstream cascades to focus on 
thrombin generation via the common pathway, either ignoring the effects of flow (91) or 
including it via lumped mass-transfer coefficients (84).  
 To illustrate the complexity involved in modeling these reactions, the state of the art is 
embodied by the recent work of Kuharsky and Fogelson (88). They model the extrinsic cascade 
and common pathway, taking into consideration effects of transport via lumped mass-transfer 
coefficients and accounting for both bulk and surface-adherent platelets and coagulation factors, 
as well as platelet activation and three inhibitory pathways. This comprehensive model, which 
still ignores the intrinsic cascade and spatial variations in reactant concentrations, requires the 
solution of a system of 59 coupled ordinary differential equations. 
 Additionally, models which focus solely on the final steps of agonist generation and 
subsequent transport away from the production site have been developed. Basmadjian and Sefton 
(92) simulated thrombin transport from a constantly-produced wall source and its inactivation by 
surface-bound and bulk heparin, mapping critical thrombin concentration ranges as a function of 
dimensionless mass transfer coefficients. Chung and O’Rear (93) simulated thrombin generation 
from prothrombin in tube flow assuming a fixed concentration of Va-Xa-phospholipid complex. 
Adams and Feuerstein (94, 95) used a convection-diffusion equation to estimate the release rate 
of ADP from platelet thrombi at the wall of a tube, while Fogelson (96) modeled the release of 
ADP from a single spherical platelet, showing the agonist’s effect is prolonged if it is released 
from granules centralized within the platelet, rather than extruded at the surface. Generation and 
transport of TxA2, ADP, and thrombin were investigated by Folie and McIntire (97) in a study of 
two-dimensional flow that extended the results for one-dimensional flow of Hubbell and 
McIntire (98). They studied the influence of small (5-20 µm) rectangular and semicircular model 
thrombi on flow and agonist transport in a micro-domain (200 × 200 µm) computational model, 
using constant surface fluxes to simulate agonist generation. They predicted shear-rate-
dependent accumulation of platelet-activating agonist concentrations in the recirculation regions 
near the thrombi, with thrombin the dominant species. 
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 As mentioned in section 1.2.3, embolization has not been widely studied, one exception 
being Basmadjian’s series of papers using classical fluid dynamical correlations to estimate 
critical ranges of thrombus height and fluid shear rate which predispose to embolization (66-68). 
He also predicts that thrombus porosity and fluid inertial effects have relatively less effect on 
thrombus stability than drag forces. Wilson et al. (69) simulated time-dependent protein and 
platelet deposition and embolization. Rather than directly accounting for fluid dynamic forces, 
their model used a constant critical height to determine when embolization would occur, and 
included a fixed detachment time after which proteins desorbed from the surface. 
 Recent computational studies have attempted more detailed modeling of platelet 
deposition and activation than could be undertaken in the early efforts. Using a single-species 
convection-diffusion equation for platelet transport, with deposition simulated by the saturable 
surface-flux boundary condition of Grabowski et al. (73) and treating the platelet-surface 
reaction rate and diffusivity as adjustable parameters, Strong et al. (99) obtained excellent 
correspondence between average predicted and experimental platelet deposition values for 
collagen, glass, and polymeric biomaterials. Since the model equations were solved numerically, 
there were few restrictions on the possible flow fields or boundary conditions that could be 
simulated. Although the model predicts platelet deposition as a function of position, the authors 
reported only a single, domain-averaged value as a function of time. This was done to match the 
form of the experimental results to which the model was being fit. As numerous studies have 
shown (59, 100-102), platelet deposition can be highly spatially variable, especially when flow 
disturbances or highly reactive surfaces are present. Predicting such variations may be important 
if one is to accurately determine where clinically significant thrombi will form.  
 Similar models which specifically attempt to predict spatially varying platelet deposition 
in the presence of two-dimensional disturbed flow have recently been published by David et al. 
(103), who consider stagnation-point flow, and Wootton et al. (104), who simulated 
axisymmetric stenoses. Both models use steady-state two-dimensional convection-diffusion 
equations to model platelet transport, with adhesion simulated by a non-saturating surface-flux 
boundary condition whose rate constant is the only adjustable parameter in the model. Wootton 
et al. (104) also modify their platelet concentration and diffusivity to mimic the effects of red 
cell-augmented platelet transport, whereas David et al. (103) neglect these effects because they 
are modeling deposition from RBC-free platelet-rich plasma. The latter group also employ a 
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shear-stress dependent surface reaction coefficient, in contrast to the former group’s assumption 
of a constant value. Surprisingly, both models show the poorest agreement between predicted 
and experimental results in the downstream, fully-developed-flow regions of their geometries, 
rather than in the disturbed flow regions. 
Perhaps the most comprehensive models of platelet activation and aggregation have been 
developed by Fogelson, who simulates platelet activation, agonist generation and transport, and 
bulk aggregation with a continuum model (105) which includes a fictitious fluid-dynamic body 
force to mimic flow disturbances due to platelet aggregation. Although surface adhesion and 
embolization are not simulated, bulk aggregates can be broken up by hydrodynamic forces. The 
same author has also proposed a discrete-platelet model of platelet-surface adhesion and bulk 
aggregation (106). The former model, although never experimentally validated, provided much 
guidance in the development of our equations, explained in the next chapter. The latter version, 
while perhaps more physically realistic in its depiction of thrombosis as an event resulting from 
interactions of discrete cells with each other and with surfaces, may be computationally 
untenable, since transport, deposition, and aggregation would have to be simulated on a single-
platelet basis for each of the approximately 2 × 105 platelets µl-1 in human blood, putting 
milliliter-size simulations out of reach.  
Finally, numerous computational and experimental studies have been performed which 
attempt to qualitatively relate flow features such as recirculation and separation regions (59, 101, 
107), low-velocity flow (108), wall-directed streamlines (59), vortex shedding (109, 110), 
turbulence (111), and shear stress (101, 112) to platelet deposition and aggregation. One would 
expect a priori that such features would correlate with a high predilection to thrombosis, and 
these studies tend to bear out that expectation. However, by focusing solely on fluid dynamics, 
they neglect many important aspects of the thrombogenic process and therefore tend to lack 
predictive ability across surface types or blood conditions. That is, these models can only predict 
that a higher-than-average level of platelet deposition will occur in a region with a given flow 
pattern, while some of the more urgent questions from a thrombosis standpoint would be whether 
the platelet mass is composed primarily of resting or activated platelets, whether the rate of 
deposition will increase, decrease, or go to zero, and whether the thrombus is likely to embolize. 
Answering such questions requires attention to the other two legs of Virchow’s triad. 
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2.0 MODEL DEVELOPMENT2 
“Well, it should be obvious to even the most dim-witted individual who holds an advanced 
degree in hyperbolic topology…” 
 -Prof. Frink, “The Simpsons” #3F04 
2.1 Introduction 
 The first specific aim of this thesis is to develop a comprehensive model of platelet-
mediated thrombogenesis. Chapter 1 described the key attributes of such a model, as well as 
previous modeling efforts. In an effort to improve upon that work, we have combined parts of 
several previously published models with additional elements we deemed necessary to make our 
equations more widely applicable. The result of these efforts is a two-dimensional model which 
attempts to simulate the following phenomena: 1) platelet-platelet and platelet-surface adhesion; 
2) platelet activation by relevant agonists; 3) platelet-phospholipid-dependent thrombin 
generation; and 4) thrombin inhibition by antithrombin III (ATIII) with heparin catalysis. This 
chapter describes the development of the model and its sensitivity to several key variables. 
2.2 Model Equations 
 As discussed in Chapter 1, thrombosis in blood-wetted prosthetic organs is largely a 
platelet-mediated phenomenon. For this reason, our model focuses on platelet thrombus 
formation as the process of primary interest. Since platelets are discrete elements suspended in 
blood, it would be most physically realistic to simulate thrombus formation and growth on a 
platelet-by-platelet basis. However, as was pointed out in Section 1.3.1, the high number 
concentration of platelets in blood makes this an infeasible approach at present due to limitations 
in computing power. For this reason, we have chosen to follow the majority of previous work 
and adopt a continuum approach, treating platelets, agonists, and coagulation factors as dilute 
species dissolved in plasma. Thus our model is described by a coupled set of convection-
diffusion equations, each of which has the form:
 
( ) ( ) .][][][ iiiii SCDCt
C +⋅=⋅+ graddivudiv∂
∂
 [1] 
                                                 
2 This chapter was adapted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):436-448 (71). 
Copyright 1999, Biomedical Engineering Society. 
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Here, div is the divergence operator and grad is the gradient operator. Di refers to the diffusivity 
of species i in blood (in cm2 s-1); u is the two-dimensional fluid velocity vector (in cm s-1); [Ci] is 
the concentration of species i; and Si is a source term representing generation or consumption of 
species i. The model is comprised of equations to describe the transport of: 1) normal, resting 
platelets (PLTs); 2) activated platelets; 3) platelet-granule-released and platelet-synthesized 
platelet agonists, which can be inhibited via first-order reactions; 4) prothrombin; 5) thrombin, 
generated from prothrombin on platelet phospholipid membranes; and 6) ATIII, which inhibits 
thrombin and whose action is catalyzed by heparin via the kinetic model of Griffith (113, 114). 
Table 2 lists the appropriate form for the source terms Si, along with the abbreviation and units 
used for Ci, for each species included in the model. The subscript j in the table and as used 
hereafter refers to the jth platelet agonist, i.e. thrombin or any of the platelet-released or platelet-
synthesized agonists. 
 
Table 2. Model species and source terms 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):436-448 (71). Copyright 1999, 
Biomedical Engineering Society. 
 
Species Ci abbrev. Ci units Si function 
Resting PLT [RP] PLT ml-1 -kpa·[RP] 
Activated PLT [AP] PLT ml-1 +kpa·[RP] 
PLT-released agonists [apr] nmol ml-1 (µM) +λj·kpa·[RP]-kj·[apr] 
PLT-synthesized agonists [aps] µM +sp,j·[AP]-kj·[aps] 
Prothrombin [PT] µM −β [PT](kat·[AP]+krt·[RP]) 
Thrombin [T] NIH Units (U) ml-1 [PT](kat·[AP]+krt·[RP]), and: 
-Γ·[T], [H] >0, or 
-k’’·[AT]·[T], [H] = 0 
ATIII [AT] µM -Γ·β [T], [H] > 0, or 
-k’’·[AT]·β·[T], [H] = 0 
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The equations for [RP], [AP], and [apr] (see Equation 1 and Table 2) are based on 
Fogelson’s continuum model (105) of platelet transport, activation by a single, lumped agonist, 
and bulk aggregation. We have extended Fogelson’s work by adding the capability for multiple 
platelet agonists, rather than a single, lumped one, as well as the possibility of agonist inhibition 
via first-order reactions. In these equations, kpa represents a first-order reaction rate constant (in 
s-1), for platelet activation. This phenomenon is modeled as the “consumption” of resting 
platelets and the “generation” of activated platelets by the first-order reaction kpa·[RP]. The 
coefficient kpa is a function of local agonist concentrations [aj], as indicated below. In the agonist 
generation equations, λj is the amount of agonist j released per platelet (in nmol PLT-1), so that 
λj·kpa·[RP] represents the rate at which agonist j is generated from newly activated platelets. It is 
assumed that agonist release from platelet granules takes place instantly upon platelet activation. 
Fogelson (105) did not specify a functional form for kpa in his model, but rather assumed a static 
distribution of initially activated platelets in his simulations. Although platelet agonists are 
known to act synergistically (115, 116), very little quantitative information is available about the 
kinetics of these interactions (or of platelet activation itself, for that matter). For this reason, we 
have assumed a linear rate equation with an activation threshold: 

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where Ω is the activation function: 
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In Equations 2 and 3, na is the total number of agonists in the model; [aj] is the concentration of 
the jth agonist; [aj,crit] is the concentration of that agonist causing platelet activation when 
platelets are exposed to that agonist alone; wj is an agonist-specific weighting coefficient to 
mimic the relative strength of each agonist in the activation reaction; and tact is a “characteristic” 
time constant for platelet activation (in s). For all simulations reported in this dissertation, the 
weights wj have all been set to one, meaning the contribution of each agonist to the cumulative 
activation function is neither amplified nor attenuated. We have also assumed tact = 1 s, based on 
the observation by Frojmovic et al. (117, 118) that expression of platelet GpIIbIIIa receptors, 
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which signals platelet activation and incipient aggregation, occurs within approximately 1-3 s 
after maximal platelet stimulation by ADP. One will note from the form of Equation 2 that no 
activation takes place until the weighted sum of the normalized agonist concentrations reaches 
unity, which represents an “on-switch” threshold for platelet activation. However, beyond this 
threshold, we allow the rate of platelet activation to increase linearly with agonist concentration, 
with no limit to the maximal rate. It should also be noted that only chemical activation is being 
considered; platelet activation by fluid shear stresses is ignored. One reason for this is because a 
quantitative, experimentally validated function relating shear-induced activation to the 
magnitude and duration of the applied shear stress is not yet available. Even if it were, tracking 
exposure times in the continuum Eulerian framework of our model equations would extract a 
very high computational cost. 
 The behavior of the [RP] source term -kpa·[RP] can be better understood by considering a 
static (i.e., convection- and diffusion-free), but well-mixed, suspension of resting platelets being 
activated by a first-order reaction. In this case, the rate of consumption of resting platelets is 
given by d[RP]/dt = -kpa·[RP], so that [RP] = [RP]0·exp(-kpa·t), where t is time and [RP]0 is the 
initial concentration of resting platelets. If all wj = 1 and the normalized sum of the agonist 
concentrations is equal to one, then kpa = 1, and 36.7% of the initial concentration of resting 
platelets will remain after one second, meaning 63.3% will have become activated. This rate can 
be adjusted to yield exponentially faster or slower activation by scaling tact by a constant. 
 The source-term equation for [aps] represents the generation and inhibition of an agonist 
which is synthesized by the activated platelet, rather than released from its granules. In this 
equation and that for [apr], kj is a first-order reaction rate constant (in s-1) for the inhibition of 
agonist j. We have assumed that activated platelets synthesize these agonists at a constant, non-
diminishing rate, represented by the term sp,j (nmol PLT-1 s-1). This would represent a worst-case 
scenario in terms of thrombogenesis. 
 The equations for [PT], [T], and [AT] represent the coagulation-cascade-related portion of 
our model. We assume the generation of thrombin from prothrombin takes place both on surface-
bound and bulk platelets. The equations for surface-based thrombin generation are incorporated 
into the boundary conditions, described below. As demonstrated by Rosing et al. (119), activated 
platelets support phospholipid-mediated thrombin generation at a much higher rate than do 
resting platelets. This is likely due to the procoagulant effect of the phosphatidylserine residues 
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exposed on the outer surface of the activated platelet. To simulate this phenomenon, we employ 
the rate constants krt and kat in the source terms for [PT] and [T] to represent the different 
conversion rates of prothrombin to thrombin at the surface of resting and activated platelets, 
respectively, in units of U PLT-1 s-1. In the source terms for [T] and [AT], Γ (in s-1) is Griffith’s 
template model for the kinetics of the heparin-catalyzed inactivation of thrombin by ATIII (113, 
114): 
.
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In Equation 4, kT is a first-order rate constant (in s-1); KT and KAT are the dissociation constants 
(in µM) for heparin/thrombin and heparin/ATIII, respectively; ξ represents a factor to simulate a 
change in affinity of heparin for ATIII when it is bound to thrombin or for thrombin when it is 
bound to ATIII; and β is a conversion factor to convert thrombin concentration from U ml-1 to 
µM. The bulk heparin concentration, [H] (in µM), is assumed constant in both space and time. 
Note that this kinetic model yields zero thrombin inhibition by ATIII at zero heparin 
concentration regardless of ATIII concentration, which is incorrect. Therefore, in the absence of 
heparin, this model is replaced by a second-order reaction for the inhibition of thrombin by ATIII 
alone (120), as given in Table 2, where k” is a second-order rate constant. 
 Platelet adhesion to the biomaterial surface and to other deposited, activated platelets is 
modeled via surface-flux boundary conditions. Platelet activation due to surface adhesion, as 
occurs on collagen and many biomaterials, is also included, as are surface-based agonist 
generation and agonist-induced activation of wall-bound resting platelets. The equations for 
these boundary conditions are as follows, where a positive term indicates an efflux or 
consumption from the domain, and a negative term indicates an influx or generation (x here is 
distance along a reactive wall, in cm): 
Reactive wall flux boundary condition (BC) for resting platelets: Adhesion to surface only, not to 
other platelets (PLT cm-2 s-1): 
][),(),( RPktxStxJ rsr ⋅⋅=  [5] 
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Reactive wall flux BC for activated platelets: Adhesion to surface and to deposited, activated 
platelets, but not to deposited, resting platelets (PLT cm-2 s-1): 
][
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Reactive wall flux BCs for platelet-released agonists: Generation due to platelet activation  
(nmol cm-2 s-1):
 ( )),(][),(),( txMkRPktxStxJ rparsjpr ⋅+⋅⋅⋅−= θλ  [7] 
Reactive wall flux BCs for platelet-synthesized agonists: Generation due to platelet activation 
(nmol cm-2 s-1): 
jpatps stxMtxJ ,),(),( ⋅−=  [8] 
Reactive wall flux BC for prothrombin: Consumption due to thrombin generation  
(nmol cm-2 s-1):  ( ) ][),(),(),( PTktxMktxMtxJ rtratatpt ⋅⋅+⋅⋅= β  [9] 
Reactive wall flux BC for thrombin: Generation from prothrombin on surface-adherent platelets 
(U cm-2 s-1): ( ) ][),(),(),( PTktxMktxMtxJ rtratatt ⋅⋅+⋅−=  [10] 
Here, species concentrations are the values at a reactive wall. Equations 5-6 are based in part on 
the single-component platelet-transport model of Strong et al. (99). In these equations, krs, kas, 
and kaa are heterogeneous reaction rate constants (in cm s-1) that govern the rates of adhesion 
between, respectively: resting platelets and the surface; activated platelets and the surface; and 
depositing and surface-bound activated platelets. It is assumed that all three parameters are 
dependent on blood composition; krs and kas are also surface-dependent. These surface-deposition 
equations include a saturation effect that prevents additional platelet-surface adhesion once the 
capacity of the surface for platelets, M∞, is reached. In contrast to the work of Strong et al. (99) 
in which M∞ is material-dependent, we assume it to be independent of surface composition and 
equal to monolayer coverage. This amounts to the assumption that all surfaces will 
asymptotically approach monolayer coverage at sufficiently long times, with the surface 
reactivity parameters determining the rate.   
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This saturation effect is embodied in the S(x,t) term in Equations 5-7, where: 
S(x,t) = 1-M(x,t)/M∞ [11] 
( )∫ ⋅⋅+= t asr dtAPtxSktxJtxM
0
.][),(),(),(  [12] 
M(x,t) is the sum of activated and resting platelet-surface adhesion (in PLT cm-2). Our model 
augments that of Strong et al. by adding a platelet-platelet adhesion term (the second term in 
parentheses in Equation 6). We believe this more accurately represents the growth patterns of a 
thrombus, as platelets should continue to adhere to those already deposited on the surface after 
monolayer surface coverage is reached. In this expression, Mas(x,t) (PLT cm-2) represents the 
portion of the total surface coverage M(x,t) comprised of activated platelets: 
( ) .),(][),(),(),(
0
∫ ⋅+⋅⋅+⋅= t rpaasras dttxMkAPtxSktxJtxM θ  [13] 
Here, θ is the surface-dependent fraction of adhering, resting platelets which activate upon 
surface contact; kpa is the activation rate constant of Equation 2 evaluated at the wall; and Mr(x,t) 
(PLT cm-2) is the portion of the total surface coverage due to resting platelets: 
( ) ),,(),(),(),()1(),(
0
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so that kpa·Mr(x,t) is the rate of activation of deposited, resting platelets by agonists. The reaction 
coefficient kaa in Equation 6 is scaled by the fraction of the surface covered with activated 
platelets, Mas/M∞. This scaling reflects the notion that as the number of surface-bound, activated 
platelets increases, more surface area is available for platelet-platelet adhesion, and the surface 
flux of activated platelets should increase accordingly. 
The agonist-related surface fluxes are described by Equations 7-10. Equation 7, based 
loosely on prior theoretical work by Adams and Feuerstein (94, 95), is the surface-flux 
counterpart of the agonist generation term for [apr]. As in the bulk source function, those platelets 
which activate are assumed to degranulate instantaneously. Likewise, Equation 8 is the surface-
flux counterpart of the agonist source term for [aps], with activated platelets assumed to 
synthesize the relevant agonists at a constant rate for their entire lifespan.  
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Equations 9-10 are the thrombin-related surface fluxes and are identical to the bulk 
thrombin generation source terms with bulk concentrations replaced by surface concentrations. 
In these equations, Mat(x,t) is the total surface coverage (in PLT cm-2) with deposited, activated 
platelets (equal to activated platelet-surface plus platelet-platelet adhesion): 
( ) .),(),(),(),(
0
∫ ⋅++⋅= t rpaarat dttxMktxJtxJtxM θ  [15] 
 Obviously, thrombin generation is considerably more complicated than the simple 
conversion of prothrombin at a platelet phospholipid surface, as we have modeled it. However, 
simulating the upstream coagulation reactions was deemed too computationally expensive. For 
example, simulating only the extrinsic and common pathways using the model of Kuharsky and 
Fogelson (88) would require 59 equations, rather than three, so that the computational expense of 
merely computing thrombin concentration would greatly exceed the cost of solving the rest of 
the model (four equations). Consequently, we assume that the common pathway has been 
reached and that local concentrations of factors Xa and Va are not rate-limiting. Also, we allow 
the rate of thrombin generation to increase linearly with the amount of platelet surface area 
present, with no lower or upper limit. Evidence supporting this assumption can be found in 
Rosing et al. (119), where it was shown that the rate of platelet-phospholipid-mediated thrombin 
generation (albeit in buffer medium, rather than whole blood) is approximately linear in platelet 
phospholipid concentration over the range 0 to 4 µM phospholipid. They also showed thrombin 
generation by platelets stimulated by thrombin, collagen, or both to increase without saturating 
over the range 0 to 3 × 107 PLT ml-1. However, the upper limit studied represents activation of 
roughly 10% of the normal platelet concentration, so further investigation of this assumption 
may be warranted if higher levels of activation are expected. 
Finally, the fluid velocity field for the convection-diffusion-reaction equations is obtained 
by solving the incompressible, laminar Navier-Stokes equations. As a first approximation, we 
neglect the effect of the geometry of the growing thrombi on the flow field. That is, we obtain a 
single flow solution and assume it holds for all time. The impact of this assumption is discussed 
further in Chapters 3 and 4, where the model predictions are compared to experimental results. 
Several additional simplifying assumptions are made when solving these equations. First, blood 
is assumed to be a continuous medium, rather than a suspension of cells and proteins. This means 
that the physical effect of RBCs on the platelet concentration profile cannot be simulated 
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directly. Second, blood is assumed to be an incompressible, Newtonian fluid. The assumption of 
Newtonian behavior is considered valid at high shear rates (> ~200 s-1) (121), which are typical 
of the arterial flows that are our primary interest. However, this assumption may not be valid in 
regions of retarded flow, such as stagnation zones following an obstruction.  Finally, we have 
assumed the flow is in local chemical equilibrium, so that the Navier-Stokes equations can be 
solved decoupled from the convection-diffusion-reaction equations. With these assumptions, the 
appropriate form of the steady-state Navier-Stokes equations is (122): 
( ) ugradugradu ∆+−=• µρ )()( p  [16] 
( ) 0=udiv  [17] 
Here, ∆ is the Laplacian operator; ρ is fluid density (in g cm-3); p is pressure (in dynes cm-2); and 
µ is the asymptotic (high-shear) viscosity of blood (in g cm-1 s-1). 
2.3 Methods 
 Values for the species-specific parameters required in Equations 1 and for the boundary 
and initial conditions were taken from various sources in the literature and are summarized in 
Table 3. In addition to thrombin, we have incorporated the agonists ADP and TxA2. ADP is a 
platelet-released agonist, stored in the dense granules, while TxA2 is synthesized enzymatically 
by the activated platelet. Once released, TxA2 is rapidly hydrolyzed to thromboxane B2, which is 
relatively inactive. This process is incorporated into the model via a first-order inhibition 
reaction whose rate constant is given in Table 3. In selecting a value of [aj,crit] for TxA2, we have 
adopted the reasoning of Folie and McIntire (97) and Hubbell and McIntire (98) and have 
assumed that the platelet-activating behavior of this agonist is similar to that of its stable 
synthetic analogue, U46619. The values for resting platelet concentration in Table 3 represent 
roughly a normal range for whole blood. The value of [RP] for a particular simulation would 
typically be given as part of the experimental conditions. For the preliminary studies in this 
chapter and Chapter 3, we also assume a level of background platelet activation equal to 5% of 
the initial concentration of resting platelets, i.e. [AP] is set to 0.05⋅[RP] at the inlet. This value is 
consistent with that reported by Matzdorff et al. (123) for platelet P-selectin expression in 
normal subjects; values in the literature range from 1% (124) to nearly 20% (125). Table 4 gives 
values for the additional parameters required in the model.  
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As discussed in Section 1.2.3, RBCs have been shown to have a shear-dependent, 
diffusion-augmenting effect on the transport of platelets and large proteins. One way to simulate 
this is by adjusting the diffusivities Di of the “larger” species (thrombin, prothrombin, and ATIII) 
from the Brownian values reported in Table 3. The most common methods are ones such as 
those proposed by Keller (78) and Zydney and Colton (126), in which the augmentation factor is 
linearly proportional to local shear rate and to particle size. We have selected Keller’s version 
(78) for our initial studies, where Di = Db,i + Ds, and Db,i and Ds are the Brownian and “shear-
enhanced” diffusivities, respectively. Keller’s formula for Ds is: 
Ds = 0.18·drbc2· &γ /4, [18] 
where drbc is the diameter of a red blood cell (assumed to be 5.5 µm) and &γ  is the local fluid 
shear rate in s-1. Following Folie and McIntire (97), we use the shear rate at the wall, &γ w , in 
Equation 18 to compute a constant enhancement factor which is applied at all locations 
throughout the domain.  
 We believe applying a constant enhancement, rather a shear-proportional one, is 
justifiable because increasing diffusivity with local shear rate (for Poiseuille-type flows) results 
in the level of enhancement being the opposite of what one would expect intuitively – zero at the 
centerline, where most of the red cells reside, and highest at the wall, where they are excluded. 
 For platelets, we use a combination of a wall-skewed inlet boundary condition and an 
enhanced diffusivity to mimic the near-wall platelet excess which red cells induce (53, 79). The 
skewed platelet inlet boundary conditions are set using the quadratic profile applied previously 
by Wagner (127), and derived from unpublished work by Hubbell. This equation is:
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where y is the vertical coordinate (in cm) measured from the bottom of the channel; H is the 
channel half-height; Lb is the excess-platelet boundary layer thickness, assumed to be 35% of the 
channel half-height; A is an augmentation factor that determines the degree of excess at the wall, 
taken as 5.6; and C0 is the uniform concentration outside the boundary-layer region. For Lb and A 
as assumed here and for parallel-plate Poiseuille flow, C0 would be 60% of the desired bulk 
average (cup-mixed) platelet concentration.  
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Table 3. Species-specific parameter values 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):436-448 (71). Copyright 1999, 
Biomedical Engineering Society. 
 
Species Db,i  
(cm2 s-1)a 
kj 
(s-1)b 
λj  
(nmol PLT-1)c 
sp,j  
(nmol PLT-1 s-1)d 
Initial conc. in 
simulations 
[aj,crit]e 
RP 1.58 × 10-9 N/A N/A N/A 1.5 × 108 - 3 × 108 
PLT ml-1 
N/A 
AP 1.58 × 10-9 N/A N/A N/A 0.05·[RP] N/A 
ADP 2.57 × 10-6 N/A 2.4 × 10-8 N/A 0.00 µM 2.00 
µM 
TxA2 2.14 × 10-6 0.0161 N/A 9.5 × 10-12 0.00 µM 0.60 
µM 
PT 3.32 × 10-7 N/A N/A N/A 1.100 µM N/A 
T 4.16 × 10-7 N/A N/A N/A 0.00 U 0.10  
U ml-1 
ATIII 3.49 × 10-7 N/A N/A N/A 2.844 µM N/A 
N/A = not applicable for this species 
asee (97, 98) for agonists, (128) for platelets 
bsee (98), for hydrolysis to inactive compound TxB2 
csee (95) 
dsee (97) 
esee (129) for thrombin, (130) for TxA2 (based on activity of U46619); see (131), fig. 9 for ADP, assuming 
approximately 60% activation 
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Table 4. Additional parameter values 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):436-448 (71). Copyright 1999, 
Biomedical Engineering Society. 
 
Parameter Value Units Ref. 
kT 13.33 s-1 (113, 114)
k” 7.083 × 10-3 µM-1 s-1 (120) 
KAT 0.10 µM (113, 114)
KT 3.50 × 10-2 µM (113, 114)
ξ 1.00 -- (113, 114)
β 9.11 × 10-3 nmol U-1 --a 
M∞ 7.00 × 106 PLT cm-2 (132)b 
kat 3.69 × 10-9 U PLT-1 s-1 (µM PT)-1 (119)c 
krt 6.50 × 10-10 U PLT-1 s-1 (µM PT)-1 (133) 
µ 0.035 g cm-1 s-1 (128) 
ρ 1.1064 g cm-3 (97) 
aassuming thrombin specific activity 3000 U mg-1 and molecular weight 36.6 kDa 
bsee fig. 8 of (132): value for asymptotic level of deposition of washed PLTs in buffer medium onto collagen at 
shear rate of 300 s-1 in cone-and-plate device (approximate monolayer coverage assumed) 
csee table 1 of (119): value for PLTs stimulated by thrombin 
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 In numerical experiments with non-reactive walls, we discovered that combining the 
skewed inlet profile given by Equation 19 with the Keller diffusion-enhancement factor proved 
self-defeating because the very high diffusivity rapidly obliterated the non-uniform profile. On 
the other hand, using only the Brownian diffusivity neglects the red-cell-enhancement factor.  
For these reasons, we have decided to adopt the approach of Strong et al. (99) and estimate a 
constant platelet diffusivity that gives the best fit to experimental results. 
The system of species transport equations is solved using a finite-volume method for 
unstructured triangular meshes (134). In our algorithm, the convection terms are treated using 
first-order low-numerical-diffusion fluctuation-splitting schemes (135). The coupled system of 
equations is solved with a segregated iterative procedure involving equation-level and system-
level convergence criteria. A time-accurate solution is obtained by sub-iterating the solution to a 
steady-state using either pseudo-time stepping or successive under-relaxation, and then 
advancing that solution forward in physical time (136). This dual time-stepping approach allows 
the use of arbitrarily long physical time steps without affecting the stability of the scheme, 
although, as one would expect, temporal accuracy decreases as longer physical time steps are 
used. Unstructured meshes are generated using the public-domain program Triangle (JR 
Shewchuk, Carnegie Mellon University). 
2.4 Model Behavior and Parameter Sensitivity 
 In fitting the model to experimental results, the independent parameters are: 1) platelet 
concentration; 2) heparin concentration; 3) percent of resting platelets activated by surface 
contact; 4) platelet diffusivity; and 5) the three platelet reaction rate constants krs, kas, and kaa. 
The first three should be deducible from the experimental data, while the last four must be 
estimated for each experiment, although one would expect platelet diffusivity to be a function of 
shear rate and hematocrit and the platelet-platelet reaction rate to be constant given constant 
blood composition (i.e. it would only have to be changed if the simulation involved an adhesive-
protein-deficient suspension rather than normal whole blood).  
 Preliminary simulations were performed on a simple flow geometry to establish the 
baseline performance of the model. A hypothetical experiment was simulated wherein whole 
blood was perfused within a parallel-plate flow channel. This enabled the analysis of the relative 
importance of the aforementioned variable model parameters. 
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For these studies, a micro-domain (200 µm high × 11 mm long) rectangular flow channel 
was simulated. This configuration was selected because it is similar to the design of the parallel-
plate flow chambers employed in the experimental platelet deposition studies discussed in 
Chapter 3. Vertical symmetry about the channel centerline was assumed, so that the 
computational domain was 100, rather than 200 µm tall, and the lower surface was modeled as a 
platelet-adhesive biomaterial. Assuming fully-developed flow at the inlet to the computational 
domain, the incompressible Navier-Stokes equations for these cases are exactly satisfied by the 
Poiseuille solution (122), which is independent of blood density and viscosity: 
u U
H y
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2
2  [20] 
where y is again measured from the bottom of the channel, and Umax is the maximum velocity (at 
the centerline) in cm s-1. Note that for a Newtonian fluid,  
( ) ( ) ,/2/)(2/ max02max HUHyHUyu ywallxw ⋅=−⋅⋅== =∂∂γ&  [21] 
and hence ux can be written as a function of &γ w . To simulate the high-shear arterial flow typical 
of a cardiovascular device, a &γ w  = 1000 s-1 was prescribed and was used for computing both the 
flow field and the Keller diffusivity correction factors discussed above. 
The sensitivity of the model to mesh density was investigated through refinement studies. 
The model solution for a given set of test conditions was found to vary negligibly (less than ~5% 
change in peak concentration and platelet deposition magnitudes) as the mesh was progressively 
refined from approximately 10,000 to approximately 24,000 mesh nodes. Therefore, all results 
reported have been obtained on a 10,000 node domain. Figure 3A shows the dimensions of the 
computational domain and the inlet velocity profile, while Figure 3B shows a portion of the 
10,000 node mesh. A 25 µm-high region near the reactive surface was refined to better capture 
the near-wall phenomena being simulated. The elements in this region have areas roughly 40% 
the size of those in the rest of the domain. The height of this region was somewhat arbitrarily 
chosen, as there was no a priori way of calculating the mass transfer boundary layer thickness. 
Finally, we have chosen to simulate 300 s of perfusion, for which 100 three-second time steps 
were used in our algorithm.  
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Figure 3. Details of computational domain 
(A) Dimensions (note discrepancy in scale between x and y axes), boundary zones and inlet velocity profile.  
(B) Zoomed detail of unstructured triangle mesh. Reprinted with permission from Sorensen et al., Ann. Biomed. 
Eng., 1999;27(4):436-448 (71). Copyright 1999, Biomedical Engineering Society. 
 
The initial condition Ci = 0 was imposed on all species everywhere in the computational 
domain except the inlet, where uniform, constant-concentration Dirichlet boundary conditions 
were employed. In simulating experimental data, we generally used the resting and activated 
platelet concentration profiles given by Equation 19. However, to more clearly demonstrate the 
effects of diffusion and surface reaction effects without the added complexity of the artificial 
concentration gradient created by that profile, we have assumed a nominal uniform inlet [RP] 
value of 2 × 108 PLT ml-1 for these parameter studies. Additionally, we have set the inlet 
concentration of activated platelets to zero, rather than our typical 5% “background activation” 
value. This was done to avoid “seeding” the field with initially activated platelets so that the 
effects of the surface and generated agonists on platelet activation would be more readily 
apparent.  
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At the lower, reactive wall, the surface-flux boundary conditions given in Equations 5-10 
were imposed. Since ATIII is not involved in surface-based reactions, a zero-normal-flux 
boundary condition, ( )∂ ∂[ ] /AT y wall = 0 , was applied for that species. At the outlet, a fully 
developed concentration profile was assumed, which allowed a zero-normal-flux boundary 
condition to be imposed for all species, i.e. ( )∂ ∂[ ] /C xi outlet = 0 . Since the 100 µm upper plane of 
our computational domain was treated as a symmetry plane, the boundary condition 
( )∂ ∂ µ[ ] /C yi y m= =100 0  was imposed on all species. 
Figures 4-7 show total platelet deposition (platelet-surface plus platelet-platelet adhesion) 
versus distance along the reactive wall after 300 seconds of simulated flow. The numerically 
predicted deposition values have been averaged over 200 µm intervals to facilitate viewing. 
Figure 4 shows the effects of the ratio of surface reactivity to platelet diffusivity, as 
measured by the Damkohler number based on a heterogeneous reaction, Da = k·H/DPLT. For 
these cases, it was assumed that krs = kas = kaa, i.e. all reaction rates (and the three corresponding 
Damkohler numbers) are equal. Additionally, a relatively low heparin concentration ([H]) of 2 
U·ml-1 was used, and it was assumed that all resting platelets became activated on surface contact 
(θ = 1 in Equations 7 and 13-15) so that large amounts of agonist generation and bulk platelet 
activation would be induced. 
As the figure shows, increasing the reaction rates results in a transition from a reaction-
limited regime, represented by the relatively flat deposition curve at Da =1, to a clearly 
diffusion-limited regime at Da =100, where most of the platelets are consumed upstream, 
resulting in a rapid drop-off in deposition in the downstream tail of the curve. The highly 
nonlinear variation in deposition magnitude as the Damkohler number is increased shows the 
effects of the positive feedback created by the platelet activation process: platelet deposition 
leads to increased platelet activation on the surface, which leads to increased surface-based 
agonist generation, which in turn induces bulk platelet activation and agonist generation, and 
which then completes the loop by increasing platelet-platelet adhesion. 
The relatively jagged curve for Da = 100 (and in subsequent figures where surface 
reaction rates are high) is due to the discretization process necessary to numerically solve the 
governing partial differential equations. Since the discrete equations are solved point-wise, 
numerically predicted platelet deposition is a very local event determined by the concentration of 
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platelets at a given wall node. At a very high reaction rate, the concentration of platelets in the 
boundary layer will be greatly decreased through deposition within a few upstream nodes, 
thereby locally depleting the boundary layer and resulting in a much lower level of deposition at 
the next few downstream nodes, since diffusive mechanisms cannot replenish the boundary layer 
rapidly enough.  
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Figure 4. Dependence of axial platelet deposition on platelet Damkohler number 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):436-448 (71). Copyright 1999, 
Biomedical Engineering Society. 
 
Figure 5 shows effects of the ratio of activated-to-resting platelet reaction rate kas/krs, 
again for [H] = 2 U·ml-1 and θ = 1. Here, it was assumed that kas = kaa, i.e. activated platelets 
adhere to the surface and to each other with equal affinity. The figure shows deposition versus 
distance as a function of the ratio kas/ krs, for a fixed platelet Damkohler number (based on krs) of 
10. Again, the amount of upstream deposition and the accompanying rapid drop in downstream 
values both increase with increased activated platelet reactivity, with diffusion-limited behavior 
shown for all ratios greater than one. The effects of the large reaction rates on depletion of the 
platelet boundary layer are apparent when one compares the curves for kas/ krs = 5 and kas/ krs = 
10. The two curves have very similar shapes; however, upstream deposition for kas/ krs = 10 is 
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approximately 50% higher than for kas/ krs = 5, while for x greater than about 3 mm, the two 
curves are essentially identical. The difference in upstream deposition is likely a result of 
increased agonist generation and bulk activation due to the higher number of platelets depositing 
near the inlet at the higher ratio, while for both cases, most of the available activated platelets are 
consumed from the boundary layer by x = 3 mm. 
 
 
Figure 5. Dependence of axial platelet deposition on ratio of activated to resting platelet-surface reactivity 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):436-448 (71). Copyright 1999, 
Biomedical Engineering Society. 
 
Figure 6 shows the effects of surface-induced activation (modeled by the parameter θ,  
the fraction of adherent resting platelets activated by surface contact), for the same conditions as 
in Figure 4, but with platelet Damkohler number fixed at 10. In Figure 6A, agonist-induced 
activation occurs both in the bulk flow and on the surface, while in Figure 6B only bulk 
activation is permitted. When θ = 0, no surface-induced platelet activation occurs. Since there are 
no activated platelets and no agonists in the domain at the start of the simulation, and since the 
rate of thrombin generation by resting platelets is too low to result in a supra-threshold thrombin 
concentration for these simulation conditions, no agonist-induced platelet activation occurs. 
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Hence, there is no platelet-platelet adhesion; the only event occurring is resting platelet-surface 
adhesion, which ceases at the saturation limit M∞, resulting in a monolayer of resting platelets 
regardless of whether agonist-induced activation is permitted at the surface. For θ = 1, 100% of 
adherent platelets are activated by surface contact. Hence, identical deposition values are 
obtained for both sets of simulations, since agonist activation of surface-bound platelets is 
irrelevant. For θ = 0.25 or 0.5, however, the relative effects of agonist- and surface-induced 
activation are apparent. When agonist-induced activation is allowed to occur at the surface, it 
appears to overwhelm any surface-induced activation effects for the parameter values chosen, 
resulting in the deposition values for θ = 0.25 and 0.5 being identical to those for θ = 1. Without 
agonist-induced activation at the surface (Figure 4B), however, platelet deposition increases 
fairly steadily with increasing θ as expected, since a higher surface concentration of activated 
platelets leads to a larger platelet-platelet adhesion flux (cf. Equation 6). 
Figure 7 shows the effect of heparin concentration, and therefore thrombin generation, on 
platelet deposition for the same conditions as in Figure 6, but with θ fixed at one. It is clear from 
these results that thrombin is the dominant agonist as modeled in our system, since decreasing 
thrombin generation by increasing heparin concentration greatly decreases overall platelet 
deposition, with platelet-platelet adhesion nearly abolished for the [H] = 20 U ml-1case. Note that 
this occurs despite thrombin having been given the same weight (when normalized by its platelet 
activation threshold) as the weaker agonists ADP and TxA2 in the platelet activation function 
(Equation 3). However, these results also indicate that heparin is typically not 100% effective in 
removing thrombin. That is, thrombin concentrations sufficient to activate platelets (i.e., ≥ 0.1 U 
ml-1) were observed at 300 s in all cases except [H] = 20 U ml-1, and even for that case the 
maximum predicted thrombin concentration had reached 80% of threshold. 
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Figure 6. Dependence of axial platelet deposition on degree of surface-induced activation 
(A) Agonist-induced activation of surface-adherent platelets allowed. (B) Agonist-induced activation of surface-
adherent platelets not allowed. Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):436-
448 (71). Copyright 1999, Biomedical Engineering Society. 
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Figure 7. Dependence of axial platelet deposition on bulk heparin concentration 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):436-448 (71). Copyright 1999, 
Biomedical Engineering Society. 
 
2.5 Conclusions 
 This chapter has presented the equations for and basic properties of a computational 
model of platelet-mediated thrombogenesis which has been designed to capture the crucial 
aspects of all three components of Virchow’s triad. The model attempts to simulate platelet 
transport, adhesion to reactive biomaterial surfaces, agonist generation and platelet activation. 
We believe it is easily applicable to a wide range of platelet-biomaterial interactions. As 
demonstrated by Haycox and Ratner (50), there are four distinct modes of interaction between 
platelets and polymeric biomaterial surfaces: (a) little or no platelet adhesion or activation; (b) 
adhesion followed by formation of a passivating platelet monolayer; (c) activation without 
adhesion; and (d) adhesion with activation. Since our model differentiates between the amount of 
deposited resting versus activated platelets, allows separate reaction rates for resting platelet-
surface, activated platelet-surface, and activated platelet-platelet adhesion, and incorporates the 
ability to relate the fraction of adhering platelets which activate (θ) to surface properties, it is 
well-suited to modeling these four types of interactions. 
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 In the next chapters, we examine the model’s ability to reproduce experimental results for 
platelet deposition onto a specific material substrate, type I collagen, both in unidirectional 
Poiseuille flow and two-dimensional disturbed flow. 
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3.0 MODEL VALIDATION: POISEUILLE FLOW3 
“I am a scientist 
I seek to understand me 
all of my impurities 
and evils yet unknown” 
 -Guided by Voices, “I Am a Scientist” 
3.1 Introduction 
 In Chapter 2, a continuum model of platelet-mediated thrombosis was developed and its 
sensitivity to key parameters investigated. In this chapter, we focus on the second specific aim, 
model validation. As such, we attempt to predict experimentally measured platelet deposition, 
using simple test cases from the literature involving parallel-plate Poiseuille flow of whole blood 
over a type I collagen substrate. One set of training cases is used to calibrate the independent 
parameters of the model and to demonstrate its ability to realistically simulate the effect of 
thrombin inhibition. Then, the model is applied to additional validation cases to investigate its 
robustness and predictive performance under varying fluid shear rates and additional 
anticoagulation conditions.  
3.2 Methods 
3.2.1 Training Cases 
 The independent model parameters (resting platelet-surface adhesion rate krs [cm·s-1], 
activated platelet-surface adhesion rate kas [cm·s-1], activated platelet-platelet adhesion rate kaa 
[cm·s-1], and shear-dependent platelet diffusivity DPLT [cm·s-2]) were estimated by fitting the 
model to the experimental results of Wagner and Hubbell (102), who studied the axial 
dependence of platelet deposition from flowing, heparinized whole blood onto a type I collagen 
surface, using a parallel-plate flow chamber. Since these studies measured platelet deposition as 
a function of time and examined the effects of removing thrombin (via the active-site inhibitor 
PPACK), the results are ideal for calibrating our model. 
                                                 
3 This chapter was adapted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):449-458 (137). 
Copyright 1999, Biomedical Engineering Society. 
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Model parameters specific to these cases and the equations to which they are relevant are 
listed in Table 5; all other parameters are as given in Tables 3-4. The resting platelet 
concentration was estimated by comparing Figure 6 of Wagner and Hubbell (102), which shows 
maximal platelet deposition for heparinized blood as a function of platelet count, to the 
maximum value in Figure 1 of that report, which contains the results we are attempting to 
predict. The parameter Ds is the Keller correction factor (78) to the Brownian diffusivity of the 
“large” species (prothrombin, thrombin, and ATIII). As mentioned in Chapter 2, this parameter 
is taken as a constant, with its value computed using Equation 18 and the wall, rather than the 
local, shear rate. Wagner and Hubbell (102) estimated the wall shear rate for their experiments to 
be 1000 s-1. Also, the value for the rate of thrombin generation by activated platelets, kat, has 
been increased at the collagen surface relative to its bulk value. The increase in this parameter 
relative to its value in Chapter 2 is based on the experimental data of Rosing et al., wherein 
activated platelets stimulated by both collagen and thrombin supported thrombin generation at a 
rate 8.7 times greater than did platelets activated by thrombin alone (119). The heparin 
concentration listed corresponds to the 2 U ml-1 used in the experiments. Finally, the value of 1.0 
assumed for θ implies that all resting platelets deposited on the thrombogenic type I collagen 
surface become activated on contact.  
The experiments of Wagner and Hubbell (102) employed a 200 µm high × 20 cm long 
channel, with the inlet portion (3 cm in length) coated with relatively non-adhesive albumin and 
the remaining 17 cm coated with type I collagen. The width of this channel was 20 times larger 
than the height, so that two-dimensional flow could be assumed along its axial midline. Using 
the reported wall shear rate of 1000 s-1 and assuming fully-developed flow, a Poiseuille solution 
for the flow field (Equations 20-21) can be computed, and the resulting velocity terms inserted 
into the transport equations. Then, the transport model, consisting of the seven coupled species-
conservation equations (Equations 1), can be solved once suitable boundary and initial 
conditions are imposed and values for the platelet-surface and platelet-platelet reactivities and 
platelet diffusivity are assumed. In the case where PPACK was used to inhibit thrombin, the 
thrombin-related species (prothrombin, thrombin, and ATIII) were eliminated from the model. 
This is equivalent to assuming that PPACK completely inhibits platelet-mediated thrombin 
generation. In the remaining four equations, all parameters were identical to those used for the 
heparin-only case.  
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Table 5. Specific parameter values for training cases 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):449-458 (137). Copyright 1999, 
Biomedical Engineering Society. 
 
Parameter Value Equations Ref. 
[RP] 2 × 108 PLT·ml-1 1,5,7 (102)a
C0 (for [RP]) 1.2 × 108 PLT·ml-1 19 --a 
Ds 1.36 × 10-5 cm2 s-1 18 (78)b 
[H] 0.417 µM 4 (102)c
kat --surface 3.22 × 10-8 U PLT-1 s-1 (µM PT)-1 9,10 (119)d
θ 1.00 7,13-15 -- 
avalues for [AP] are 5% of these values (to simulate 5% background PLT activation) 
bused to correct diffusivities of thrombin, prothrombin, and ATIII for effect of red blood cells in shear flow 
cfor 2 U ml-1 heparin as used in ref. 13, assuming specific activity 300 U mg-1 and molecular weight 16 kDa 
dsee table 1 of (119): value for PLTs stimulated by thrombin + collagen 
 
 Our transport model was solved on a 100 µm high × 11 mm long rectangular domain, 
designed to simulate a portion of the lower half of Wagner and Hubbell’s flow chamber. The 
first 1 mm of the computational domain was designed to replicate a portion of the 3 cm albumin 
entrance length, where Wagner and Hubbell (102) observed negligible platelet deposition. 
Accordingly, platelet-surface reactivities there were arbitrarily set to 10-8 of the values for the 10 
mm collagen region, and the parameter θ was set to zero. This had the effect of preventing the 
adherent resting platelets in this region from activating and releasing agonists. The results of 
Wagner and Hubbell (102) indicate that the experimental platelet deposition curves reached an 
essentially constant, asymptotic value at approximately 10 mm into the collagen portion of the 
chamber, and those authors report data for only the first 15 mm of collagen. Therefore, we chose 
10 mm for the length of the collagen portion of our computational domain, rather than the full 17 
cm used in the experiments.  
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Initial and boundary conditions were imposed as discussed in Chapter 2, with constant 
inlet concentrations used for all species, a wall-skewed quadratic concentration profile employed 
for resting and activated platelets, and 5% background platelet activation assumed. Since the 
upper wall was collagen-coated in Wagner and Hubbell’s experiments, the 100 µm upper plane 
of our computational domain was treated as a symmetry plane, and the boundary condition 
( )∂ ∂ µ[ ] /C yi y m= =100 0  was imposed on all species. 
The mesh used for these cases was the same 10,000 node unstructured triangle mesh used 
for the parameter sensitivity studies in Chapter 2; mesh refinement studies were conducted as 
described therein. Since time accuracy was an important consideration for these cases, time-step 
refinement studies were also conducted. Negligible variation in root-mean-square species 
concentrations between simulations was found for physical time steps less than 2.5 s for a 75-
second simulation. For the results presented herein, a time step of 0.5 s was used. 
The variable model parameters krs, kas, kaa, and DPLT were adjusted by trial and error until 
one set of parameters gave the best possible fit (as judged by visual inspection) to the 
experimental results for both the heparin and heparin + PPACK case. This was done by first 
varying each parameter independently until a relatively good fit to the heparin-only case was 
obtained. This took several iterations (roughly on the order of 25), as the sensitivity of platelet 
deposition to each parameter was observed by varying each parameter over a wide range, after 
which finer trial-and-error adjustments could be made to obtain an acceptable fit to the 
experimental data. Once such a fit was obtained for the heparin-only case, the heparin + PPACK 
case was simulated using the parameters from the most recent best-fit heparin-only case, and 
those parameters were further tuned to obtain an acceptable fit to the heparin + PPACK data. The 
tuned parameters from the most recent heparin + PPACK case were then used to simulate the 
heparin-only case, further tuning was done if necessary, and iteration between the two cases 
continued until the best visual fit to both cases was obtained.  
In tuning the parameters, guidance was obtained from physical arguments. First, since the 
highly thrombogenic collagen substrate should activate nearly all resting platelets that contact it, 
the magnitudes of krs and kas should be similar. Likewise, activated platelets should likely bind to 
each other with about the same avidity as they attach to this very adhesive surface, so that kas and 
kaa should be roughly equal. Finally, the Keller model correction factor computed using the wall 
shear rate (Ds in Table 5) served as a starting point for our estimate of DPLT. 
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3.2.2 Validation Cases 
 Two sets of experimental results from the literature, those of Hubbell and McIntire (138) 
and of Alevriadou et al. (139), were selected to validate the model after the platelet reaction rate 
constants for collagen and the platelet diffusivity were estimated using the training cases. In both 
studies, parallel-plate flow chambers with 200 µm slit widths were used, human blood was 
perfused, and type I collagen was the substrate. Thus, the same inlet, outlet, symmetry-plane, and 
surface boundary conditions as applied for the training cases were used, with inlet concentration 
magnitudes altered appropriately, and the Poiseuille flow field was re-computed using the 
prevailing wall shear rate for the corresponding experimental study.  
Hubbell and McIntire (138) measured deposition over 25 mm of collagen after 120 s of 
flow of heparinized (10 U ml-1) whole human blood at wall shear rates of 100, 500, and 1500 s-1; 
the two lower shear rates were simulated here. The 100 s-1 wall shear rate is very near the lower 
limit for Newtonian blood behavior (121); however, as a first approximation, we have continued 
to employ a Poiseuille flow field for this case. For both cases, a grid with the same mesh density 
and 1 mm entrance length as that used in the previous cases, but with the total length extended to 
26 mm, was constructed. This larger grid contained 24,000 mesh points, and a time step of 1.2 s 
was used for the model solution. Alevriadou et al. (139) measured platelet deposition along 10 
mm of collagen after 60 s of flow of citrated whole human blood at a wall shear rate of 1500 s-1. 
By the same reasoning as for the heparin + PPACK training case, the thrombin-related equations 
were not solved for this case, since it was assumed that citrate completely inhibited thrombin 
generation. Additionally, since the geometry of the flow chamber is basically identical to that of 
the chamber used in the training cases, the same unstructured 10,000 node mesh was employed, 
with the first 1 mm again assumed to be a non-adhesive entrance length. A time step of 0.6 s was 
used in the simulations.  
 Table 6 lists the parameters that were altered from the training cases to match the 
experimental conditions for the validation cases. Neither study gave any indication of average 
platelet counts in the perfusates for which platelet deposition results were reported. For this 
reason, the concentrations were adjusted to provide the best fits to the experimental results 
(values in Table 6 are the best fits). Note, however, that this was the only parameter fitting done 
for these cases. Rather than estimating the shear-dependent platelet diffusivity, which we take as 
an adjustable constant, we assumed it to vary linearly with wall shear rate and assumed no 
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augmentation at zero shear, so that the values calculated for the validation cases were 
extrapolated from the best-fit value for the 1000 s-1 wall shear rate of the training cases, given 
below. 
 
Table 6. Parameter values altered for validation cases 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):449-458 (137). Copyright 1999, 
Biomedical Engineering Society. 
 
Parameter Alevriadou et al. Hubbell & McIntire 
[RP]a 2.5 × 108 PLT·ml-1 2.0 × 108 PLT·ml-1 
C0 (for [RP])a 1.5 × 108 PLT·ml-1 1.2 × 108 PLT·ml-1 
Ds N/Ab 1.36 × 10-6 cm2 s-1 (γw = 100 s-1); 
6.80 × 10-6 cm2 s-1 (γw = 500 s-1) 
[H] 0.00 µM 2.09 µMc 
N/A = not applicable for this case 
avalues for [AP] are 5% of these values (to simulate 5% background PLT activation) 
b“large” species (thrombin, prothrombin, ATIII) eliminated from model for this case due to assumption of 
100% thrombin inhibition by citrate 
cfor 10 U ml-1 heparin as used in (138), assuming specific activity 300 U mg-1 and molecular weight 16 kDa 
3.3 Results 
3.3.1 Training Cases 
 The experimental results presented by Wagner and Hubbell (102) and our model 
solutions correspond to 75 s of flow. The platelet-surface and platelet-platelet reaction rate 
constants and platelet diffusivity were adjusted by trial and error as explained in Section 3.2.1 to 
yield the best fit to the data. Figure 8 compares our computational results with the experimental 
data; x = 0 corresponds to the start of the collagen-coated region. This figure shows the axial 
distribution of total platelet deposition, i.e. platelet-surface plus platelet-platelet adhesion, for 
heparin only or heparin + PPACK as the anticoagulant. In Figure 8, the numerically predicted 
deposition values have been averaged over 200 µm intervals. This was done to give 
approximately the same number of data points as in Wagner and Hubbell’s results and to mimic 
the averaging effect of the 4 × 104 µm2 field of view of the fluorescent microscope used to track 
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platelet deposition in that report (102). Best-fit values of kaa = kas = 4.6 × 10-3 cm s-1, krs = 3.7 × 
10-3 cm s-1, and DPLT = 1050·Db,PLT = 1.66 × 10-6 cm2 s-1 for resting and activated platelets gave 
the best agreement with both experimental curves. The computational results reproduce the 
experimental trends in total deposition very well, with the no-thrombin (heparin + PPACK) 
results an especially close match. However, the heparin-only model under-predicts deposition far 
downstream of the inlet, while slightly overestimating values near the inlet. Since no uncertainty 
estimates were given for the platelet deposition values in Wagner and Hubbell’s report (102), it 
is unclear whether our results fall within the range of experimental error. 
 
 
 
Figure 8. Comparison of predicted axial platelet deposition to experimental results of Wagner & Hubbell 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):449-458 (137). Copyright 1999, 
Biomedical Engineering Society. 
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a much slower, almost undetectable rate of increase for the rest of the simulation, likely due to its 
continuing release by platelets being activated in the bulk. While TxA2 concentration also 
continues to increase due to platelet activation, its level is well below its activation threshold 
throughout the simulation. For the case where PPACK was used to completely inhibit thrombin, 
ADP concentration increases initially, due to surface-induced agonist release, then begins to 
decrease rapidly as surface saturation is approached and the bulk-released agonists begin to wash 
away, reaching a relatively negligible value after approximately 30 s of flow. Normalized TxA2 
concentration remains very low throughout. The maximum concentration of TxA2 observed in all 
simulations performed in this chapter was approximately 320 nM, slightly more than half its 
assumed threshold for platelet activation (see Figure 10A, inset). 
 The effect of flow on the spatial distributions of agonists is shown in Figure 10. This 
figure shows normalized concentrations as a function of axial position at two lateral stations, the 
wall (y = 0) and y = 25 µm, taken as representative of the bulk flow, after 75 s of flow. Results 
for the no-thrombin case have been omitted because normalized ADP and TxA2 concentrations 
are negligible at this point in time (see Figure 9B). At the wall, it is clear that thrombin is the 
dominant agonist, with concentrations ranging from approximately 40- to 600-fold greater than 
threshold. ADP concentrations range from about 5- to 8-fold greater than threshold, while levels 
of TxA2, when expressed in terms of its platelet activation potential, are about half the threshold 
level. At a distance of 25 µm from the wall, the ADP trend is the opposite of that at the wall: 
increasing axially, as compared to the steady decrease at the wall. This is likely due to the 
increased convection at this location relative to the wall, as ADP released from platelets 
activated in the bulk at this location will be more rapidly washed downstream. Levels of TxA2 
are negligible. Relative to their respective values at the wall, the level of thrombin at y = 25 µm 
drops approximately two orders of magnitude, whereas the level of ADP decreases by only about 
a factor of four. Some of the decrease in thrombin concentration is because the rate of thrombin 
generation on bulk activated platelets is an order of magnitude lower than that selected for 
platelets activated by both agonists and collagen at the wall. However, given the disparate levels 
of the two agonists at the wall, it is apparent that heparin has a very noticeable effect on bulk 
thrombin concentration. This inhibitory effect was confirmed by numerical experiments 
conducted without heparin (data not shown). In these simulations, ADP and TxA2 concentrations 
were similar to the values shown in Figure 12. However, without heparin, the maximum 
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normalized thrombin concentration at the wall was roughly double the maximum value in the 
simulation with heparin, while at y = 25 µm, the maximum normalized value was nearly two 
orders of magnitude greater than the value for blood with 2 U ml-1 heparin. We note that these 
results agree qualitatively with the simulations of Folie and McIntire (97), who considered four 
agonists (thrombin, ADP, TxA2, and von Willebrand factor) and heparin inhibition. 
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Figure 9. Predicted normalized agonist concentrations vs. time at point 2.5 mm downstream of inlet, training 
cases 
(A) Model with thrombin. (B) Model without thrombin. Reprinted with permission from Sorensen et al., Ann. 
Biomed. Eng., 1999;27(4):449-458 (137). Copyright 1999, Biomedical Engineering Society. 
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Figure 10. Predicted normalized agonist concentrations vs. distance, training case with thrombin 
(A) Concentrations at wall. Inset: Magnified detail of ADP and TxA2 trends. (B) Concentrations 25 µm from wall. 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):449-458 (137). Copyright 1999, 
Biomedical Engineering Society. 
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 Figure 11 shows the sensitivity of the overall model, as measured by predicted platelet 
deposition values, to agonist generation for the model-training simulations. Further confirming 
the dominance of thrombin generation in determining platelet activation, the greatest difference, 
corresponding to approximately a fivefold decrease in peak deposition, is noted between the full 
model (“HEPARIN ONLY”) and the model with thrombin generation turned off to simulate 
PPACK inhibition (“HEPARIN+PPACK”). By contrast, removing TxA2 from the model, either 
with or without thrombin present, makes essentially no difference in the final platelet deposition 
values. The removal of ADP makes a noticeable but relatively small difference in platelet 
deposition for both the thrombin and no-thrombin cases.  
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Figure 11. Sensitivity of predicted platelet deposition to agonist generation 
 
 The axial distributions of activated platelets for the model with and without thrombin at 
the same two locations as above (wall, y = 0, and y = 25 µm) are shown in Figure 12. At the wall, 
trends in activated platelet concentration for the simulation with thrombin mirror trends in 
agonist concentration, with more activated platelets located where agonist concentrations are 
higher. In the bulk flow (y = 25 µm), activated platelet concentration increases with downstream 
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distance due to the concomitant rise in bulk agonists. Despite the much higher concentrations of 
agonists at the wall, the maximum activated platelet concentration there is only approximately 
three times the maximum concentration at y = 25 µm. This is due to rapid consumption of 
activated platelets at the wall by platelet-surface and platelet-platelet adhesion, as modeled by the 
kaa and kas terms. For the no-thrombin case, the concentration at the wall falls off rapidly due to 
deposition, while at y = 25 µm the concentration varies only slightly with axial distance since 
little or no bulk activation occurs in this case. The slight decrease in concentration with 
downstream distance at y = 25 µm is likely due to diffusion of platelets toward the wall to 
replace those consumed by the surface. 
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Figure 12. Predicted activated platelet concentrations vs. distance, training cases 
(A) Model with thrombin. (B) Model without thrombin. Reprinted with permission from Sorensen et al., Ann. 
Biomed. Eng., 1999;27(4):449-458 (137). Copyright 1999, Biomedical Engineering Society. 
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3.3.2 Validation Cases 
 Figure 13 shows model predictions of total platelet deposition versus the experimental 
data of Hubbell and McIntire (138) for 120 s of flow of heparinized whole human blood at wall 
shear rates of 100 and 500 s-1. Extrapolating linearly from the best-fit value DPLT = 1.66 × 10-6 
cm2 s-1 at 1000 s-1 for the training cases and assuming zero enhancement at zero shear, the DPLT 
values used for these cases were 1.66 × 10-7 and 8.33 × 10-7 cm2 s-1, respectively. Aside from the 
inlet platelet concentration, as listed in Table 6, and the flow rate for the velocity solution, no 
other parameters were adjusted from the values obtained for the training cases. Again, the model-
predicted data were averaged to give approximately the same number of points as for the 
experimental data. For &γ w = 100 s-1, the model predicts the shape of the deposition curve and its 
magnitudes fairly well, although, similar to the heparin-only training case, values near the inlet 
are slightly overestimated, while downstream values are underestimated. For &γ w = 500 s-1, on the 
other hand, the shape of the curve is well predicted, but the amount of deposition is generally 
over-predicted, with the error greater than 100% of the experimental values near the inlet and 
decreasing with downstream distance. 
Figure 14 compares the model’s predicted total platelet deposition values to the 
experimental results of Alevriadou et al. (139) for 60 s of flow of whole human blood with 
0.38% wt/vol sodium citrate at a wall shear rate of 1500 s-1. The experimental results represent 
the average of two sets of platelet deposition values given in that report for identical perfusion 
conditions; the model data were spatially averaged to give an equal number of data points. The 
value for shear-dependent platelet diffusivity used for the simulation, interpolated linearly from 
the best-fit training-case value, was 2.49 × 10-6 cm2 s-1. While the predicted values agree roughly 
with the experimental platelet deposition magnitudes near the inlet and outlet, in general the 
model greatly underestimates the measured values, by more than 50% at some locations, and the 
shapes of the two curves do not match at all. Since this case is substantially similar to the no-
thrombin training case, which the model fit extremely well, this result is somewhat puzzling. 
Either the use of citrate, rather than heparin and PPACK, as the anticoagulant, or the higher shear 
rate, has altered the thrombogenic process for this case in a way that the model does not capture 
adequately by assuming the only effect of this anticoagulant is 100% thrombin inhibition. 
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Figure 13. Comparison of predicted axial platelet deposition to experimental results of Hubbell & McIntire 
(A) Wall shear rate = 100 s-1. (B) Wall shear rate = 500 s-1. Reprinted with permission from Sorensen et al., Ann. 
Biomed. Eng., 1999;27(4):449-458 (137). Copyright 1999, Biomedical Engineering Society. 
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Figure 14. Comparison of predicted axial platelet deposition to experimental results of Alevriadou et al. 
Reprinted with permission from Sorensen et al., Ann. Biomed. Eng., 1999;27(4):449-458 (137). Copyright 1999, 
Biomedical Engineering Society. 
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create macroscopic thrombi, which, combined with the low fluid shear rate, would generate 
slow-moving vortices which could be local “hot spots” for agonist generation and platelet 
activation, thereby increasing downstream deposition. Since the model does not capture this 
behavior, it under-predicts downstream deposition. The effects of recirculation zones on agonist 
generation, platelet activation, and downstream deposition are investigated in Chapter 4. 
An additional mechanical aspect of fluid-thrombus interaction which is neglected in our 
model is platelet embolization due to fluid dynamic forces. Our model allows the simulated 
thrombus to continue to grow as long as there are activated platelets available for platelet-platelet 
adhesion and some activated platelets are deposited on the surface to initiate a platelet-platelet 
flux. Furthermore, the process of platelet deposition is not limited by local fluid dynamics. That 
is, there is no part of the model that explicitly accounts for the time scale of platelet interactions 
with each other and the surface. Hence, we have assumed that the reaction rates governing 
agonist generation and platelet activation are not shear-dependent. These would be important 
factors in limiting thrombus growth, since a sufficiently high local shear rate could: 1) prevent a 
passing platelet from having sufficient time to “recognize” a biomaterial surface and adhere to it; 
2) prevent a passing platelet from having enough time to form a sufficiently tight bond with an 
already deposited platelet; or 3) inhibit local agonist generation, thereby decreasing platelet 
activation and activated platelet-platelet adhesion.  
The neglect of these shear-dependent phenomena would provide a reasonable rationale 
for the model’s very poor fit for the 1500 s-1 case, as that high shear rate would be expected to 
inhibit upstream deposition, as well as to create a higher predilection for embolization of weakly 
adherent platelets or platelet aggregates, resulting in a deposition pattern with an irregular, 
“bumpy” shape similar to that of the experimental curve. For the simulation performed at 500 s-1 
with heparin as the anticoagulant, the model’s inability to simulate embolization of platelets from 
thrombi near the entrance might explain the over-fitting of upstream deposition values. However, 
it would not explain the continued over-fitting of downstream values. Additionally, if 
embolization were important at this shear rate, one would expect its effects to be even more 
pronounced for the 1000 s-1 model training case, for which a much better fit was observed. One 
explanation for this discrepancy would be that the shorter perfusion time used in the 1000 s-1 
case (75 s, vs. 120 s for the 500 s-1 case) was not sufficient for thrombolysis or embolization to 
begin.  
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The issues of shear-dependent platelet adhesion and activation reaction rates could be 
addressed by investigating functional kinetic relationships which are more complex than the 
simple first-order ones included in the present model and which take into account the shear-
dependence of the reactions. Addressing the problems of fluid-thrombus interaction is a more 
challenging task. First, simulating thrombus growth would require coupling the mass transport 
equations to the fluid flow equations, necessitating a computationally expensive flow-field 
solution at every iteration of the mass transport equations. Second, a reasonably accurate way of 
introducing the mechanical interactions between the thrombus and the flow field would have to 
be incorporated into both sets of equations. Fogelson (105) has proposed doing this by 
incorporating a fictitious body force into the Navier-Stokes equations which would account for 
deformation of the flow field by thrombus growth. However, simulating embolization would be 
more challenging, since it would require depicting the shape of the thrombus somehow so that 
the fluid dynamic forces on it could be accurately computed, as well as knowing something 
about the fracture mechanics of the thrombus structure. 
Despite the computational complexity of simulating these phenomena, the possibility of 
their inclusion in the model needs to be considered, as they have a direct bearing on the 
usefulness of the simulations as design aids. For example, in attempting to design a relatively 
“thrombosis-proof” device for long-term use, one would need to know when or if thrombus 
growth will stabilize. The present model would only be able to simulate such a phenomenon in a 
particular way: for a given geometry and a sufficiently high shear rate, generated agonists might 
be convected quickly away and would not be able to accumulate in concentrations sufficient to 
cause platelet activation. Combined with a sufficiently low rate of platelet-surface adhesion, this 
would lead to a cessation of deposition, i.e. to the formation of a passive, stable thrombus, but 
not until the surface concentration reached a monolayer level, which would clearly not be 
representative of all biomaterials. The time at which this passivated monolayer was reached 
could be controlled by varying the platelet-surface and platelet-platelet reaction rates, but surface 
deposition would never reach a sub-monolayer steady state. 
Since the concentration of platelets at a reactive surface directly determines the amount 
of platelet deposition in our simulations, solution accuracy depends heavily on the model for 
lateral transport of platelets to the wall. One of the most important deficiencies in the present 
model is its relatively crude method of inducing a near-wall excess. With a true near-wall platelet 
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excess, the RBC-enhanced diffusivity of platelets should be low near the wall, where red cells 
are excluded, and much higher near the core region, where most of the red cells reside. Our 
model uses a single value for diffusivity at all transverse locations, which could help explain its 
predictive error, since the higher diffusivity near the wall gradually destroys the skewed 
concentration profile. Furthermore, red-cell-induced platelet motion should be directed away 
from the channel center regardless of the platelet concentration gradient, whereas an enhanced 
diffusivity requires a gradient to produce platelet motion. Also, platelet diffusivity is currently an 
unknown parameter. It cannot be obtained by direct measurement, and must therefore be 
estimated for each case to be fit. In this chapter, a linear variation of platelet diffusivity with wall 
shear rate was assumed, so that a great deal of the error in our simulations could be attributed to 
a linear fit being the wrong functional form for this parameter. To more accurately reproduce this 
phenomenon, it would be preferable to have a more accurate mathematical description of near-
wall excess. One model of this phenomenon which has shown the ability to reproduce 
experimental platelet concentration profiles for flow in small-diameter tubes is Eckstein’s 
concept of red-cell-induced drift (79, 80). 
Thrombin is clearly the most important platelet agonist in the reported simulations, with 
its concentration at the surface and in the bulk much higher than its threshold for platelet 
activation. This occurs despite the inhibitory effects of heparin concentrations up to 10 U ml-1 
and despite the fact that our platelet-activation rate constant (Equation 3) weights threshold-
normalized concentrations of all agonists equally. It is possible that thrombin’s dominance is due 
to the agonist generation model we employed, which allows the rate of thrombin production to 
increase linearly with platelet deposition and imposes no upper bound on this rate. Although a 
linear increase in thrombin generation with platelet concentration was shown by Rosing et al. 
(119), the studies were conducted using platelets suspended in buffer medium, rather than whole 
blood, thereby removing the inhibitory effects of various plasma proteins (e.g. C and S). The key 
contributing factor in thrombin’s dominance, however, is likely our choice of an increased rate of 
thrombin generation at the reactive surface relative to the bulk flow; such an increase is 
consistent with the behavior of platelets activated by both collagen and thrombin vs. thrombin 
alone (119).  
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The agonist ADP was also shown to be an important mediator of platelet activation in 
these simulations. Its concentration was also generally supra-threshold throughout the domain, 
with normalized levels 25 µm from the wall comparable to those of thrombin. TxA2 
concentrations were generally well below the platelet activation threshold we proposed. 
Consequently, this species did not play a significant role in platelet activation in our simulations. 
This is consistent with the experimental results of Turner et al. (141), who observed that aspirin, 
which inhibits platelets’ ability to synthesize TxA2, failed to decrease platelet deposition on type 
I collagen and had very little effect on platelet aggregation under flowing conditions. It is notable 
that our results were obtained despite the fact that the model gave platelets an inexhaustible 
capacity to generate this agonist. However, it is possible that our simplistic model of agonist 
interaction may not correctly capture the contribution of TxA2, or that this agonist might 
participate in other important thrombogenic processes aside from platelet activation. Wagner and 
Hubbell (142) postulated a role for TxA2 in thrombus stabilization, observing that administration 
of aspirin reduced platelet-platelet adhesion on type I collagen. However, statistically significant 
reductions in deposition for aspirinized versus control blood were only obtained at longer flow 
times than those simulated here. 
3.5 Conclusions 
 In this chapter, the model of platelet-mediated thrombogenesis proposed in Chapter 2 has 
been calibrated against several sets of experimental results for platelet deposition on type I 
collagen under simple parallel-plate (Poiseuille) flow. In general, the predicted results 
demonstrate good agreement with the experimental trends in spite of many unmodeled effects, 
such as fluid-thrombus interactions. Based on a calibration case with a wall shear rate of 1000 s-1 
and only heparin as the anticoagulant, the model was able to fit cases with: 1) PPACK added as 
the anticoagulant; and 2) a five-fold increase of heparin concentration, a wall shear rate lowered 
by a factor of two or ten, a domain 2.5 times as long, and an almost two-fold longer perfusion 
time. We believe this indicates, at least in a preliminary fashion, the robustness of the model for 
this range of conditions. However, for the case with a higher wall shear rate (1500 s-1) and 
sodium citrate as the anticoagulant, the model was not as accurate in predicting deposition along 
the length of the perfusion channel. This could be due to a shear-dependent decrease in platelet 
adhesion or agonist generation kinetics which only becomes apparent at shear rates greater than 
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1000 s-1, or to a fluid-dynamic mechanical effect such as embolization, all of which are neglected 
in the present model. Alternatively, it could be that citrate’s effects on thrombogenesis are more 
extensive than thrombin inhibition alone. Either way, it is apparent that the citrate case has 
revealed that the model was not capturing all of the physics of the system being simulated. 
As for the model’s behavior with regard to agonists, the distinctly different platelet 
deposition patterns observed when thrombin is present versus when it is inhibited can be 
explained by considering the ways agonist generation and platelet activation are simulated. 
Without thrombin, the rate of agonist generation at the surface will depend on: 1) the rate at 
which resting platelets adhere, activate, and degranulate, releasing ADP; and 2) the rate at which 
activated, surface-bound platelets synthesize TxA2. This surface-generated agonist production 
will induce platelet activation and agonist generation in the bulk fluid. However, our model only 
allows resting platelets to adhere to the exposed surface, not to other deposited platelets. Also, 
the surface deposition rate goes to zero at the surface saturation limit (see Equations 11-12). 
Thus, after surface saturation, only activated platelet-platelet adhesion can occur, and the only 
sources of agonist generation will be TxA2 synthesis by activated platelets (at the surface and in 
the bulk) and ADP release by activating platelets (in the bulk only). At a high shear rate such as 
that used in the model-training simulations, the bulk agonists will be quickly convected away by 
the flow. Despite the worst-case assumption that activated platelets have an inexhaustible 
capacity for TxA2 synthesis, Figure 9 shows that levels of this agonist remain approximately a 
factor of two below the level required for platelet activation throughout our simulations. Thus, in 
the absence of thrombin, the model predicts minimal platelet activation, and therefore minimal 
activated platelet-platelet adhesion occurs once the surface-saturation limit is reached. 
The rate of thrombin generation, on the other hand, is proportional to local platelet 
concentration, either on the surface or in the bulk. Therefore, when thrombin is not completely 
inhibited, platelets will adhere to the collagen surface and become activated, generating ADP and 
TxA2 and providing a phospholipid surface for additional thrombin production. This will lead to 
a higher bulk concentration of agonists, causing increased platelet activation and deposition. 
After the surface saturation limit is reached, activated platelet-platelet adhesion continues, which 
provides even more phospholipid surface for thrombin generation, thereby leading to increased 
thrombin production and further bulk activation. Thus, thrombin-mediated platelet activation and 
deposition behaves as a positive-feedback system. Theoretically, TxA2 synthesis should have a 
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similar effect, since its rate is also proportional to the total concentration of activated platelets, 
both at the surface and in the bulk flow. However, the sub-threshold levels of TxA2 found in our 
simulations prevent it from making a significant contribution to the rate of platelet activation. 
Conversely, in the no-thrombin case surface saturation leads to a negative-feedback cascade, in 
which increased platelet deposition results in more rapid saturation, which induces decreased 
ADP generation, which, combined with the washing effect of the high-shear flow and the low 
rate of TxA2 synthesis, eventually leads to a cessation of new platelet deposition. 
As discussed in Chapter 2, the model is applicable to a much wider range of conditions 
than the simple flows and single biomaterial studied in this chapter. In Chapter 4, the robustness 
of the model is further tested by using it to attempt to predict platelet deposition onto collagen 
from disturbed, fully two-dimensional flows. 
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4.0 MODEL VALIDATION: TWO-DIMENSIONAL DISTURBED FLOW 
“Something is happening here and you don’t know what it is 
Do you, Mr. Jones?” 
  -Bob Dylan, “Ballad of a Thin Man” 
4.1 Introduction 
 In this chapter, the validation efforts begun in Chapter 3 continue. Here, we apply the 
model to flow in two different axisymmetric geometries, a tubular expansion and a stenosis, for 
which experimental measurements of platelet deposition onto type I collagen are available from 
the literature. For the tubular expansion cases, the in vitro experiments were conducted to 
minimize platelet aggregation and release. Additionally, results are available at several Reynolds 
numbers (Re = ρ·U·dT/µ, where U is mean velocity and dT is tube diameter) and at both 0% and 
20% hematocrit (Hct). These cases are therefore ideal for testing the platelet-transport-related 
portions of the model, especially our methods of modeling RBC-enhanced platelet motion. For 
the stenotic geometry, non-anticoagulated blood was used in a baboon ex vivo shunt. Thus these 
two sets of cases allow us to test the effects of disturbed flow both in the presence and absence of 
agonists on predicted platelet activation and deposition. Furthermore, the model predictions for 
the stenosis cases can be compared to those of Wootton et al. (104), who simulated deposition in 
this geometry using a one-parameter steady-state model. 
4.2 Methods 
 For both sets of cases considered in this chapter, closed-form solutions to the Navier-
Stokes equations (Equations 16 and 17) are unavailable. Thus, it was necessary to solve these 
equations numerically. A finite volume solver built on top of the existing convection-diffusion 
code was developed for this purpose. Following the method of Prakash and Patankar (143), a 
two-dimensional, pressure-based, node-centered computational fluid dynamics (CFD) code for 
unstructured meshes was written. This code is capable of solving the steady or unsteady Navier-
Stokes equations, i.e., incompressible, laminar flow of a Newtonian fluid is assumed. To 
accelerate convergence of the pressure equation, an algebraic multigrid solver (144) was also 
developed. The combined CFD and convection-diffusion code was then extended from Cartesian 
to polar axisymmetric coordinates following the technique of Masson et al. (145). As before, 
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meshes are generated using the freeware program Triangle. Additionally, we continue to assume 
the Navier-Stokes equations can be decoupled from the species conservation equations of the 
thrombosis model, allowing us to solve for a steady-state flow field. The CFD solver was 
validated using benchmark cases from the literature; these results are presented in the Appendix.  
4.2.1 Axisymmetric Tubular Expansion  
 Simulations for the case of a sudden expansion of flow in a tube were performed, 
corresponding to the experimental results of Karino and Goldsmith (59). In their studies, 
suspensions of platelets and RBCs (at 0% and 20% Hct) were perfused (at Re = 29 – 113, based 
on upstream tube diameter) through an axisymmetric expansion made from a 0.917 mm i.d. 
stainless steel tube fit into a 3 mm i.d. collagen-coated glass tube. Experiments were performed 
for both one and three minutes at 0% Hct and for one minute at 20% Hct. To test the effect of 
hematocrit on the model’s ability to predict platelet transport, we first simulated results for both 
0% and 20% Hct for one minute of perfusion at Re = 38. The best-fit model parameters from 
these simulations were then used to predict deposition for the additional Reynolds numbers and 
perfusion time. 
 Since the suspensions used in these experiments contained no clotting factors or adhesive 
proteins, and since apyrase was added to inhibit platelet-released ADP, it was assumed no 
agonist activity would take place. Therefore, all platelet agonists and clotting factors were 
eliminated from the model, leaving resting and activated platelets as the only species simulated. 
The reaction coefficient governing platelet-platelet aggregation (kaa, see Equation 6) was also set 
to zero, since aggregation should be essentially negligible in the absence of fibrinogen and vWF. 
Furthermore, Karino and Goldsmith (59) specifically attempted to minimize aggregation through 
their choice of perfusion times; very little platelet-platelet contact was observed in their 
experiments. 
 Model parameters specific to these cases are listed in Table 7; all other parameters are as 
given in Tables 3-4. As previously, the surface activation parameter θ has been set to one for all 
cases, reflecting the assumption that all platelets contacting the collagen surface are activated by 
it. Viscosity µ was assumed constant at each hematocrit. Its values at 0% and 20% Hct were 
calculated from the Reynolds number equation, Re = ρ·U·dT/µ,  using the mean velocities given 
by Karino and Goldsmith at Re = 38, assuming a density of 1.05 g cm-3. 
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 The computational domain consisted of an axisymmetric cross-section of the cylindrical 
geometry 25 mm in length and with a 1.5 mm inner radius, corresponding to the larger tube. This 
length was sufficient to ensure fully developed flow at the outlet for all Reynolds numbers in the 
CFD simulations. The inlet was taken as the leading edge of the sudden expansion (the axial 
position where the 0.917 mm i.d. tube enters the 3 mm i.d. tube).  
 For the flow field solution, a fully developed parabolic velocity profile was assumed at 
the inlet, with U equal to the average velocity reported by Karino and Goldsmith for each 
Reynolds number and hematocrit. No slip (uz = ur = 0) was assumed at solid walls, and the 
symmetry condition was enforced at the centerline r = 0 by the imposition of the conditions 
0/ == rz uru ∂∂ . At the outlet (z = 25 mm), fully-developed flow ( 0// == zuzu rz ∂∂∂∂ ) 
was assumed. For pressure BCs, a zero normal gradient was imposed at all boundaries, and 
pressure was fixed at zero in the lower right corner of the domain (r = 0, z = 25 mm). 
 For the platelet transport simulations, most boundary conditions were identical to 
previous cases, with the adhesion fluxes given by Equations 5 and 6 governing platelet reactions 
at the collagen-coated wall. Symmetry about r = 0 was enforced with BC 0/][ =rC i ∂∂ . Fully 
developed concentration profiles ( 0/][ =zC i ∂∂ ) were assumed at the outlet (z = 25 mm). In 
the interior domain, the initial condition for all species was [Ci] = 0. 
 
Table 7. Specific parameter values for tubular expansion cases 
 
Parameter 0% Hct 20% Hct Equations
[RP] 4.5 × 108 PLT·ml-1 4.5 × 108 PLT·ml-1 1,5,7a 
C0 (for [RP]) N/A 2.7 × 108 PLT·ml-1 19a 
M∞ 7.00 × 105 - 7.00 × 106 PLT·cm-2 7.00 × 105 - 7.00 × 106  PLT·cm-2 6,11b 
DPLT 1.58 × 10-9 cm2 s-1 Equations 22-23 -- 
θ 1.00 1.00 7,13-15 
µ 1.10× 10-2 g cm-1 s-1 2.30 × 10-2 g cm-1 s-1 16 
ρ 1.05 g cm-3 1.05 g cm-3 16 
N/A = not applicable for this case 
avalues for [AP] are 1/9 of this value (for background activation = 10% of total PLT concentration)  
btwo values of this parameter were used; see text for explanation 
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 Because there was no RBC enhancement effect for the 0% Hct cases, the platelet 
diffusivity was set to its Brownian value, and the inlet condition was a uniform concentration 
profile.  
 To simulate RBC-enhanced platelet transport for the 20% Hct cases, the quadratic wall-
skewed profile (Equation 19) was used as the inlet boundary condition for resting and activated 
platelets, as in Chapter 3. However, for both platelets and large species, the constant shear-
enhancement factors used for the parallel-plate simulations were replaced with the enhanced 
diffusivity proposed by Zydney and Colton (77). The relationship they obtained is: 
( ) ( ) 8.02 12/15.0 HctHctdD rbcs −⋅⋅⋅⋅= γ&  [22] 
,, sibi DDD +=  [23] 
where Hct represents the bulk average hematocrit (taken as constant) expressed as a decimal, 
rather than a percent. Zydney and Colton suggest setting drbc to the RBC major diameter, rather 
than the equivalent spherical diameter. Since Karino and Goldsmith used human blood, the 
appropriate value is approximately drbc = 8 µm. The Zydney and Colton formula was chosen 
over others such as the Keller correlation of Equation 18 (78) because it was based on a wide 
range of experimental results, rather than a purely theoretical treatment, and because it accounts 
for the effects of both hematocrit and shear rate. Additionally, using an empirical relationship 
instead of treating DPLT an independent model parameter, as we did for the platelet diffusivity in 
Chapters 2 and 3, reduces the number of undetermined parameters by one, improving the 
predictive capacity of the model and reducing the ambiguity of its parameters. 
 Thus far, we have either estimated a constant diffusion-enhancement factor as a model 
parameter or calculated it by using the wall shear rate -- which is constant for the parallel-plate 
Poiseuille flow fields considered in Chapters 2 and 3 -- in Equation 18, rather than the local 
shear rate, which varies linearly as a function of y. For the current geometry, the wall shear rate 
will vary spatially, making it impossible to calculate a single enhancement factor for the flow 
field based on that variable. Thus, in the current simulations, we retain the local shear rate in 
Equation 22, meaning that platelet diffusivity can vary with both z and r.  
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 The level of background platelet activation was increased from the 5% assumed 
previously to a value of 10%. Based on Karino and Goldsmith’s total platelet concentrations 
(59), this corresponds to 5 × 107 PLT·ml-1. This value was increased based on the extensive 
separation and washing procedures used to prepare platelets for these studies, which would 
inevitably cause increased platelet activation.  
 Additionally, the surface saturation parameter M∞ was altered from the value assumed in 
Chapters 2 and 3. Two values of M∞ were tried: the previously assumed monolayer concentration 
(7.00 × 106 PLT·cm-2) and 10% of this value. This parameter was varied in an attempt to mimic 
experimental conditions reported by Karino and Goldsmith, who observed microscopically that 
“as little as 5%” of the surface of the glass tubes they used were coated with collagen fibrils. 
Since there were no adhesive proteins in their suspensions and since they pre-adsorbed the glass 
surface with non-adhesive albumin, very little platelet deposition was observed on the glass 
interstices between fibrils (59). However, they measured deposition values greater than 5% of 
our assumed monolayer value. This motivated our somewhat arbitrary choice of an “effective 
saturation” of 10% of a monolayer. However, in our pilot studies, we used the standard 
monolayer value. This was done to keep M∞ a fixed parameter across all our simulations; the 
underlying physical assumption was that at longer times than those studied, platelets would 
spread or be translocated by fluid shear stresses, eventually resulting in a monolayer covering the 
glass regions of the slide. It was assumed that altering the values of krs and kas appropriately 
would control this transient behavior. In the results presented below, the M∞ value used for a 
particular case is given. 
 In summary, the undetermined model parameters for these cases are the reaction 
coefficients krs and kas, governing platelet-surface adhesion for resting and activated platelets, 
respectively. Since these coefficients are assumed to be functions of both surface and blood 
protein composition, it was necessary to re-fit them for the protein-free suspensions considered 
here, rather than using the best-fit values for type I collagen in contact with whole blood 
determined in Chapter 3. Separate trial-and-error fits were conducted for the 0% and 20% Hct 
cases at Re = 38, perfusion time = 1 minute. The best fits at each hematocrit were then applied to 
the other hematocrit case to see if either set of parameters could fit both data sets. Then, the best-
fit parameters for each hematocrit level were used to simulate additional Reynolds number 
and/or perfusion time cases at that hematocrit. 
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 Due to our assumption that the flow and concentration fields can be decoupled, the 
steady-state Navier-Stokes equations were solved to obtain the flow field. The unsteady 
convection-diffusion equations were then solved using a time step of 0.6 s for both one- and 
three-minute perfusion times. Since mesh-dependence effects play a large role in the results for 
these cases, that issue is discussed separately. 
4.2.2 Axisymmetric Stenosis 
 The flow within an axisymmetric stenosis was simulated to correspond to the 
experimental results used by Wootton et al. (104) to validate their computational model of acute 
platelet deposition and vessel occlusion in the presence of disturbed flow. Collagen-coated 
ePTFE grafts, 4 mm in diameter, with sinusoidal stenoses of 50%, 75%, and 90% area reduction 
were inserted into baboons in an ex vivo shunt preparation. Platelet deposition at several time 
points was assessed with a gamma camera, which gave average deposition over five regions of 
interest (ROIs) covering the 2.4 cm long collagen-coated portion of the shunt. The Reynolds 
number based on upstream velocity and diameter was estimated to be 160. Wootton et al. 
simulated these experiments using a one-parameter model whose only undetermined variable 
was a lumped mass-transfer coefficient governing platelet activation, aggregation, and adhesion 
at the reactive wall. This model also used the enhanced diffusivity of Zydney and Colton (77) 
and incorporated near-wall excess by setting the uniform inlet concentration to twice the normal 
bulk value. Their normalized measure of predicted platelet deposition was the steady-state 
maximum platelet “accumulation velocity”, Vmax (units: cm s-1). Re-written in terms of the 
corresponding variables in our model, this is given by:  
∫∫ +∆⋅⋅= ∞ dtdAJJtACV arROI )(
1
max , [24] 
where C∞ is free-stream platelet concentration used in the Wootton model, AROI is the area of the 
region of interest, ∆t is the total time of the simulation, and Jr and Ja are the resting and activated 
platelet-surface fluxes, given by Equations 5 and 6. The predicted values for each ROI were 
compared to the average rate of accumulation derived from gamma camera measurements taken 
between 10 and 25 minutes after the start of perfusion, during which time the rate of platelet 
accumulation was approximately constant (104).  
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 Due to the very long computing times for these cases, we chose to simulate the results for 
only the 50% and 75% stenoses. Baboon blood was assumed to be sufficiently similar to human 
blood that the kinetic parameters used for the Poiseuille flow collagen training cases could be 
employed. So, with the exception of those parameters listed in Table 8, the values listed in 
Tables 3-5 were applied unaltered. The basis for this assumption is the experimental studies of 
Grabowski et al. (146), which found no significant difference in platelet deposition onto the 
biomaterial Cuprophan (cellulose hydrate) between baboon and human blood. The values 
selected for [RP] and [AP] correspond to the average total platelet count measured by Schneider 
et al. for baboons in similar shunt experiments (147); following Wootton et al., appropriate 
baboon values of drbc = 8.8 µm and Hct = 0.35 were used in Equation 22 to compute Ds. Wootton 
et al. chose twice the bulk-average platelet concentration as their uniform inlet boundary 
condition rather than attempting to impose a non-uniform near-wall excess profile. For this 
reason, the value of C∞ we used in Equation 24 corresponded to 2·([AP] + [RP]) = 7.0 × 108 
PLT·ml-1 so that the Vmax value computed from our platelet deposition results would be scaled by 
the same factor used by those authors. Since non-anticoagulated whole blood flowed through the 
shunts, the heparin concentration was set to zero, and the full seven-equation model was solved. 
The values of µ and ρ used in the CFD solution correspond to the values used by Wootton et al. 
(104) in their simulations. 
 Additionally, we assumed that the best-fit platelet-surface and platelet-platelet reaction 
coefficients from the Poiseuille flow collagen training cases could be used. These were krs = 3.7 
× 10-3 cm s-1, kas = kaa = 4.6 × 10-3 cm s-1. These values are very close to the best-fit value of 5.0 
× 10-3 cm s-1 that Wootton et al. obtained for the single surface reaction parameter used in their 
model (104). There was therefore no parameter re-fitting done for these cases, representing a 
very stringent test of the applicability of the model   
 Boundary conditions for the collagen-coated region of the shunt were identical to those 
described in the previous section for the 20% Hct tubular expansion cases, and a zero initial 
condition was applied for all seven species in the interior of the domain. A 6 mm long non-
adhesive entrance region was added to the inlet of the domain to account for the silicon rubber 
tubing used in the experiments. The steady-state flow field was computed using the CFD code 
and then input into the unsteady convection-diffusion problem. To ensure fully developed flow at 
the outlet, straight 4 mm diameter tubes of 45 mm (50% stenosis) and 56 mm (75% stenosis) 
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length were added beyond the collagen-coated region. In the platelet deposition simulations, 
these zones represented the non-adhesive silicone rubber tubing; hence a zero-flux boundary 
condition was applied at the walls. To minimize the computational cost of the unsteady platelet 
deposition simulations, solutions corresponding to a time of 10 minutes were run. This time 
represents the very start of the experimental window during which a constant platelet 
accumulation rate was observed by Wootton et al. (104). The maximum time step used in these 
simulations was 6 s. Due to the extremely long computing times needed for these cases (several 
weeks, depending on processor used and load), mesh independence studies were not conducted. 
The meshes used contained 79144 nodes for the 50% stenosis and 82168 nodes for the 75% 
stenosis. In the 24 mm long collagen-coated region, a 50 µm wide zone extending out from the 
wall was filled with elements of approximately the same area as those placed in the near-wall 
zone of the 77612 node grid used for the tubular expansion cases (discussed below). 
 
Table 8. Specific parameter values for axisymmetric stenosis cases 
 
Parameter Value Equations
[RP] 3.15 × 108 PLT·ml-1 1,5,7a 
C0 (for [RP]) 1.02 × 108 PLT·ml-1 19a 
[H] 0.00 µM 4 
Ds Equation 22 --b 
µ 3.50× 10-2 g cm-1 s-1 16 
ρ 1.06 g cm-3 16 
N/A = not applicable for this case 
avalues for [AP] are 1/9 of this value (for background activation = 10% of total PLT concentration)  
bused to correct diffusivities of “large” species (thrombin, prothrombin, ATIII) and PLTs for effect of red 
blood cells in shear flow; DPLT is given by Equation 23 
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4.3 Results 
4.3.1 Axisymmetric Tubular Expansion 
a) Baseline case 1: 0% Hct, Re = 38 
 Figure 15 shows fluid shear rate along the tube wall (r = 1.5 mm) as a function of 
unstructured mesh density for the 0% Hct, Re = 38 case. In the legend, “non-uniform” and 
“uniform near-wall” refer to the way the mesh was refined to resolve the boundary layer. The 
former method involved an option in the grid generation software by which the area of all 
elements touching a surface could be increased or decreased. While this method did result in a 
high concentration of elements near the wall, it also interspersed them very non-uniformly with 
large elements, as illustrated in Figure 16A. The latter approach involved creating a 50 µm 
domain near the upper wall which was uniformly filled with much smaller elements than were 
used in the rest of the domain. The results of this approach are illustrated for the 23630 node 
mesh in Figure 16B.  
 Neither refinement method nor grid density affected the CFD results, which are mesh-
independent at all grid resolutions tested. Figure 17 shows velocity profiles and streamlines in a 
cross-section extending from r = 0 to r = 1.5 mm, i.e. the upper half of the tube. The plot is 
truncated at z = 11 mm, after fully-developed flow has been re-established. Figure 17A illustrates 
the velocity profiles at the inlet (z = 0), inside the vortex (z = 2.5 mm) and in the fully-developed 
region (z = 10 mm). Figure 17B, which plots streamlines, illustrates the size and extent of the 
separated-flow region caused by the sudden expansion. The recirculation zone begins at the inlet 
and extends approximately 4.4 mm (~ 1.5 diameters) downstream, with fully-developed flow 
reestablished approximately 2.5 – 3 mm (~ 1 diameter) beyond the flow reattachment point. In 
their studies, Karino and Goldsmith’s microscopic observations yielded 4.4 mm as the distance 
from the expansion to the reattachment point for this case (59); the close agreement between this 
measurement and the CFD result serves as further validation of the solver. 
 To predict the experimental platelet deposition values, the surface reaction rate constants 
krs and kas were adjusted by trial and error to give the best fit to the data. The first attempts at 
doing this were made using the 25984 node grid with a non-uniform near-wall mesh (Figure 
16A). The saturation parameter M∞ was set to 7.0 × 106 PLT cm-2 for these trials. Best-fit 
parameter values were krs = 3.94 × 10-6 cm s-1 and kas = 4.89 × 10-6 cm s-1, an almost thousand-
fold reduction relative to the whole blood-collagen cases simulated in Chapter 3. 
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Figure 15. Wall shear rate vs. axial distance, effect of grid density: 0% Hct, Re = 38 tubular expansion case 
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Figure 16. Comparison of near-wall meshes used for tubular expansion cases 
(A) 25984 node mesh with non-uniform near-wall refinement. (B) 23630 node mesh with uniform near-wall 
refinement. 
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Figure 17. Velocity profiles and streamlines: 0% Hct, Re = 38 tubular expansion case 
(A) Velocity profiles at z = 0, 2.5, and 10 mm. (B) Streamlines. 
 
 To verify grid independence of this result, the case was re-run on the 77612 node, 
uniformly-refined mesh, which revealed the surprising behavior shown in Figure 18. In the 
figure, the model results have been averaged to correspond to the experimental grid. Fairly good 
agreement between the experiment and both sets of predictions is observed in the recirculation 
zone and near the reattachment point. However, it was necessary to increase the platelet-surface 
reaction coefficients by more than 50% for the fine-grid case (to krs = 6.2 × 10-6 and kas = 8.0 × 
10-6 cm s-1) to obtain roughly the same agreement between predicted and measured deposition 
values in this region. The second item of interest is the steep drop-off in platelet deposition 
downstream of the reattachment point, within the fully-developed region of the flow. While the 
coarse-grid results decay noticeably relative to the experimental values, the fine-grid values drop 
much more rapidly, with deposition falling almost to zero beyond z = 14 mm.  
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Figure 18. Initial model predictions of platelet deposition: 0% Hct, Re = 38 tubular expansion case 
“SAT” refers to the surface saturation parameter M∞. 
 
 Additional insight into the differences between the coarse- and fine-grid model results 
can be obtained by considering platelet concentrations at the wall, which are shown in Figure 19. 
This figure also shows the results of a simulation run on the fine grid in which krs = kas = 0, i.e. 
no platelet-surface reaction was allowed, so that unsteady platelet transport was the only 
mechanism simulated. After 60 s simulation time, the concentrations at the wall on the coarse 
mesh have reached a virtually constant value everywhere. In contrast, on the fine grid, very few 
platelets have reached the wall in the downstream, fully-developed-flow region. The nearly 
identical results obtained for the cases with and without surface reaction indicate that the 
perfusion time of the simulation is insufficient for platelets to be transported to the wall. 
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Figure 19. Predicted platelet concentrations at wall: 0% Hct, Re = 38 tubular expansion case 
“+adhesion”: PLT-surface adhesion allowed; “-adhesion”: no PLT-surface adhesion allowed. 
 
 To examine the effect of platelet diffusion on the near-wall downstream depletion 
observed on the 77612 node mesh, additional numerical studies were carried out with this case, 
again at M∞ = 7.0 × 106 PLT cm-2 and krs = 6.2 × 10-6, kas = 8.0 × 10-6 cm s-1. For these 
simulations, the Brownian diffusivity of platelets in the 0% Hct suspension was augmented by an 
RBC-enhancement-like, additive shear-dependent factor Ds = a0·γ& , where a0 is a constant. The 
values chosen for a0 ranged from 10-10 to 10-8 cm2, which represent factors ranging from ~10× 
less to ~10× greater than the RBC enhancement value of 4.02 × 10-9 cm2 computed using 
Equation 22 for the 20% Hct case. The results of these studies are shown in Figure 20, where the 
curve for no enhancement corresponds to the original model. Very little change in platelet 
deposition values is observed until a0 reaches 10-8 cm2. The effect of the enhancement is to 
increase deposition values everywhere along the tube surface. This results in no improvement in 
agreement between model and simulation as the augmentation is increased, since deposition in 
the recirculation zone rises too high, while the values computed for the downstream region are 
still too low relative to the experimental results. 
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Figure 20. Effect of platelet diffusivity on predicted deposition: 0% Hct, Re = 38 tubular expansion case 
 
 Next, additional grid-sensitivity studies were conducted by re-running this case on three 
additional grids, holding krs and kas fixed at the best-fit values from the 77612 node mesh. An M∞ 
value of 7.0 × 106 PLT cm-2 was used. Figure 21 shows the results of these numerical 
experiments; Karino & Goldsmith’s experimental results are omitted for clarity. It should be 
noted here that the differences in mesh density among the uniformly refined grids are entirely 
due to refinement of the 50 µm near-wall region. The downstream depletion effect is observed 
for all four such grids, despite an approximately four-fold variation in near-wall cell size. More 
importantly, although it appears the results grow closer to those of the previous grid at each level 
of refinement, true mesh independence is not achieved, despite the heavily refined grids used for 
the 77612 and 123691 node cases. 
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Figure 21. Effect of mesh density on predicted platelet deposition: 0% Hct, Re=38 tubular expansion case 
 
 Ideally, these grid dependence studies would have been performed prior to conducting 
the final simulations for the cases discussed subsequently. Unfortunately, however, because of 
the grid-independent results observed for the CFD solution, it had been assumed that the 77612 
node mesh was “refined enough”, and all of the remaining platelet deposition simulations had 
been conducted using that grid. However, given the following considerations, we believe the 
value of these simulations is not completely lost. First, there is the issue of time. A 60 s case at 
0% Hct could typically be completed on the 77612 node mesh in two to four days on a 1 GHz 
Athlon machine, depending on processor load. The 123691 node case shown in Figure 21 
required more than a week on the same CPU. Second, given the slow convergence to grid 
independence seen in Figure 21, it is likely that even the 123691 node mesh is under-refined, 
perhaps very much so, so that a much finer mesh, requiring even more CPU time, would likely 
be necessary to fully resolve this problem. Third, the results for all of the uniformly refined 
meshes are very similar in shape and in the relative heights of the primary and secondary 
deposition peaks. This, combined with the somewhat similar deposition magnitudes seen in 
Figure 18 between the non-uniformly-refined 25984 node grid and the 77612 uniformly refined 
grid when the reaction coefficients are adjusted, likely implies that similar deposition levels 
could be achieved on all grids by increasing krs and kas as the level of grid refinement increases. 
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What this means is that the krs and kas values reported in what follows for the 77612 node mesh 
must be taken as very approximate values which likely underestimate the “true” mesh-
independent magnitudes of these parameters. Finally, judging by the results of Figure 21, it 
appears highly unlikely that increasing mesh density will improve agreement between model 
predictions and experiments or reveal any new behavior of the model that is not apparent on the 
77612 node mesh.  
 To see if a discrepancy between modeled and experimental conditions could be 
contributing to the discrepancies between predicted and measured deposition, some of the key 
underlying assumptions being used for these simulations were examined. As noted above, up to 
this point, the saturation parameter M∞ had been set to an assumed monolayer value, 7.0 × 106 
PLT cm-2. Based on the justification given in Section 4.2.1, this parameter was reduced by a 
factor of 10 to account for the sparse distribution of collagen fibrils on Karino and Goldsmith’s 
tubes. It was believed this change might improve the model’s predictive ability because a lower 
M∞ would decrease the platelet flux more rapidly in the upstream regions where the peaks are 
seen (see Equations 5-6). A decreased upstream flux would presumably allow more platelets to 
be transported downstream, possibly correcting the near-wall depletion effect observed there. In 
conjunction with this parameter change, the possibility that only activated platelets would adhere 
to the collagen surface in the absence of plasma proteins was investigated. For these cases, krs 
was held at zero and M∞ at 7.0 × 105 PLT cm-2 while kas was varied to give the best fit to the data.  
 A comparison of best-fit values on the 77612 node mesh is given in Figure 22. The first 
case (filled triangles), for which M∞ = 7.0 × 106 PLT cm-2, krs = 6.2 × 10-6 cm s-1, kas = 8.0 × 10-6 
cm s-1, reproduces the best-fit results from Figure 17. The open circles are predicted deposition 
values for the case wherein M∞ = 7.0 × 105 PLT cm-2, for which the best-fit values are krs = 4.0 × 
10-6 cm s-1 and kas = 4.0 × 10-5 cm s-1. The deposition magnitudes are nearly identical to those for 
the initial case. Finally, the large X’s represent the case with reduced M∞ and no resting platelet-
surface adhesion, obtained using a best-fit kas of 1.35 × 10-4 cm s-1. The same trend in deposition 
is observed as for the other two cases, but deposition on either side of the reattachment point is 
slightly reduced. 
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Figure 22. Comparison of best-fit final model predictions to experimentally measured platelet deposition: 0% 
Hct, Re = 38 tubular expansion case 
“SAT” refers to the surface saturation parameter M∞. 
 
 Finally, since the “best-fit” values we report are obtained by trial and error, it is helpful to 
give an idea of the sensitivity of the model to changes in the fit parameters krs and kas. This is 
shown in Figure 23 for the 77612 node mesh and M∞ = 7.0 × 105 PLT cm-2. Reducing krs by 80% 
with kas fixed reduces peak deposition by approximately 60%. Subsequently halving both krs and 
kas reduces peak values by about another 35%. Finally, a one-unit change in both parameters, 
corresponding to a 20% reduction in krs and a 25% reduction in kas, further reduces deposition by 
approximately 20%. Thus, the sensitivities of the two parameters appear to be within the same 
order of magnitude. 
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Figure 23. Sensitivity of predicted deposition to krs and kas: 0% Hct, Re = 38 tubular expansion case 
 
b) Baseline case 2: 20% Hct, Re = 38 
 CFD results for the case of 20% Hct, Re = 38 are shown in Figures 24 and 25 for the 
77612 node mesh, which has been used for all cases discussed in the remainder of this section. 
Although the shear rate everywhere along the wall is well below the ~200 s-1 limit for Newtonian 
blood flow (121), non-Newtonian effects should not be as large a concern here as they would be 
in whole blood because the experimental perfusate was free of fibrinogen, so that there should be 
no RBC rouleaux formed. Due to dynamic similarity with the 0% Hct case, the streamline plot of 
Figure 25B is basically identical to Figure 17B. Again, the CFD-predicted recirculation zone 
extends approximately 4.4 mm downstream from the expansion, with fully developed flow re-
established approximately 7.5 – 8.0 mm downstream of the inlet. For this experiment, Karino 
and Goldsmith measured the length of the separated flow region as 5.0 mm. No explanation of 
how this measurement was made or the degree of uncertainty in it is given in their paper, so it is 
difficult to determine how large a departure from the computed results this represents. 
Comparing Figures 25A and 17A, the velocity profiles are similar, although, as expected the 
magnitudes are higher at 20% Hct due to the higher average velocity needed to obtain the same 
Reynolds number for the higher viscosity of the suspension at this hematocrit. 
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Figure 24. Wall shear rate vs. axial distance: 20% Hct, Re = 38 tubular expansion case 
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Figure 25. Velocity profiles and streamlines: 20% Hct, Re = 38 tubular expansion case 
(A) Velocity profiles at z = 0, 2.5, and 10 mm. (B) Streamlines. 
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 For all the platelet deposition cases that follow, an M∞ value of 7.0 × 105 PLT cm-2 was 
assumed. Figure 26 compares the best-fit predicted deposition values to the experimental values 
for this case. Two models were fit: one with both resting- and activated platelet-surface adhesion, 
and one with only activated platelet adhesion. Best-fit parameters were krs = 1.0 × 10-5 and kas = 
1.0 × 10-4 cm s-1 for the former and kas = 3.5 × 10-4 cm s-1 for the latter.  
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Figure 26. Comparison of best-fit final model predictions to experimentally measured platelet deposition: 
20% Hct, Re = 38 tubular expansion case 
 
 Both models display similar good agreement with the experimental data in the separated-
flow region; further downstream, the one with krs = 0 shows better agreement at and just past the 
reattachment point, while the model with both adhesion terms on appears to fit better overall due 
to its higher level of predicted deposition in the fully-developed-flow region. In comparison to 
Figure 22, there is a much less severe downstream diminution of predicted platelet deposition. 
Based on the hypothesis that this error is due to slow transport to the wall for these cases, the 
likely explanation for this result is the higher average flow velocity (U = 9.0 cm s-1 at the inlet), 
as compared to the 0% Hct case (4.3 cm s-1).   
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 Sensitivity of the model to variations in krs and kas for 20% Hct, Re = 38 is shown in 
Figure 27. The krs and kas values used here are identical to those tested for the 0% Hct 
simulations (see Figure 23). In general, the effects of krs and kas on predicted deposition are 
approximately identical to the 0% Hct case: an ~35% drop in peak deposition is seen for a 50% 
decrease in both krs and kas from the second to the third lowest curves, while an ~20% decrease is 
seen for a 20% reduction in krs and a 25% reduction in kas between the third and fourth lowest 
curves. The only difference is that at 20% Hct only a ~40% decrease in deposition occurs for an 
80% reduction in krs between the two highest curves, versus ~60% for the 0% Hct case. This is 
likely because deposition values for the highest curve at 20% Hct approach 100% saturation, 
whereas for the 0% Hct case, the peak value reaches only about 50% saturation.  
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Figure 27. Sensitivity of predicted deposition to krs and kas: 20% Hct, Re = 38 tubular expansion case 
 
c) Cross-validation cases  
 Since the only difference between the two Re = 38 test cases is hematocrit, and since the 
platelet-surface reaction coefficients are assumed to depend only on surface composition and 
blood protein content, kas and krs should be the same for both cases. To see if one set of 
parameters could fit both data sets, the best-fit values of kas and krs for the 0% Hct, Re = 38 case 
were used to simulate deposition at 20% Hct, Re = 38, and vice-versa for the 20% Hct best-fit 
coefficients. For these studies, the “best fit” values were taken as those for which both resting 
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and activated platelet-surface adhesion were allowed (krs = 4.0 × 10-6, kas = 4.0 × 10-5 cm s-1 at 
0% Hct; krs = 1.0 × 10-5, kas = 1.0 × 10-4 cm s-1 at 20% Hct). These values were chosen because 
their simulations tended to predict the experimental data better than the simulations with no 
resting platelet-surface adhesion. Also, since collagen should activate most of the resting 
platelets that contact it, making them just as likely to adhere as bulk-activated platelets, it was 
difficult to justify excluding the resting platelet adhesion term. An additional simulation using 
the mean values of these 0% and 20% Hct best-fit parameters was also conducted. 
 Figure 28 shows the results of these “cross-validation” studies. Not surprisingly, using 
the 20% Hct best-fit kas and krs, which are 2.5× greater than the best-fit 0% Hct values, to 
simulate the 0% Hct case results in over-prediction of deposition. The peak values are over-
estimated by as much as 100%. In the downstream fully-developed flow region, near-wall 
depletion due to transport limitations again results in nearly zero deposition at locations where z 
> ~14 mm. Likewise, the 20% Hct simulation using the best-fit 0% Hct parameters under-
predicts the experimental results by as much as 50% at the primary peak and in the farthest distal 
downstream regions, although the discrepancy there is not as great as for the 0% Hct case. When 
the means of the best-fit values (krs = 7.0 × 10-6, kas = 7.0 × 10-5 cm s-1) are used, the predicted 
deposition values, unsurprisingly, fall approximately halfway between the predictions using the 
0% and 20% Hct best fit values for both simulations, still over-predicting the 0% Hct 
experimental data and under-predicting the measured 20% Hct values. 
 In a further attempt to fit both sets of data with one set of parameters, additional cases 
were run at  20% Hct, Re = 38 using the best-fit 0% Hct coefficients while increasing the 0.15 
factor in Ds (see Equation 22) by one to three orders of magnitude. Figure 29 shows the results of 
these simulations, where “1X ENHANCEMENT” represents the baseline value of Ds given by 
Equation 22. In general, increasing the level of diffusion enhancement raises deposition levels 
everywhere, while simultaneously flattening the entire curve, consistent with a transition from 
diffusion- to reaction-limited behavior. At the highest level of enhancement (1000X) deposition 
decreases, likely due to homogenization (smearing out) of the wall-skewed inlet boundary 
condition, which would lead to fewer platelets reaching the wall. Although downstream 
deposition levels and longitudinal profiles are more consistent with the experiments at the higher 
enhancement levels, the flattening of the upstream peak prevents further improvement in these 
predictions over those of the baseline simulations. 
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Figure 28. Cross-validation studies: 0% and 20% Hct, Re = 38 tubular expansion cases 
Predicted vs. experimental deposition values for : (A) 0% Hct. (B) 20% Hct. 
 
 88 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
0 5 10 15 20
Z (mm)
Pl
at
el
et
s/
10
00
 µm
2
MODEL-0% Hct BEST FIT + 1X ENHANCEMENT (baseline)
MODEL-0% Hct BEST FIT + 10X ENHANCEMENT
MODEL-0% Hct BEST FIT + 100X ENHANCEMENT
MODEL-0% Hct BEST FIT + 1000X ENHANCEMENT
EXPERIMENT
 
Figure 29. Effect of enhanced diffusivity on predicted deposition using 0% Hct, Re = 38 best-fit krs & kas: 20% 
Hct, Re = 38 tubular expansion case 
 
d) Effect of Reynolds number and perfusion time  
 To further test the extensibility of the model, the best-fit parameters for 0% Hct, Re = 38 
were used to simulate the additional 0% Hct steady-flow cases evaluated experimentally by 
Karino and Goldsmith (59). These consisted of runs at Re = 64 for perfusion times of one and 
three minutes. At 20% Hct, additional cases corresponding to Reynolds numbers of 29, 51, and 
113 were simulated. All three were for a perfusion time of one minute – no three-minute 
experiments were carried out at 20% Hct. 
 Figures 30 and 31 show the CFD results for the 0% Hct, Re = 64 simulation. Due to 
increased fluid inertia relative to the Re = 38 cases, the computed recirculation region extends 
approximately 7.1 mm downstream from the inlet, with fully-developed flow established 
approximately 5.5 – 6.0 mm distal to the reattachment point. The reattachment length observed 
experimentally by Karino and Goldsmith was 7.9 mm.  
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 Figure 32 compares predicted and experimental platelet deposition for 0% Hct, Re = 64 at 
perfusion times of one and three minutes. For the one-minute perfusion case, the magnitudes of 
the predicted and experimental deposition agree reasonably, within about 20% except in the far-
downstream tail, where once again the predicted values drop off. Due to increased convective 
transport, the downstream wall-depletion effect is not as pronounced as for the Re = 38 case at 
this hematocrit.  
However, agreement in the shape of the deposition curves in the recirculation region is 
poorer than at the lower Reynolds number, with the predicted primary peak flattened and shifted 
proximally toward the inlet relative to the sharper experimental peak. After three minutes, the 
shape discrepancy remains. Additionally, the deposition magnitude is over-predicted by a factor 
of 2.5 – 3, indicating that some time-dependent inhibitory mechanism present in the experiments 
is not being simulated by the model. 
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Figure 30. Wall shear rate vs. axial distance: 0% Hct, Re = 64 tubular expansion case 
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Figure 31. Velocity profiles and streamlines: 0% Hct, Re = 64 tubular expansion case 
(A) Velocity profiles at z = 0, 4, and 15 mm. (B) Streamlines. 
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Figure 32. Experimental and predicted platelet deposition after 1 & 3 min flow: 0% Hct, Re = 64 tubular 
expansion case 
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 Figures 33 and 34 depict the CFD solution for 20% Hct, Re = 29. As expected, the peak 
wall shear rate and recirculation zone size are decreased relative to the Re = 38 case. The extent 
of the recirculation zone in the simulation is approximately 3.5 mm, as compared to Karino and 
Goldsmith’s measured value of 3.9 mm. Fully developed flow is established approximately 3 
mm beyond the reattachment point.  
 Figure 35 compares experimental and predicted platelet deposition for this case (at t = 1 
minute). Agreement is similar to that observed at Re = 38 for this hematocrit (Figure 26, open 
diamonds), except that the primary peak of deposition in the separated flow region is under-
predicted by about 20%, while better prediction of the secondary peak just past the reattachment 
point is obtained. Again, the predicted deposition levels tail off in the distal fully-developed flow 
region, while experimentally measured deposition attains an approximately constant level. 
 Figures 36 and 37 are the results of the fluid dynamic simulation for 20% Hct, Re = 51. 
Peak wall shear rate and recirculation zone size are increased relative to the Re = 38 case. The 
extent of the recirculation zone predicted by the CFD code is approximately 5.5 mm, which is 
approximately 15% lower than Karino and Goldsmith’s measured value of 6.5 mm. Fully 
developed flow is established approximately 5 – 6 mm past the end of the recirculation zone.  
 Figure 38 is a plot of experimental vs. predicted platelet deposition for this Reynolds 
number. Similar to the case at 0% Hct, Re = 64, the primary deposition peak is flattened and 
shifted toward the inlet. Unlike that case, the nadir in deposition at the reattachment point is also 
shifted proximally. This may be due to the discrepancy in recirculation zone length between the 
experiment and the CFD model. In contrast to previous cases at both 0% and 20% Hct, 
deposition in the downstream region is generally over-predicted, although the downward-sloping 
shape of the curve is consistent with the diffusion-limited behavior observed in this zone in all 
cases simulated thus far. 
 Figures 39 and 40 display the CFD simulation results for 20% Hct, Re = 113. Continuing 
the trend observed at 0% Hct, Re = 64 and 20% Hct, Re = 51, the reattachment length predicted 
by the code, 10.8 mm, is 21% less the experimentally observed value of 13.7 mm. Fully 
developed flow is established roughly 20 mm downstream of the inlet. 
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 Figure 41 shows the results of the platelet deposition simulation. The effect of the under-
predicted reattachment length is apparent, with the deposition plateau in the recirculation region 
shifted noticeably upstream as observed at Re = 51. Also similar to that case, the predicted 
upstream deposition peak is flatter and deposition magnitudes are over-predicted in both the 
recirculation and fully-developed-flow regions, with a slight downward slope to the deposition 
curve in the distal portion of the tube.  
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Figure 33. Wall shear rate vs. axial distance: 20% Hct, Re = 29 tubular expansion case 
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Figure 34. Velocity profiles and streamlines: 20% Hct, Re = 29 tubular expansion case 
(A) Velocity profiles at z = 0, 2.5, and 10 mm. (B) Streamlines. 
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Figure 35. Comparison of best-fit model prediction to experimentally measured platelet deposition: 20% Hct, 
Re = 29 tubular expansion case 
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Figure 36. Wall shear rate vs. axial distance: 20% Hct, Re = 51 tubular expansion case 
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Figure 37. Velocity profiles and streamlines: 20% Hct, Re = 51 tubular expansion case 
(A) Velocity profiles at z = 0, 2.5, and 12.5 mm. (B) Streamlines. 
 95 
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
0 5 10 15 20
Z (mm)
P
la
te
le
ts
/1
00
0 
µm
2
MODEL
EXPERIMENT
 
 
Figure 38. Comparison of best-fit model prediction to experimentally measured platelet deposition: 20% Hct, 
Re = 51 tubular expansion case 
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Figure 39. Wall shear rate vs. axial distance: 20% Hct, Re = 113 tubular expansion case 
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Figure 40. Velocity profiles and streamlines: 20% Hct, Re = 113 tubular expansion case 
(A) Velocity profiles at z = 0, 5, and 20 mm. (B) Streamlines. 
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Figure 41. Comparison of best-fit model prediction to experimentally measured platelet deposition: 20% Hct, 
Re = 113 tubular expansion case 
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4.3.2 Axisymmetric Stenosis 
a) 50% area-reduction stenosis 
 Figure 42 displays wall shear rate and Figure 43 the CFD-predicted streamlines for the 
50% area-reduction stenosis. In these figures and all that follow for the stenoses, z = 0 mm 
represents the beginning of the collagen-coated region. In Figure 43A, the domain has been 
truncated once the flow becomes fully developed to facilitate viewing. For this case, the flow 
remains attached downstream of the stenosis throat, so no recirculation region is present. The 
peak shear rate, with a magnitude of approximately 1380 s-1, occurs proximal to the location of 
the stenosis throat (z = 12 mm). The flow in the post-stenotic collagen-coated region is not fully 
developed, as Poiseuille flow is not reestablished until roughly 45 mm beyond the throat.  
 Table 9 lists the locations of the five ROIs in which Wootton et al. (104) measured 
platelet deposition. Note that ROI 1 begins 3.6 mm before the start of the collagen-coated region, 
and ROI 5 ends 3.6 mm past the end of the collagen coating. ROI 3 contains the stenosis throat, 
while ROIs 2 and 4 each contain 2.9 mm of the sinusoidal contraction that forms the stenosis. 
 Figure 44 is a bar graph comparing the platelet accumulation velocity Vmax predicted by 
our model to the experimental data of Wootton et al. and to their corresponding simulation 
results (104). In general, both models show similar agreement with experiments, with a generally 
good fit to the data obtained upstream and at the throat and a poor one observed downstream of 
the throat, where both sets of predicted accumulation velocities are much lower than the 
measured ones. However, our model does not predict the upstream accumulation velocity as 
accurately as does Wootton’s. That model’s predictions are basically identical to the mean 
experimental values in ROIs 1 and 2, while our model under-predicts the experimental data in 
ROI 1 and over-predicts it in ROI 2. At both locations, our predictions lie outside the 
experimental error bars, which represent the standard error of the mean. 
 Figures 45 and 46 display predicted agonist concentrations, normalized by their platelet 
activation thresholds (see Table 3 for these values), in the collagen-coated stenosis region. Figure 
45 shows contours of bulk concentration, while Figure 46 plots concentrations at the wall. For all 
three agonists, bulk concentrations are greatest downstream of the stenosis throat. Additionally, 
supra-threshold concentrations (normalized level ≥ 1.0) are only observed in a thin region very 
near the wall. For ADP and TxA2, this thin region extends noticeably into the bulk flow 
downstream of the throat, while supra-threshold thrombin concentrations are only barely visible 
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near the throat and very close to the wall. However, as Figure 46A illustrates, the normalized 
thrombin concentrations at the wall upstream of and at the throat reach levels one to two orders 
of magnitude greater than the other two agonists. Figure 46B shows that magnitudes of TxA2 and 
ADP are relatively equal over the entire collagen-coated region; downstream of the throat, all 
three agonists are present at roughly the same levels. Finally, the normalized concentrations of 
the three agonists are > 1.0 along the entire length of the collagen-coated graft, indicating all are 
contributing to ongoing platelet activation in this region. 
 Figure 47 depicts model-predicted concentrations of resting and activated platelets in the 
bulk and at the wall of the collagen-coated portion of the shunt. Figure 47A shows bulk 
concentrations of resting platelets, which are very low near the wall along the entire length, but 
especially so downstream of the stenosis throat. In contrast, the activated platelet concentrations 
displayed in Figure 47B tended to be higher near the wall and in the downstream region. Both 
trends track with the agonist concentrations observed in Figures 45 and 46, with resting platelet 
concentrations lowest where agonist concentrations are highest and vice-versa for activated 
platelet concentrations. Figure 47C shows the extent of this agonist-induced activation: despite 
an inlet BC that sets the incoming concentration of resting platelets at the upstream inlet to a 
value nine times greater than that of activated platelets, the activated platelet concentration at the 
wall is approximately two orders of magnitude greater than that of resting platelets along the 
entire collagen-coated graft. In addition, the concentration of resting platelets drops precipitously 
in the region near z = 17 mm, approximately 1 mm before the end of the sinusoidal expansion 
portion of the stenosis.  
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Figure 42. Wall shear rate vs. axial distance: 50% stenosis case 
Only every 8th grid point is plotted for viewing clarity. z = 0 corresponds to start of collagen-coated region. 
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Figure 43. Streamline plots: 50% stenosis case 
(A) Plot extending from start of collagen-coated region (z = 0) to establishment of fully-developed flow. (B) 
Collagen-coated region only. 
 
 
Table 9. Locations of regions of interest (ROIs): stenosis cases 
 
ROI Extent in z-direction (mm) 
1 -3.6 to +2.6 
2 2.6 to 8.9 
3 8.9 to 15.1 
4 15.1 to 21.4 
5 21.4 to 27.6 
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Figure 44. Comparison of model predictions to experimentally measured platelet accumulation velocity, Vmax: 
50% stenosis case 
Error bars on experimental results are + standard error of the mean. 
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Figure 45. Contours of predicted, activation-threshold-normalized bulk agonist concentrations: 50% stenosis 
case 
(A) ADP. (B) TxA2. (C) Thrombin. See Table 3 for activation thresholds used in normalization. Note that only 
collagen-coated region is shown.  
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Figure 46. Predicted, activation-threshold-normalized agonist concentrations at wall: 50% stenosis case 
(A) All agonists (note log scale). (B) Detail of ADP and TxA2 concentrations, linear scale. See Table 3 for activation 
thresholds used in normalization. Note that only the collagen-coated region is shown, and only every 25th grid point 
is plotted for viewing clarity. 
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Figure 47. Predicted bulk and wall platelet concentrations: 50% stenosis case 
(A) Contours of resting platelet concentration. (B) Contours of activated platelet concentration. (C) Concentrations 
of resting and activated platelets at the wall (every 25th grid point plotted). Only the collagen-coated region is 
shown. 
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b) 75% area-reduction stenosis 
 Figures 48 and 49 show the CFD results for the 75% area-reduction stenosis. In contrast 
to the 50% stenosis, a large recirculation zone forms distal to the stenosis throat, as shown by the 
streamline plot in Figure 49A. The reattachment point is at approximately z = 29 mm, which is 
17 mm downstream from the stenosis throat and 5 mm downstream of the end of the collagen-
coated region. Thus, as illustrated by the zoomed streamline plot in Figure 49B, the entire 
collagen-coated area downstream of the throat is covered by the recirculation cell. As seen in the 
50% stenosis, the peak shear rate (magnitude 4975 s-1) occurs just before the stenosis throat. Due 
to the strength of the stenotic jet, fully developed flow is not established until 63 mm 
downstream of the throat (at approximately z = 75 mm). 
 Figure 50 compares our predictions of platelet accumulation velocity Vmax to both the 
simulations and experiments of Wootton et al. (104). Once again, both models tend to fit the data 
obtained upstream and at the throat fairly well but badly under-predict the downstream 
accumulation rate. Distinct from the 50% stenosis results, our simulations for this case predict 
upstream accumulation velocity in ROIs 1-2 as well as or slightly better than do Wootton’s; 
however, our model under-predicts deposition at the throat (ROI 3), while their predictions lie 
very near the experimental mean. 
 Figures 51 and 52 show predicted, activation-threshold-normalized agonist 
concentrations in the collagen-coated stenosis region. Figure 51 shows contours of bulk 
concentration, and Figure 52 is concentration at the wall. In contrast to the 50% stenosis case, 
where supra-threshold concentrations were only observed very near the wall, Figure 51 shows 
that the recirculation zone creates a “hot spot” for agonist accumulation. Bulk concentrations of 
TxA2 and thrombin peak just distal to the throat, reaching their highest levels at the stagnation 
point where the flow separates. Downstream of the throat, ADP concentrations reach supra-
threshold levels in a very wide region that spans the recirculation zone. While generally at sub-
threshold levels, TxA2 and thrombin concentrations in the vortex are also elevated. As Figure 
52A illustrates, agonist trends at the wall are similar to those observed in the 50% stenosis, with 
normalized thrombin concentrations near the throat reaching levels one to two orders of 
magnitude greater those of ADP and TxA2. Again, magnitudes of TxA2 and ADP are relatively 
close over the entire collagen-coated region (Figure 52B). Downstream of the throat, a sharp 
drop in all three agonist levels is observed beginning at the separation point. Distal to it, 
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thrombin concentrations begin to rise again, gradually reaching levels roughly 10 times higher 
than the other two agonists, which remain at the low concentrations seen at the stagnation point. 
Once again, normalized concentrations of all three agonists are > 1.0 along the entire length of 
the collagen-coated graft, indicating all are contributing to ongoing platelet activation in this 
region. 
 Figure 53 shows simulated concentrations of resting and activated platelets in the bulk 
and at the wall along the collagen-coated portion of the shunt. In Figures 53A and 53B, contours 
of bulk resting and activated platelets, respectively, are plotted. These show the post-stenosis 
vortex to be a region of very active platelet activation, with resting platelet levels highly depleted 
there and activated platelet concentrations greatly increased. As noted for the 50% stenosis case, 
these trends agree with the agonist concentrations observed in Figures 51 and 52, with resting 
platelet concentrations lowest where agonist concentrations are highest and vice-versa for 
activated platelet concentrations. Also similar is the trend in platelet concentrations at the wall, 
shown in Figure 53C: the activated platelet concentration at the wall is again roughly two orders 
of magnitude greater than that of resting platelets along the entire collagen-coated region. 
However, the sudden drop in resting platelet concentration that was seen downstream of the 50% 
stenosis does not occur to as great an extent for this geometry.  
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Figure 48. Wall shear rate vs. axial distance: 75% stenosis case 
Only every 8th grid point is plotted for viewing clarity. z = 0 corresponds to start of collagen-coated region. 
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Figure 49. Streamline plots: 75% stenosis case 
(A) Plot extending from start of collagen-coated region (z = 0) to establishment of fully-developed flow. (B) 
Collagen-coated region only. 
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Figure 50. Comparison of model predictions to experimentally measured platelet accumulation velocity, Vmax: 
75% stenosis case 
Error bars on experimental results are + standard error of the mean. 
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Figure 51. Contours of predicted, activation-threshold-normalized bulk agonist concentrations: 75% stenosis 
case 
(A) ADP. (B) TxA2. (C) Thrombin. See Table 3 for activation thresholds used in normalization. Note that only the 
collagen-coated region is shown. 
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Figure 52. Predicted, activation-threshold-normalized agonist concentrations at wall: 75% stenosis case 
(A) All agonists (log scale). (B) Zoomed detail of ADP and TxA2 (linear scale). See Table 3 for activation 
thresholds used in normalization. Note that only the collagen-coated region is shown, and only every 25th grid point 
is plotted for viewing clarity. 
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Figure 53. Predicted bulk and wall platelet concentrations: 75% stenosis case 
(A) Contours of resting platelet concentration. (B) Contours of activated platelet concentration. (C) Concentrations 
of resting and activated platelets at the wall (every 25th grid point plotted). Note that only collagen-coated region is 
shown in all three plots. 
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4.4 Discussion 
4.4.1 Axisymmetric Tubular Expansion 
 In these simulations, the model applied was greatly simplified compared to the one used 
to model deposition from whole blood in Chapter 2. Because the experimental perfusates 
consisted only of washed platelets and RBCs in a protein-free suspension and because perfusion 
times were chosen to avoid platelet aggregation, the effects of agonist generation by platelets, 
platelet activation by agonists, and platelet-platelet aggregation could be neglected. Additionally, 
unmodeled phenomena which were suspected of causing errors in the previous simulations, such 
as aggregation-induced flow disturbances, aggregate embolization and shear-dependent 
inhibition of adhesion, could be justifiably neglected. The first was neglected for the 
aforementioned reasons, the last two because of the relatively low-shear flows studied. Thus, 
these simulations allowed us to focus on platelet transport in the presence and absence of RBCs 
and on the kinetics of platelet-surface adhesion. Doing so revealed that our model of platelet 
transport is grossly deficient. 
 For the 0% Hct cases, even though diffusion-enhancing red cells are absent, it appears 
transport of platelets in the near-wall region is not adequately described by the Brownian 
diffusivity alone. At Re = 38, it was discovered that the model predicts very few platelets 
reaching the wall in the downstream, fully-developed flow region, even in the absence of 
platelet-surface adhesion. Similar, though not as severe, behavior was observed at Re = 64. 
Surprisingly, a grid with non-uniform cells near the wall produced better agreement with 
experimental data than did one with uniformly fine cells. We attribute this to enhanced numerical 
diffusion caused by the coarse regions of the non-uniform mesh (see Figure 16A), which 
artifactually augments platelet transport compared to the fine grid analysis. However, the 
beneficial effect of the numerical diffusion on downstream deposition could not be replicated on 
the uniformly refined grid by adding a shear-dependent enhancement factor to the diffusion 
coefficient, at least for the three orders of magnitude variation in this parameter that were tested.  
 For the 20% Hct cases, using the best-fit coefficients from the 0% Hct simulations failed 
to provide agreement between model and experiment. Increasing the diffusivity by up to 1000× 
still did not reconcile the simulation with the experimental results. Agreement could only be 
obtained by increasing the platelet-surface reaction coefficients relative to the 0% Hct case. 
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Thus, in the presence of RBCs, an enhanced diffusivity, even when combined with a wall-
skewed inlet concentration profile designed to mimic experimentally observed platelet 
concentration profiles (53), still gives poor agreement with experimental values.  
 By re-fitting krs and kas, we have in essence re-defined these coefficients to be lumped 
parameters governing not only surface reactivity, as assumed in the development of the model, 
but also red-cell enhanced near-wall platelet transport. This is very unsatisfactory, since it would 
imply that these model parameters depend not only on surface composition, but also on 
hematocrit and shear rate. If krs and kas were only surface-dependent, they could presumably be 
determined for a given material by simulating simple parallel-plate flow experiments like those 
discussed in Chapter 3, after which their best-fit values could be used to predict deposition onto 
that substrate for different flow rates, geometries, blood conditions, etc. However, if they also 
depend on shear rate and hematocrit, experimental data for each new case would be needed for 
parameter fitting, destroying the utility of the model for predicting deposition in complex 
geometries where such measurements may not be feasible. Of course, it might eventually be 
possible to determine a functional form for the dependence of krs and kas on hematocrit and shear 
rate. This would allow the parameters to be calculated a priori, rather than fit, for each new flow 
situation, but one would expect that quite a large set of “training data” would be needed to 
determine this relationship. Additionally, these parameters lose their physical meaning, and 
consequently the model would no longer be mechanistic, but would become semi-empirical.  
 In all the cases simulated – independent of Reynolds number, hematocrit, and perfusion 
time – the experimentally observed platelet deposition trend appears to follow reaction-limited 
kinetics in the fully-developed flow region of the tube, as evidenced by the flat deposition values 
measured there by Karino and Goldsmith (59). This is especially evident at 20% Hct, where 
nearly identical downstream deposition values were measured over a Reynolds number range 
from 29 to 113. In contrast, the model results appear diffusion-limited, with platelet deposition 
decreasing with increasing axial distance. However, model and simulation results generally agree 
in the upstream, separated-flow region. One exception is at the higher Reynolds numbers, i.e. Re 
= 64 at 0% Hct and Re = 51 and 113 at 20% Hct. For these cases, the primary deposition peak is 
flattened somewhat and occurs closer to the inlet than observed experimentally. For simulations 
at both hematocrits, this can be partly attributed to numerical diffusion in the convection 
schemes. For the flow simulations, this resulted in under-prediction of the reattachment length, 
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while for the platelet deposition simulations, it resulted in smearing of concentration peaks. The 
more severe discrepancies at 20% Hct are also likely due in part to the suspension having a non-
uniform viscosity due to the presence of RBCs. Such effects are not modeled in our Newtonian 
CFD simulations.  
 Another departure of the simulation from the experiments occurred in the cases at 20% 
Hct, Re = 38 wherein the best-fit krs and kas from 0% Hct, Re = 38 were used and the diffusion 
enhancement factor was increased. In these cases, reaction-limited deposition profiles were 
obtained in the downstream region, but at the expense of flattening the upstream deposition 
peaks and thereby removing the good agreement with experiments previously observed there.  
 The underlying source of these problems is likely the approximation of blood as a single 
continuum. This was expected to be an issue for non-zero hematocrits due to the well-known 
effects of RBCs on platelet concentration profiles (53, 79). However, even in the absence of 
RBCs, platelets have been shown to exhibit a non-uniform, wall-skewed concentration profile 
(53) consistent with the “tubular pinch” effect observed for dilute particulate suspensions (148). 
One explanation for the better agreement of the predicted and experimental results in the 
recirculation zone could be that such discrete-particle effects are not important there because the 
vortex creates a relatively uniform, well-mixed solution in which particle segregation does not 
take place. In contrast, the fully-developed flow in the downstream region will lead to shear-
induced particle migration (148, 149), moving platelets toward the wall and RBCs toward the 
tube centerline (53). Using an enhanced diffusivity in the continuum model fails to replicate this 
behavior because it enhances transport in both the upstream and downstream regions, thereby 
destroying the good agreement between prediction and experiment in the recirculation zone, as 
seen in Figures 20 and 29.      
 In recent work, David et al. (103) attempted to model platelet adhesion from RBC-free 
platelet-rich plasma in a stagnation-point flow chamber using a one-equation steady-state model 
in which the surface reaction coefficient was a linearly increasing function of wall shear stress. 
This approach is attractive since the platelet deposition experimentally measured by Karino and 
Goldsmith appears to correlate with the magnitude of wall shear stress. However, it is unlikely 
that such a strategy would improve our predictions. First, the greatest variations in the shear-
dependent reaction coefficients would be obtained in the recirculation zone, where the current 
model already predicts experimental deposition fairly accurately. Second, since the wall shear 
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stress is constant in fully-developed tube flow, a shear-dependent reaction coefficient would take 
on a constant value in the fully-developed downstream region. Thus, it would become equivalent 
to the current model in this region, where the poorest agreement with the experimental results is 
observed. 
 Besides the model’s ability to predict platelet transport in disturbed flow over a range of 
hematocrits and Reynolds numbers, its time-dependent behavior was investigated by simulating 
one- and three-minute deposition results at 0% Hct, Re = 64. Using the best-fit krs and kas from 
the one minute perfusion at 0% Hct, Re = 38, reasonable agreement for the one-minute 
simulation was obtained. However, the three-minute data were greatly over-predicted. Based on 
the low shear rate and the fact that little or no aggregation was observed in the experiments (59), 
it is unlikely that embolization was taking place. It is possible that transient attachment to and 
detachment from the collagen surface were occurring in the experiments, perhaps because the 
platelets could not form sufficiently strong bonds with the collagen in the absence of vWF and 
fibrinogen. However, Savage et al. (65) observed that inhibiting either GpIb or GpIIbIIIa had no 
effect on the levels of initial platelet adhesion onto collagen at a wall shear rate of 100 s-1, which 
is comparable to the maximum wall shear rate for this case. Furthermore, since such 
translocation should not be a time-dependent event, it would tend to affect both the one- and 
three-minute deposition results if it were occurring.  
 Since the magnitude of the saturation parameter M∞ determines how rapidly the platelet-
surface flux will decrease as deposition increases, it is possible that the value of 10% of a 
monolayer we chose to mimic the sparse collagen coatings observed on the tubes was too high, 
resulting in an overestimation of deposition at longer times. The M∞ value selected was an 
estimation based on the microscopic observations of the collagen coating by Karino & 
Goldsmith (59) and on the levels of observed deposition; sensitivity studies on this parameter 
were not carried out due to time constraints. The lower M∞ is set, the more rapidly the platelet-
surface flux will decrease for a given krs and kas. Therefore, selecting a low enough value of M∞  
might induce a more reaction-limited character in the predicted deposition curves. However, 
peak deposition values corresponding to roughly 7% of our assumed monolayer value were 
observed in the experiments. If M∞  is set to a value less than the peak of the experimental data, 
the predicted deposition peaks for those simulations will be clipped due to the saturation effect. 
This leaves a relatively limited range of M∞  values available for further investigation, i.e. > 7% 
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to < 10% of monolayer coverage. Using the results of Figure 22 as a guide, it appears unlikely 
that the model is sufficiently sensitive to variations in M∞  that varying it over this narrow range 
would make a significant difference in its predictive ability. 
 Finally, in addition to simulations predicting experimental platelet deposition, sensitivity 
studies were carried out to determine the influence of transport- and deposition-related 
parameters on the simplified model used for these cases. Predicted deposition levels were 
relatively insensitive to increases in the diffusion enhancement factor, both at 0% and 20% Hct. 
Similar sensitivities to krs and kas were observed at 0% and 20% Hct except when deposition 
levels neared saturation. The ratio of percent decrease in deposition to percent decrease in 
reaction coefficients was slightly less than 1:1.  
4.4.2 Axisymmetric Stenosis 
 These cases allowed us to test the robustness of the model including all agonists in 
disturbed flow, as well as to compare our predictions to those of the simpler, one-parameter, one-
equation steady-state model of Wootton et al. (104). For a 50% area-reduction stenosis, it was 
found that both models gave similar predictions, with the Wootton model more accurate 
upstream of the stenosis throat. For a 75% area reduction stenosis, our model was more accurate 
upstream of the throat, but predicted platelet accumulation less accurately at the throat. Both 
models greatly underestimated the rate of platelet accumulation downstream of the stenosis 
throat for both levels of stenotic narrowing, however.  
 Completing the simulations for these cases was a very time-consuming process. While 
the steady-state CFD runs could typically be finished in 2-3 days, completing both unsteady 
platelet cases for a simulated time of 10 minutes required roughly two and a half months of “wall 
clock” time. One reason for the excessive time requirement was time-sharing of a single-
processor machine for multiple (two to three) simultaneous simulations. However, it was also 
necessary to frequently adjust the under-relaxation factors and the time step to achieve 
convergence due to the stiff, coupled nature of the system of equations. This required frequent 
operator intervention and restarts. And even when only one of these cases was running on an 
otherwise unloaded machine, a single time step could still take up to four hours of CPU time if 
convergence difficulties were encountered. 
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 These extremely long simulation durations prohibited us from carrying out parameter 
sensitivity or mesh refinement studies for these cases. Based on the lack of mesh independence 
observed even at very fine grid resolutions for the tubular expansion cases, it is very likely that 
the platelet deposition simulations for the stenosis cases are not grid-independent. 
 Both our model and that of Wootton under-predicted deposition downstream of the 
stenosis. However, it is surprising that our model, which predicts persistent agonist production 
and platelet activation in that region, predicts less deposition than Wootton’s model, which does 
not simulate agonist production. The large under-predictions of platelet flux in the post-stenotic 
expansion region for both stenosis geometries are probably due to the same deficiencies in the 
platelet transport model that plagued the tubular expansion simulations; it appears that agonist-
activation effects are insufficient to overcome the extremely diffusion-limited behavior of the 
model in these regions. Wootton’s simulations, which, like ours, used a very fine near-wall 
mesh, theirs consisting of elements 1-2 µm thick (104), seem to suffer from the same malady.  
 Due to the increased complexity of these cases, however, there are other factors that 
could also have contributed to the discrepancies. One of these is that interactions between the 
flow field and the thrombus, including streamline alterations by thrombus growth and thrombus 
embolization by fluid shear stresses, are neglected by both models. This point was discussed in 
depth with respect to the Poiseuille flow cases of Chapter 3, but it would be even more pertinent 
at the higher shear rates and longer perfusion times studied here.  
 Specifically, fluid mechanical forces acting to limit thrombus size could explain both 
models’ under-prediction of platelet deposition downstream of the throat if one admits the 
possibility of a “moving front” of platelet deposition, characterized by a decrease in upstream 
platelet-surface flux once a certain level of deposition is reached. If upstream deposition slowed 
or ceased at some time point because the thrombus had grown to a size where the fluid shear rate 
at its surface was too high to permit further platelet-platelet adhesion, the near-wall excess 
boundary layer reaching the downstream surface would be far less depleted than it would be if 
the upstream surface were still fully reactive. Thus, the downstream platelet flux would be 
higher, resulting in a more even distribution of platelet deposition, as observed experimentally. 
 Wootton’s model (104) assumes a constant, steady-state platelet-surface flux and is 
therefore incapable of capturing this phenomenon. While our model forces the resting and 
activated platelet-surface fluxes to zero once a monolayer level of deposition is reached, we 
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assume that no such saturation of activated platelet-platelet adhesion occurs. This mechanism 
therefore continues to deplete the near-wall platelet boundary layer throughout the duration of 
the simulation. Our model could be altered to simulate this phenomenon by applying a shear-
rate- and thrombus-size-dependent saturation term to the platelet-platelet flux equation. 
However, this term would likely have to be estimated for each new shear rate and geometry.  
 Whether such an effect is indeed the primary cause of the discrepancy between model 
predictions and experimental results for these cases could be investigated computationally by 
simulating a stenosis whose surface is non-reactive from the inlet to the throat, then fully reactive 
thereafter. If upstream depletion is indeed responsible for the models’ under-prediction, much 
higher levels of downstream deposition should be predicted for this “non-reactive upstream” case 
than for a case with a fully reactive upstream surface. If other factors (e.g., deficiencies in the 
platelet transport model) are the primary cause, downstream deposition should be similar 
between the two cases. Due to time constraints, such studies were not performed. 
 Experimentally, the existence of such a “moving front” could be verified by using a 
stenosis coated with collagen along its entire length and perfusing platelets labeled with different 
(e.g.) fluorescent markers. This would allow one to alter the “color” of the deposited platelets 
with time, and to observe where each “color” is concentrated along the surface. That is, “red”-
labeled platelets could be perfused for the first few minutes, then “green”, then “blue”. If 
deposition indeed occurs in a “moving front” fashion, the highest concentration of deposited 
“red” platelets should be furthest upstream, and the highest levels of “blue” deposition should be 
furthest downstream. 
 Another fluid-mechanical modeling issue is our choice to neglect shear stress as a platelet 
agonist. For the 50% stenosis, this may not be of great importance because the highest wall shear 
stress value predicted by CFD is 48.3 dynes cm-2. Although this is very near the 50 dynes cm-2 
threshold for platelet activation determined by Brown et al. (150), this value occurs very near the 
stenosis throat, where exposure times should be low due to the rapid flow. In contrast, Brown et 
al. observed platelet activation at 50 dynes cm-2 after five minutes of continuous exposure. For 
the 75% stenosis, however, the peak wall shear rate of 4975 s-1 corresponds to a shear stress of 
174 dynes cm-2. Additionally, there is a rather large region on both sides of the stenosis throat 
where the wall shear rate magnitude is greater than 1430 s-1, which corresponds to a stress of 50 
dynes cm-2 (see Figure 48). Thus, for this case it is possible that high shear stresses upstream of 
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and at the throat activate platelets, which subsequently become entrapped in the post-stenotic 
vortex, enhancing the observed deposition via a mechanism not present in the model. However, 
merely having more activated platelets present in the recirculation cell due to upstream shear-
induced activation would not necessarily enhance the model’s predicted deposition if its 
deficiency is in the kinetic model of platelet-surface adhesion or in the mechanism of simulating 
platelet transport to the wall. 
 Similar to the cases of Chapter 3, thrombin is the dominant agonist in these simulations, 
with model-predicted concentrations at some locations along the tube wall reaching greater than 
1000× the activation threshold for both simulations. Of course, this raises the question of 
whether such high concentrations are realistic. Since no experimental method for measuring 
local species concentrations in flowing blood is available, this question cannot be answered at 
this time. In the simulations, these very high levels are localized to a region very close to the tube 
wall due to our assumption of a much higher rate of thrombin generation from adherent platelets 
activated by the collagen surface (see Section 3.2.1 for a justification). As demonstrated in 
Chapter 3, predicted platelet deposition is very sensitive to thrombin generation, so further work 
on validating the generation function for this agonist is likely warranted.  
 On the other hand, results different from those of Chapter 3 were observed for TxA2. In 
the present simulations, this agonist reached supra-threshold levels comparable to those of ADP 
(whose levels here are similar those predicted in Chapter 3), whereas in the simulations of 
Chapter 3, the predicted concentrations of TxA2 were always well below the critical level for 
platelet activation. This can be explained by considering the difference in perfusion times 
simulated, 75 s in Chapter 3 vs. 600 s here. Since we assume TxA2 is generated in perpetuity 
both in the bulk and at the surface once a platelet becomes activated, longer simulation times 
favor increased levels of this agonist. ADP generation, in contrast, is assumed to be a one-time 
event occurring upon platelet activation. Also, once surface saturation is reached, resting platelet 
adhesion ceases, and along with it ADP generation due to platelet activation by collagen. Thus, 
at the long perfusion times studied here, ADP is only being generated by newly activated bulk 
platelets, which does not allow its levels to outstrip those of TxA2 to the extent observed at the 
short times studied previously. 
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 Another interesting observation is that, although the thrombin levels at the wall in the 
50% stenosis simulation are greater than those of the other agonists in the upstream region before 
and at the stenosis throat, the downstream levels of all three agonists are similar, with ADP and 
TxA2 levels even higher than thrombin concentrations just downstream of the throat. Again, this 
can be traced to the much higher value assumed for surface-based thrombin generation as 
compared to bulk generation. In the post-stenotic region, predicted platelet deposition drops off 
dramatically, thereby reducing this source of thrombin. Since ADP and TxA2 are generated at the 
same rates at the surface as in the bulk, their levels do not drop in this region; rather, they tend to 
accumulate, possibly due to the nearly stagnant flow near the wall in this area.  
 By contrast, in the 75% stenosis, ADP and TxA2 levels at the wall are diminished 
downstream of the separation point, whereas thrombin levels gradually rise to become an order 
of magnitude higher than those of the other two agonists. The high downstream thrombin 
concentrations are explained by increased platelet transport to the wall at the distal reattachment 
point, which is beyond the collagen-coated region. Since these platelets do not react with the 
silicone rubber wall there, they are carried back upstream and attach immediately on contacting 
the collagen-coated region, where they produce thrombin at a higher rate than do bulk-activated 
platelets. As explained above, ADP release due to surface adhesion will be zero once saturation 
is reached, so that little generation of this agonist occurs due to downstream adhesion. The drop 
in TxA2 concentration is more puzzling, since it is generated perpetually by activated platelets, 
similar to thrombin. However, its levels do not drop to the same extent as do ADP’s, indicating 
that its behavior is similar to that of thrombin, but its downstream concentration does not 
increase like thrombin’s does because its generation rate is not augmented at the wall as is 
thrombin’s.  
 Comparing Figures 45 and 51, as well as 46 and 52, one can see the deleterious effects of 
recirculation regions on platelet activation. In Figure 45, which shows the 50% stenosis with no 
downstream vortex, agonist concentrations only reach levels noticeably different from zero in a 
very narrow boundary layer near the tube wall. In contrast, the 75% stenosis results shown in 
Figure 51 display supra- and near-threshold agonist concentrations throughout the recirculation 
zone, leading to the greatly increased bulk platelet activation seen in Figure 52B.  
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 Although the model does not predict it, one would anticipate that the high levels of bulk 
platelet activation here, combined with increased mixing due to the vortex, would create bulk 
platelet aggregates that could either: 1) attach to the wall and obstruct flow, further narrowing the 
stenosis; or 2) create macroemboli that could be transported to distal tissue beds. Simulating such 
phenomena is clearly an interesting area for future study, as one might be able to predict “safe” 
and “unsafe” levels of narrowing with respect to their thromboembolic proclivities. 
 A final issue that should be addressed is raised by the results of the time-accurate 
simulations conducted for the 0% Hct, Re = 64 case, in which it was shown that the model did 
not accurately predicted the time-dependent change in platelet-surface flux which occurred 
between one and three minutes. That observation raises the question of whether the accuracy of 
our predictions for these cases could be dependent on the simulation time chosen. We selected 10 
minutes to minimize computing time, but Wootton et al. calculated Vmax from their experimental 
data based on an average taken between 10 and 25 minutes. Perfusion time is used as a 
normalizing factor in our calculation of model-predicted Vmax (see Equation 24). However, it is 
still possible that different Vmax levels may have been obtained if the more representative average 
time of 17.5 minutes had been simulated. This possibility was not investigated due to the 
prohibitive computing times it would have required. 
4.4.3 Comparison to Other Models 
 Based on the poor predictions of platelet deposition in disturbed flow obtained in the 
simulations discussed in this chapter, it is difficult to recommend our model over the simpler 
versions presented recently by David et al. (103) and Wootton et al. (104). One theoretical 
advantage of our model is that each parameter is intended to have a physical meaning, and can 
therefore be estimated a priori based on the conditions being simulated: for example, platelet-
surface reaction coefficients should be a function only of the surface composition of the material 
onto which platelets adhere (assuming normal whole blood as the perfusate). In contrast, the 
single heterogeneous reaction coefficient employed by the simpler models is a lumped parameter 
governing several phenomena: near-wall platelet transport, activation, adhesion, and aggregation. 
However, as discussed above, if our surface reaction coefficients krs and kas need to be altered for 
different hematocrits (and possibly shear rates), they also become lumped parameters, and our 
model retains no edge over the others in this respect. 
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 Another advantage of the present model over these recent works is that it can predict 
local agonist concentrations. But, since agonist generation in our simulations is directly related to 
local levels of platelet deposition and activation, this information is of little use if it is based on 
an unreliable model of platelet transport and deposition. 
 Additionally, the computational cost of our approach weighs heavily against it. When 
solving the full seven-equation model, convergence is extremely slow due to the stiff nature of 
the source terms and to the coupling between equations. This issue could be resolved by 
investigating other solvers or by implementing a coupled, rather than sequential, solution 
method. A more pressing issue, however, is the excessive amount of time needed to solve the 
equations in time-dependent form. In essence, this process is equivalent to solving a steady-state 
problem at each time step, albeit using a reduced convergence criterion relative to a steady 
problem. Since we typically use 100 time steps for a simulation, this factor alone makes our 
seven-equation model ~700 times more expensive to solve than the one-equation, steady state 
versions of David et al. (103) and Wootton et al. (104). This expense can be justified if the time-
accurate predictions of our simulations yield more accurate information than a steady-state 
simulation. Time-dependent effects are likely to be important at short perfusion times, such as 
the one and three minute simulations shown in Figure 32. However, for these cases, our model 
was unable to predict the experimentally observed decrease in platelet-surface flux with 
increasing time, so to have an actual advantage in this respect, its time-dependent behavior 
would have to be improved. But this may be a fruitless endeavor, since blood-contact times for 
medical devices range from hours to years. Unless it can be shown experimentally that the 
relevant phenomena governing long-term device performance are predicted by early 
thrombocyte-biomaterial interactions, detailed acute deposition information may be of little 
utility as a design aid. Furthermore, our predictions of the experimental values obtained by 
Wootton et al. (104) at longer times (10 – 25 min), where the flux appears to be approximately 
constant in time, were generally slightly worse than those of Wootton’s steady-state model. The 
inability of our model to better fit the data could be attributed to our decision to use kinetic 
parameters for our agonist generation functions that were derived from experiments and 
simulations conducted with human blood. This may have led to an incorrect estimation of 
agonist production in baboon blood, contributing to erroneous predictions of platelet deposition. 
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 Raising this issue, however, reveals another shortcoming of our model relative to the 
simpler ones: there is a large number of species- and problem-specific parameters to be obtained, 
either from literature or by a cut-and-try approach. Informal, heuristic sensitivity analyses of 
some of the key parameters, such as the platelet-surface and platelet-platelet adhesion 
coefficients, platelet diffusivity, and agonist generation functions were conducted in Chapters 2 
and 4. These revealed that the model is very sensitive to the level of thrombin generation, that 
the ratio of percent change in platelet adhesion to percent change in adhesion coefficients is 
roughly 1:1, and that very large changes in platelet diffusivity are required to alter the platelet 
deposition patterns. However, such an analysis gives an incomplete picture, and the sensitivity of 
the model to most, if not all, of the parameters incorporated into all seven equations should likely 
be investigated in a systematic fashion to find which ones may have contributed to the 
shortcomings in the model predictions observed in this chapter. Performing such sensitivity 
analyses is time-consuming not only because of the number of parameters to be investigated, but 
also because of the long computing times required, as discussed above. Additionally, it was 
observed (see Figure 22) that basically identical deposition predictions could be obtained for two 
different sets of values of krs, kas, and M∞. In that case, the issue of which prediction was 
“correct” was resolved by selecting the M∞ value that was more consistent with the experimental 
situation. However, such a clear-cut justification may not always be available, as might be the 
case with adjusting krs and kas to obtain best fits. Physically, one would always expect kas > krs 
due to the increased expression of GpIIbIIIa receptors on activated platelets, but how much 
greater should it be? In the simulations of Figure 22, for M∞ = 7.0 × 105 PLT cm-2, the best-fit kas 
is an order of magnitude larger than krs, while at M∞ = 7.0 × 106 PLT cm-2, it is only greater by 
about 30%. Such ambiguity must be regarded as another drawback of the multiple parameters 
used in our model. 
 Additional sources of ambiguity are the relative importance of each of the many model 
parameters, as well as the uncertainties associated with our trial-and-error method of estimating 
the independent ones. Clearly, a more mathematically rigorous approach to fitting the model to 
the experimental results than the heuristic algorithm outlined in Section 3.2.1 would be 
preferable. One way of accomplishing this would be to mathematically optimize the variable 
model parameters to minimize the difference between the predicted and experimentally 
measured deposition curves. It may also be possible to combine such an algorithm with non-
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linear regression techniques to obtain mathematical estimates of both parameter sensitivities and 
uncertainties, i.e. confidence intervals for the parameters (151). Such analyses were not 
conducted because of the additional level of computational complexity that would be created by 
having to add an outer iteration involving the rather difficult to implement optimization and 
nonlinear regression algorithms to our already complex code and because it seemed the cut-and-
try approach provided acceptable results for the training and validation cases presented in 
Chapter 3. Furthermore, it would seem unlikely that the large discrepancies between our model 
predictions and the experimental results for the present simulations could be resolved by a more 
mathematically rigorous approach to parameter fitting. Also, the model was formulated 
mechanistically, i.e., each parameter was supposed to have a direct correspondence to some 
physical event being simulated. However, the possibility that the model is over-determined needs 
to be considered and explored. The sensitivity information provided by such an analysis would 
aid in determining which parameters have the greatest effect on the model predictions and which 
ones, if any, could either be dropped from the model or treated as constants, thereby allowing us 
to reduce the complexity of our equations. An optimization-based approach, once fully 
automated, would also speed the fitting process were the model to be applied to additional 
biomaterials or flow conditions. 
 Another method of analyzing our simulations that might aid in determining the relative 
importance of the model parameters would be to explore the possibility that our results could be 
correlated using dimensionless groups of relevant variables. If such relationships were found, 
they might reveal, for example, that only the ratios of certain parameters are important, rather 
than their individual absolute magnitudes. Additionally, it might be possible to develop 
correlations between dimensionless groups analogous to those used in determining conventional 
mass transfer coefficients. One example of where such relationships would be invaluable would 
be for determining kas and krs as a function of surface composition, hematocrit, and shear rate, 
since the tubular expansion cases seem to suggest such a dependence for them. Rather than 
heuristically re-fitting these parameters for each case, they could be determined from the 
dimensionless variable correlations. This approach was not attempted because the wide range of 
variable combinations that would have to be explored seemed prohibitive within the time 
constraints of this project, and because a wider range of simulation results than those performed 
herein would likely be required to reveal the dimensionless relationships. 
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 Another concern associated with our modeling approach is that an extremely fine near-
wall mesh is apparently required to attain a grid-independent solution. Due to time limitations, 
we did not determine the exact degree of refinement necessary, but, for the tubular expansion 
case, changing the resolution from 77612 to 123891 nodes, with the majority of the 46279 new 
points on the finer grid confined to a very small 50 µm wide × 25 mm long region, did not result 
in mesh independence (Figure 21). The necessity for such a fine grid obviously leads to greatly 
increased demands on computational resources. This, combined with the relatively poor 
predictive abilities of continuum models in general and the inherent superiority of a discrete, 
Lagrangian model for reproducing what are in reality discrete, Lagrangian phenomena, raises the 
question of how much effort should be put into continuing to improve continuum approximations 
of platelet and RBC transport. Discrete-cell-based models have already been implemented (106, 
152), and although realistic macroscopic simulations of blood flow are not feasible at present, the 
seemingly daily increases in computing power that continue to occur mean that one day they 
likely will be.  
4.5 Conclusions 
 In this chapter, the model’s ability to predict platelet deposition in two-dimensional 
disturbed flow was investigated. As in Chapter 3, the adhesive substrate under consideration was 
type I collagen. First, cases with no agonists or platelet aggregation were simulated to test the 
ability of our continuum approximation of blood to reproduce the effects of RBCs on platelet 
transport, as well as its ability to simulate the transport of platelets alone. Next, simulations of 
non-anticoagulated baboon blood were conducted to see whether the agonist generation terms in 
our full model could better predict deposition in a stenotic tube than the one-species, one-
parameter model of Wootton et al. (104), which contained no agonist generation terms. 
 It was found that the predicted deposition levels are extremely sensitive to the density of 
the computational mesh, with grid independence not obtained even for an extremely fine near-
wall grid in the tubular expansion simulations. Long simulation times hampered our abilities to 
fully determine the level of refinement required for grid independence for either of the 
geometries studied.  
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 In general, the model was capable of predicting platelet deposition fairly well in the 
upstream recirculation regions of the tubular expansion geometry, and in the upstream region and 
throat of the stenotic geometry. Rather poor predictions were obtained in the downstream fully-
developed region of the tubular expansion and the post-stenotic expansion region of the stenosis. 
These poor predictions are primarily attributed to inadequate platelet transport to the near-wall 
region, resulting in a predicted platelet-surface flux much lower than that observed 
experimentally. 
 In comparison to other, simpler continuum models, our model fairs poorly due to its lack 
of improved predictive ability in light of its relative complexity, especially due to the extremely 
high computational cost of solving the stiff, coupled, unsteady equations that it comprises.  
 However, the key conclusion which was derived from these simulations and which 
affects not only the present model but also all similar continuum approximations, is that it 
appears that continuum mass transfer equations incorporating a conventional isotropic diffusion 
coefficient are not capable of modeling platelet transport in disturbed flow. While we were able 
to reasonably approximate the effects of RBCs on local platelet concentrations via the use of an 
artificially skewed inlet boundary condition and an enhanced platelet diffusivity in the Poiseuille 
flow simulations of Chapter 2, this simple approach failed for the disturbed flows simulated in 
this chapter.  
 Thus, our model, as currently constituted, is not adequate for predicting the thrombotic 
predilections of medical devices, in which much more complex flow fields and unsteady effects 
prevail. In order to adequately model platelet-mediated thrombogenesis, it may be necessary to 
consider more complex transport models that more accurately account for the particle-like 
behavior of RBCs and platelets. In Chapter 5, we take a very preliminary step in this direction by 
investigating the utility of an “off-the-shelf” multiphase flow model for blood simulations.  
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5.0 MODEL IMPROVEMENT: TWO-PHASE FLOW SIMULATION 
“The road of excess leads to the palace of wisdom” 
  -William Blake, “Proverbs from Hell” 
5.1 Introduction 
 In Chapter 4, simulations of platelet deposition in disturbed flow revealed that the 
continuum mass transfer model currently employed is inadequate for simulating platelet 
transport, both in the presence and absence of RBCs. It was postulated that this deficiency is due 
to the particulate behavior of these blood elements. In this chapter, we attempt to simulate this 
behavior using a two-phase fluid model. Because multiphase flow modeling is far from a mature 
subject and because existing models are extremely complex, no attempt was made to create a 
model specifically tailored to emulate the properties of blood. Such an endeavor would in itself 
be enough for one or more additional dissertations. Instead, as a “proof of concept” study, we 
employ an existing fluid-solid suspension model used for gas-particle flows in an attempt to 
predict RBC and platelet concentration profiles in fully-developed tube flow. While such a 
model is not ideally suited for blood simulations, it is hoped that the preliminary results 
presented herein will stimulate the development of better blood flow models which more 
accurately take into account the nature of this unique suspension. 
5.2 Multiphase Model 
5.2.1 Background 
 Since we are interested in modeling RBCs and platelets as particles, single-phase blood 
models do not apply and recourse must be made to multiphase flow models which treat the fluid 
and dispersed phases separately. Such models can be broadly classified into Lagrangian models, 
which treat the dispersed phase as discrete particles, tracking each individually, and Eulerian 
models, which treat the dispersed phase as an effective continuum that co-exists with the fluid 
phase. While the former allow more accurate simulation of fluid-particle interaction forces, the 
large number of RBCs and platelets in blood makes individual particle tracking a computational 
impossibility at present. Thus, we chose to work with so-called “two-fluid” or mixture theory 
models, which treat the fluid and particle phases as interpenetrating continua. We found only one 
previous model in the literature that employed multiphase flow theory for describing blood flow, 
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the work presented by Hofer and Perktold (153). These investigators employed the model 
developed by Phillips et al. (154) for shear-induced particle migration in fluid-solid flows. This 
model treats the suspension as a single continuum with a density and viscosity which depend on 
the local particle volume fraction. The particle volume fraction is found by solving a transport 
equation which contains terms to simulate particle migration due to spatially varying particle 
collision frequencies and suspension viscosity (154). This results in flux terms proportional to 
the local shear rate and particle volume fraction gradients. In both the original work (154) and 
the simulations of Hofer and Perktold (153), the particle transport equation is restricted so 
migration will only be directed down the shear rate gradient. 
 Hofer and Perktold (153) applied the model of Phillips et al. to the problems of fully-
developed flow in a cylindrical tube and flow through a stenotic tube using physical parameters 
(fluid density and viscosity and particle volume fraction) appropriate for blood. No comparison 
to experiments was made. However, the simulations demonstrated that particles would migrate to 
the low-shear core of the flow, consistent with the model’s intent to drive particles down the 
shear gradient. Additionally, the suspension velocity profile was shown to be blunter than a 
Newtonian parabolic profile, consistent with experimental observations for blood (128). 
However, because of the assumption that no collisions take place in regions of zero shear rate 
and because the viscosity of the suspension becomes infinite when the particle volume fraction 
reaches its maximum value of 0.68, the model always predicts that the volume fraction reaches 
its maximum wherever the shear rate is zero. In tube flow, this results in an artificially sharp 
concentration profile with a cusp at the centerline, r = 0. Such behavior is not consistent with that 
of blood (153). Furthermore, the model was developed for dense suspensions, and would 
therefore be inappropriate for simulating an RBC-free dilute suspension of platelets, like those 
used in the experiments of Karino and Goldsmith (59) which were studied in Chapter 4.  
 In an attempt to simulate both dilute and dense suspensions corresponding to platelets 
and RBCs, respectively, in plasma, we chose to use the approach of Masson (155, 156), who 
employed the gas-solid suspension model of Lun (157) in a finite-volume-based numerical 
method. Lun’s model (157) uses the kinetic theory of gases to derive solid-phase equations 
governing the elastic or slightly inelastic collisions between spherical particles in a granular 
flow. The effect of the interstitial fluid on the solid particles is also modeled. Separate fluid- and 
solid-phase momentum and continuity equations are derived, along with an equation governing 
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transport of the solid-phase fluctuating kinetic energy, also known as the granular temperature. 
Due to the employment of the kinetic theory, the resulting equations contain expressions for the 
solid-phase pressure, stress tensor, and viscosity, which eliminates the need to estimate or fit 
undetermined coefficients in the constitutive relations. 
 An important consideration in modeling two-phase flow is the inclusion of the interaction 
forces governing momentum exchange between the phases. As reviewed by Johnson et al. (158), 
important interactions may include drag, lift, buoyancy, Magnus forces due to particle spin, and 
Basset history and virtual mass forces due to relative acceleration of the particle with respect to 
the fluid. Lun’s model (157) and Masson’s implementation of it (156) consider a granular flow in 
which the solid-phase density is much greater than the fluid-phase density, as would be the case 
in gas-solid two-phase flows. This restriction results in the omission of all interphase interaction 
forces except for the drag and virtual mass forces. Both are considered by Lun, while Masson 
neglects virtual mass.   
 There are several attractive features of this model. First, it is valid for a wide range of 
particle volume fractions, making it useful for both RBC (dense suspension) and platelet-only 
(dilute suspension) simulations. Second, it contains no “free” parameters to be fit or estimated, 
reducing the computational effort required. Finally, Masson’s finite-volume implementation is 
very similar to the one used to develop our mass transfer and CFD codes, which considerably 
eased coding and debugging of this very complex algorithm.  
 However, this is far from an optimal model for blood. Since the particles are treated as 
rigid spheres, rotational effects due to the discoid shapes of RBCs and platelets are neglected, as 
are hydrodynamic effects due to deformation of RBCs, a mechanism which may be important in 
explaining their migration to the center in fully-developed tube flow (159, 160). Additionally, 
since the densities of platelets and RBCs are approximately equal to that of plasma, the high-
density-ratio assumption that allows most interaction forces to be neglected is not valid. Since no 
model could be found which incorporated all these desirable properties, Masson’s was used in a 
preliminary attempt to see whether it could reasonably model blood flow. 
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5.2.2 Model Equations 
 What follows is a brief overview of the equations used in the multiphase model. For a 
complete derivation and thorough explanations of all terms, the reader is referred to Masson’s 
dissertation (156). Using Masson’s notation, Equation 25 is a general conservation equation in 
cylindrical coordinates: 
( ) ( ) ( ) φφφφρψφρψρφψ Srrrrzzurruzt eeiriizii + ∂∂Γ∂∂+ ∂∂Γ∂∂=∂∂+∂∂+∂∂ 1 , [25] 
where superscript i = f for fluid or s for solid phase: φ represents a generic species; ρ is density 
of the current phase; ur and uz are the radial and axial velocity components; respectively; ψ is the 
volume fraction of the respective phase; Γe is the effective diffusion coefficient for the phase 
under consideration, and Sφ is a species-specific source term.  
 Table 10 lists the specific form of each variable in Equation 25 as used in Masson’s 
model (155). In both Masson’s formulation and ours, the fluid-phase continuity equation is used 
to solve for the fluid-phase pressure, and the solid-phase continuity equation is used to obtain the 
solid volume fraction.  
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Table 10. Specific variables for Equation 25 
After Masson and Baliga (155). 
 
Conservation equation ρ Γe Γb φ Sφ 
Fluid      
z-momentum ρf µfe µfb ufz z
pSSS
f
ff
zDzz ∂
∂−+−Γ ψ  
r-momentum ρf µfe µfb ufr cyl
f
ff
rDrr Sr
pSSS +∂
∂−+−Γ ψ  
continuity ρf 0 0 1 0 
Solid      
z-momentum ρs µse µsb usz z
p
z
pSSS
sf
ss
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∂−∂
∂−++Γ ψ  
r-momentum ρs µse µsb usr cyl
sf
ss
rDrr Sr
p
r
pSSS +∂
∂−∂
∂−++Γ ψ  
continuity ρs 0 0 1 0 
granular temperature 1.5·ρs κsT 0 T BDcsTp SSW γγγψ +−−Φ+++  
 
 
In Table 10, Γb is the bulk diffusion coefficient of the current phase; µie and µib are effective and 
bulk viscosities, respectively, of that phase, and pi is the phase’s pressure. Sfz, Sfr, Ssz, and Ssr 
would be additional problem-specific body forces, such as gravity, while ST would be an external 
granular temperature source. The remaining source terms have the following forms: 
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Equations 26-27 represent diffusion source terms which arise from the non-constant viscosity 
and volume fraction of each phase. The term Scyl in Equation 28 arises due to the use of 
cylindrical coordinates. Equations 29-30 are the drag forces in the z- and r-directions, 
respectively. Equation 31 models the rate of particle kinetic energy diffusion due to gradients in 
particle volume fraction, while Equation 32 represents the work done by the solid-phase 
pressure. Finally, Equations 33-36 are kinetic energy production and dissipation terms: γC is 
dissipation due to particle collisions; γD is dissipation due to drag; γB represents the exchange of 
energy between the mean and fluctuating parts of the flow, and Φs models viscous dissipation. 
 To close the equations, the following constitutive relations are needed: 
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Equation 37 shows that the fluid-phase effective viscosity µfe depends on the solids volume 
fraction multiplied by the intrinsic (pure fluid) viscosity µf and on a Reynolds-stress-like term 
which is approximated by Equation 39. The coefficient Cs is a grid-dependent parameter between 
0.1 for a coarse grid and 0.2 for a fine grid, and LG is a measure of grid element length (in cm), 
taken as the cube root of the average element volume for the grid. Equation 40 is the coefficient 
for the drag forces (Equations 29-30). The remaining constitutive equations for the solid phase 
are based on Lun’s (157) derivation using kinetic theory. In these equations, ψsMX  is the 
maximum volume fraction of solids, g0 is the equilibrium radial distribution function, dp is the 
particle diameter, e is the coefficient of restitution for particle-particle collisions; and Res is the 
particle Reynolds number. The interested reader can consult the original works (156, 157) for 
more detail. 
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5.3 Methods 
 A finite-volume implementation of the model described by Equations 25-48 was coded 
within the framework of the existing CFD/mass transfer solver using the detailed information 
available in Masson’s dissertation (156). The solution algorithm is identical to that employed 
previously for solving the equations of fluid motion and species conservation. The seven 
equations given by Equation 25 and Table 10, along with a pressure correction equation, 
comprise the system to be solved. It is thus akin to two coupled systems of Navier-Stokes and 
continuity equations. Pseudo-time-stepping (136) was found to be the optimal method for 
relaxing this highly nonlinear and strongly coupled system. In contrast to Masson, who used a 
single time step for all the equations, we usually obtained better convergence using different time 
steps for different equations.  
5.3.1 Code Validation 
 Because of the complexity of the multiphase model, it was necessary to validate the code 
before attempting to extend it to blood-flow simulations. For this purpose, a set of benchmark 
cases simulated by Masson were used. Because the results are germane to the subsequent blood 
flow simulations, they are presented here, rather than in an appendix. 
 Masson and Baliga (155) chose fully-developed gas-solid flow in a 3.0 cm diameter 
vertical pipe as one of the test cases for their code. Although this problem is really one-
dimensional, with only radial variations in the dependent variables, they simulated it in a two-
dimensional framework. They validated their results against the earlier numerical work of 
Sinclair and Jackson (161), who solved the one-dimensional problem. 
 The model of Sinclair and Jackson is similar to that employed by Masson in that both are 
based on kinetic theory and have the granular temperature as a variable. However, the following 
parameters are specific to the Sinclair and Jackson model and therefore need to be altered from 
the forms previously specified in Equations 25-48: 
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In Equation 50, vt is the terminal velocity of a particle falling in air under the influence of 
gravity, and g is the gravitational constant. Additionally, Sinclair and Jackson neglect the 
Reynolds-like stresses in the effective fluid viscosity (Equation 37). They also ignore the 
influence of fluid drag when deriving the solid-phase constitutive equations. This means that SR 
in Equation 37 and the ζD term in Equations 34, 46, and 47 should be set to zero.  
 Table 11 lists specific parameter and source term values for these cases. The physical 
properties correspond to those of mineral particles suspended in air at 427 ºC. The non-zero 
momentum source terms are the gravitational body forces on the fluid and solid phases. 
 
Table 11. Specific parameter values for multiphase validation cases 
 
Parameter or Source Term Value or Form 
µf 3.65 × 10-4 g cm-1 s-1 
ρf 4.40 × 10-4 g cm-3 
ρs 2.50 g cm-3 
ψsMX 0.65 
vt 1.29 × 102 cm s-1 
g 9.80 × 102 cm s-2 
dp 1.50 × 10-2 cm 
Sfz -ψf· ρf·g 
Ssz -ψs· ρs·g 
Sfr, Ssr, ST 0 
 
 
 Because the fully-developed solution should be independent of axial distance z, this 
problem was solved using periodic boundary conditions at the inlet and outlet. For these 
boundary conditions, we used the single-phase formulation of Murthy and Mathur (162), adapted 
for multiphase flow. In the single-phase formulation, either the constant (non-periodic) part of 
the pressure gradient or the mass flow rate can be specified. In their work, Masson and Baliga 
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claim to implement periodic BCs for two-phase flow by specifying the fluid-phase pressure drop 
and the solid-phase mass flow rate (155). However, the numerical results of Sinclair and Jackson 
(161) clearly demonstrate that, for a given fluid pressure drop and solids mass flow rate, multiple 
solutions corresponding to different fluid-phase mass flow rates exist. Therefore, in order to 
obtain a unique solution, we specified both the fluid- and solid-phase mass flow rates in our 
periodic BC implementation. Additionally, since ps is constant in fully-developed flow (161), 
Equation 41 and the specified solids mass flow rate can be used to derive an algebraic equation 
for ψs, eliminating the solid-phase continuity equation.  
 For the other boundary conditions, zero normal fluxes at r = 0 were specified for all 
dependent variables except normal velocities, which were set to ufr = usr = 0 at both this location 
and the wall (r = 1.5 cm). Zero normal flux BCs were also specified at the wall for pf and ψs. For 
ufz, usz, and T, specified-flux wall BCs corresponding to those proposed by Sinclair and Jackson 
(161) were used. For the solid phase, this corresponds to the following specified shear stress: 
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where all dependent variables are evaluated at the wall, and φ’ is a “specularity factor” governing 
collisional momentum transfer that depends on the smoothness of the wall: φ’ = 0 for a smooth 
wall, φ’ = 1 for a rough wall. The value used for these simulations corresponds to that chosen by 
Masson and Baliga and Sinclair and Jackson, φ’ = 0.5. The specified fluid-phase shear stress is: 
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where again everything is evaluated at the wall, and LCV is an estimate of local element length, 
taken as (element volume)1/3. Finally, the expression for the granular temperature wall flux is: 
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where the first term represents energy dissipation by particle-wall collisions, with ew the 
coefficient of restitution for such events, and the second term is energy generation due to solid-
phase slip. Further information on the derivations of these BCs is given in Sinclair and Jackson 
(161). 
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 For these simulations, a regular grid consisting of three nodes in the z-direction and 11 in 
the r-direction was used. This was identical to the mesh used by Masson and Baliga. A very 
sparse axial grid can be used because there are no entrance length effects with periodic boundary 
conditions, i.e., the steady-state solution should be independent of z. Two different convection 
schemes were tested. The first was the MAW scheme, which was the one used by Masson and 
Baliga (155). This scheme was used in preliminary tests to aid in debugging the code. The 
second was the PSI fluctuation-splitting scheme (135) that we prefer over the MAW scheme due 
to its lower numerical diffusion. This scheme was used in the blood-flow simulations discussed 
below.  
 To validate their code, Masson and Baliga (155) compared their predictions of fluid-
phase flow rate and average solids volume fraction to those of Sinclair and Jackson (161). 
However, as discussed above, they claim to have specified the fluid-phase pressure drop, which 
does not seem possible given the results of Sinclair and Jackson. Since obtaining a unique 
solution required the specification of fluid-phase flow rate, we chose instead to compare 
predicted pressure drops to the specified value used by Masson and Baliga. We report our results 
in the same dimensionless variables used in both previous works (155, 161). These are the 
dimensionless volume flow rates, where i = s for solid or f for fluid phase: 
∫=
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and the dimensionless fluid-phase pressure drop: 
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We simulated five of the combinations of fluid- and solid-phase flow rates used in Masson and 
Baliga’s work. All cases had the same dimensionless fluid-phase pressure drop, -0.2.  
5.3.2 Blood Flow Simulations 
 After validating the multiphase flow code, we attempted to extend it to blood flow. Due 
to the limited time available, detailed parameter variation studies were not attempted. Rather, the 
basic model was applied “as-is” to two of the cases of fully-developed flow studied 
experimentally by Aarts et al. (53): suspensions of platelets with RBC ghosts at 20% hematocrit 
and platelets in an RBC-free buffer medium, both of which flowed at a wall shear rate of 240 s-1 
through 3.0 mm diameter tubes. In the first case, flow of the RBC ghosts was simulated by 
 139 
treating them as rigid spherical particles with an effective diameter of 5.5 µm and an average 
volume fraction of 0.2. In the second, the platelets were treated as 1.5 µm diameter spheres, with 
an estimated platelet concentration of 3 × 105 PLT µl-1, corresponding to an average volume 
fraction of 0.00424. Both platelets and RBCs were treated as neutrally buoyant, with a density of 
1.05 g cm-3, equal to that of the suspending fluid, and the fluid-phase viscosity was set to the 
plasma value of 0.012 g cm-1 s-1.  
 Both the model of Lun (157), which was the original one incorporated into Masson’s 
code (156), and the Sinclair & Jackson model (161) used in the validation cases were applied to 
this problem. The only parameter alteration made was to the particle-particle coefficient of 
restitution, e, which exerts its influence via the parameter η (Equation 48). For both models, the 
same periodic formulation used for the validation cases, with fluid- and solid-phase mass flow 
rates specified, was employed. Flow rates of the two phases were estimated based on the total 
flow rates of the suspensions and the average solids volume fraction. All boundary conditions 
were identical to those used for the validation cases, including the specified wall fluxes given by 
Equations 52-54, with the specularity factor φ’ and particle-wall restitution coefficient ew left 
unaltered at 0.5 and 0.9, respectively. For the Sinclair and Jackson model, the expression for the 
drag force given by Equation 50, which is based on gravitational sedimentation, was replaced by 
the following expression selected from the review of Johnson et al. (158), which was derived for 
suspensions of multiple particles: 
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Additionally, the effect of adding a lift force to the Sinclair and Jackson model was investigated. 
The expression used for the force of the solid phase on the fluid was the one given by Johnson et 
al. for the Saffman “slip-shear” lift: 
( ) ( )fsf2L uuDDF f −= − 4/1tr 2)46.6(3 p
sff
dπ
ψµρ , [58] 
where “tr” denotes the trace of a matrix and Df is the fluid-phase deformation rate tensor: 
( )( )Tgradgrad
2
1 ff
f uuD += . [59] 
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The forces represented by Equation 58 are added to the fluid-phase momentum equations; the 
negative of this term is added to the solid-phase momentum equations. This force was not 
incorporated into the Lun model because to do so correctly required incorporating the new 
interaction terms into the constitutive equations, which would have necessitated extremely 
complicated mathematical manipulations using the kinetic theory. Such work was deemed 
beyond the scope of this dissertation. All simulations were conducted on a grid containing three 
nodes in the z-direction (due to the periodic formulation), and 110 nodes in the r-direction. No 
grid dependence studies were conducted. 
5.4 Results 
5.4.1 Code Validation 
 Table 12 compares our model’s predictions of non-dimensional fluid-phase pressure drop 
dpf*/dz* and average solid-phase volume fraction to the numerical results of Sinclair and Jackson 
(161) for the five test cases. The average value of ψs for case 5 was not reported by Sinclair and 
Jackson. The percentage errors reported are relative to Sinclair and Jackson’s values. Identical 
results were obtained with either the MAW or PSI convection schemes. Additionally, our results 
were identical to those of Masson and Baliga to the number of significant figures shown, which 
is the degree of precision used by those authors. Our predictions also agree very closely with 
those of Sinclair and Jackson, with no error in the predicted pressure drop and a maximum error 
of 5.6% in the predicted average solids volume fraction. Since these results also matched those 
of Masson and Baliga (155), we took them as evidence that the code was functioning properly. 
 
Table 12. Results of multiphase model validation cases 
 
    Current Model Sinclair & Jackson % error 
Case e Qs* Qf* dpf*/dz* Avg. ψs dpf*/dz* Avg. ψs dpf*/dz* Avg. ψs 
1 1.00 0.34 4.4 -0.2 0.19 -0.2 0.18 0.00 5.56 
2 1.00 0.04 1.7 -0.2 0.25 -0.2 0.25 0.00 0.00 
3 1.00 -0.34 -0.022 -0.2 0.26 -0.2 0.25 0.00 4.00 
4 1.00 -0.62 -0.61 -0.2 0.46 -0.2 0.46 0.00 0.00 
5 0.99 -2.10 -2.83 -0.2 0.36 -0.2 -- 0.00 -- 
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 Since fully-developed pipe flow is very similar to blood flow in a tube, it is of interest to 
observe the behavior of the model for some of these test cases. Figure 54 shows axial velocity 
and solids volume fraction profiles for Case 4, which is typical of the four cases for which e = 
1.0. The velocity profiles are slightly blunted relative to a Newtonian parabolic profile, and due 
to the specified-shear-stress boundary conditions (Equations 52 and 53), both phases exhibit slip 
at the wall. The solids volume fraction is skewed to the wall, equal to approximately 0.4 near the 
core of the flow and rising to a maximum value of around 0.6 at the wall. Figure 55 shows the 
same profiles for Case 5, for which e = 0.99, corresponding to inelastic particle-particle 
collisions. Slightly more blunting of the velocity profile is observed, with both phases again 
slipping slightly at the wall. However, the solids volume fraction profile is nearly the reverse of 
Figure 54B, with values reaching very near the maximum packing fraction of 0.65 at the tube 
centerline, followed by a drop off and then a very slight secondary peak near the wall. The 
curves shown in these figures are essentially identical (when non-dimensionalized) in trend and 
magnitude to the plots shown by Masson (156) and Sinclair and Jackson (161) for these cases. 
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Figure 54. Results: multiphase validation Case 4 
(A) Axial velocities. (B) Solids volume fraction. 
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Figure 55. Results: multiphase validation Case 5 
(A) Axial velocities. (B) Solids volume fraction. 
 
5.4.2 Blood Flow Simulations 
 Due to the very long code-debugging process required (approximately one year), 
relatively little time was available to conduct these studies. Additionally, for most of the 
attempted simulations, it was very difficult to achieve convergence. Pseudo-time stepping 
relaxation parameters of the order 10-5 to 10-6 had to be employed, compared with typical values 
of order 1 for mass-transfer simulations. Because of this, several hundred thousand to a few 
million iterations were often required to reduce the residuals by as little as four to five orders of 
magnitude. Also, sometimes the residuals would stall and not converge further than a three- to 
four-order-of-magnitude reduction. Thus, no uniform convergence tolerance was employed, and 
many of the cases may not have achieved iteration independence. For these reasons, the results 
presented herein should be taken as very preliminary work, and the comparison to experiments 
as highly qualitative, rather than quantitative. 
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 Based on the results observed for the validation cases, wherein a value of e = 1.0 tended 
to make particles accumulate near the wall (Figure 54) and a value of e = 0.99 tended to make 
them accumulate near the tube axis (Figure 55), a value of e = 0.99 was used for the RBC ghost 
suspension simulations, since the experimental results indicated RBC crowding near the axis. 
Attempts to use lower values of e were unsuccessful because the cases would not converge to a 
fully-developed, periodic steady state, i.e., the volume-fraction concentration profiles were not 
axially invariant. Figure 56 compares the predictions of particle volume fraction (equivalent to 
hematocrit) to the experimentally measured RBC ghost concentration profiles of Aarts et al. 
(53). In the figure, “S&J MODEL” refers to the Sinclair and Jackson model, while “+lift” 
indicates this model with the “slip-shear” lift force (Equation 58) added. The base Sinclair and 
Jackson model best reproduces the shape of the experimental curve, showing depletion of 
particles from the near-wall region and accumulation near the tube axis. Quantitatively, the 
degree of both depletion and accumulation are over-predicted. The effect of the lift force is to 
make the concentration profile essentially flat, except near the wall, where a smaller degree of 
depletion than observed without the lift force is observed. While the Lun model also predicts 
near-constant concentration over approximately 80% of the tube radius, it shows an 
accumulation of particles near the wall, the opposite of the experimentally observed behavior. 
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Figure 56. Comparison of experimental and predicted hematocrit: 20% Hct RBC ghost suspension, 240 s-1 
wall shear rate 
“S&J MODEL” refers to equations of Sinclair & Jackson (161). “+lift” refers to addition of lift force. 
 
 Figure 57 shows predicted velocity profiles for these cases, along with the single-phase 
Newtonian profile for this total flow rate. Solid-phase velocity profiles are shown; on the scale of 
the graph, fluid- and solid-phase profiles are indistinguishable for all three simulations. The Lun 
model yields a velocity profile very similar to the parabolic Newtonian profile; the specified-
shear-stress wall BCs result in very little slip for this case. In contrast, the Sinclair and Jackson 
model predicts a much more blunted velocity profile, especially when the lift force is included. 
Also, very large slip velocities, between 4 and 6 cm s-1, are observed at the wall. Attempts to use 
no-slip wall BCs for comparison were unsuccessful as the code could not be made to converge 
for these cases. 
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Figure 57. Simulated solid-phase and analytical single-phase Newtonian velocity profiles: 20% Hct RBC 
ghost suspension, 240 s-1 wall shear rate 
“S&J MODEL” refers to equations of Sinclair & Jackson (161). “+LIFT” refers to addition of lift force. 
 
 Figure 58 shows the results for simulations of RBC-free platelet suspensions, along with 
the concentration profile measured by Aarts et al. (53) for a wall shear rate of 240 s-1. Because 
the experimentally observed concentration peak occurred roughly midway between the wall and 
tube axis, simulations at both e = 0.99 and e = 1.0 were conducted. Unfortunately, achieving 
converged, periodic results was very difficult for these cases. Thus, the results shown are 
somewhat sporadic: for instance, at e = 1.0 the only case which converged was the Sinclair & 
Jackson model with lift included – neither the base model nor the Lun model would converge. 
As Figure 58A shows, neither restitution coefficient yields a concentration profile similar to the 
experimental one. Both yield a peak at the tube axis, and the model with e = 0.99 predicts a much 
greater excess than observed experimentally. In Figure 58B the results for the Lun model are 
shown; a relatively flat concentration profile with a sudden, very high peak at the tube wall is 
predicted, in very poor agreement with the data of Aarts et al.  
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 Figure 59 shows the velocity profiles for these cases, along with the single-phase 
Newtonian profile for comparison. Again, only solid velocities are shown, since the solid and 
fluid curves are essentially identical. The velocity profile predicted by the Lun model is 
indistinguishable from the Newtonian profile, and the results for the two cases using Sinclair and 
Jackson’s equations are identical. Both models yield velocity profiles with a parabolic shape, 
with the Sinclair and Jackson model displaying a less blunted profile than predicted for the RBC 
ghost cases. Similar to the results for the RBC ghost simulations, essentially no slip at the wall is 
observed for Lun’s model, while the Sinclair and Jackson cases display very large slip velocities.  
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Figure 58. Comparison of experimental and predicted platelet concentration: RBC-free platelet suspension, 
240 s-1 wall shear rate 
(A) Sinclair & Jackson model. “+lift” refers to addition of lift force. (B) Lun model. 
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Figure 59. Simulated solid-phase and analytical single-phase Newtonian velocity profiles: RBC-free platelet 
suspension, 240 s-1 wall shear rate 
“S&J MODEL” refers to equations of Sinclair & Jackson (161). “+LIFT” refers to addition of lift force. 
 
5.5 Discussion and Conclusions 
 In general, these studies were severely hampered by convergence difficulties, yielding 
relatively few simulation results that could be reported. Overall, it appears the model of Sinclair 
and Jackson (161) is better suited to simulating the fully-developed tube flow cases considered in 
this chapter than is the model of Lun (157). The model of Sinclair and Jackson neglects the effect 
of interstitial fluid in deriving the solid-phase constitutive equations, while the Lun model 
incorporates such effects. For this reason, this result is contrary to what one would expect, as the 
presence of a liquid in a particle suspension should have a large effect on the particle-phase 
behavior. 
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 For cases corresponding to flow of 20% Hct RBC ghosts, a particle-particle restitution 
coefficient of 0.99 and a model neglecting the lift force yields a profile qualitatively similar to 
the experimental data. This restitution coefficient corresponds to slightly inelastic particle 
collisions. One would expect collisions between gel-like red cells to be very inelastic, but 
attempts to use lower values of e failed to converge. The velocity profile for this case is also 
blunter than the parabolic Newtonian profile, in agreement with previously reported results for 
blood (128). However, the very large slip velocities computed for this model are not consistent 
with any known behavior of blood. As mentioned previously, cases with no-slip wall BCs failed 
to converge. Since the fluid-phase wall shear stress BC is based on a somewhat ad hoc derivation 
by Sinclair and Jackson for gas-solid flows in vertical pipes (161), it is likely not adequate for 
predicting liquid-particle flow. Investigating more accurate boundary conditions is left for future 
work.  
 For cases corresponding to RBC-free platelet suspensions, neither model agreed 
qualitatively or quantitatively with the experimental data. The models tend to predict 
concentration peaks either at the wall or at the tube axis, while the experimentally observed peak 
lies roughly halfway along the tube radius. It was somewhat surprising that the model failed for 
these cases, as the experimentally observed platelet behavior is similar to that of rigid spherical 
particles, as studied by Segre and Silberberg (148), who also measured concentration peaks at 
around 60% of the distance from tube axis to the wall. As discussed by Johnson et al. (158), this 
behavior has been attributed to inertial effects, which the “slip-shear” lift force attempts to 
mimic. Unfortunately, including this force in the Sinclair and Jackson model did not move the 
predicted concentration peak away from the tube axis. Again, this model predicts very large, 
probably unphysical, slip velocities at the tube wall, while the Lun model predicts essentially 
Newtonian behavior more consistent with a dilute suspension.  
 Clearly, there are several issues that bear investigation which the limited time for these 
studies precluded. First is the choice of the model itself. The model selected is designed for flows 
of rigid, spherical particles suspended in gas; one can therefore question its applicability to flows 
of highly deformable, discoid particles suspended in a viscous liquid. However, no Eulerian 
model which included particle deformation effects was available, and Lagrangian models are 
currently too computationally intensive. Ideally, if an Eulerian model is required, one specific to 
blood, or at least to deformable particles should be developed and experimentally validated. 
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Second is the issue of parameter sensitivity. Due to numerical difficulties, we were unable to test 
the model’s sensitivity to variations in e. The maximum particle volume fraction was also left at 
the value of 0.65 used by Masson; one would expect deformable particles to be capable of tighter 
packing. Also of interest would be the effects of varying the specularity factor φ’ and wall-
particle coefficient of restitution ew in the specified-wall-flux BCs (Equations 52-54), as this will 
influence the magnitude of the slip velocity and the degree of particle accumulation near the 
wall. Besides these parameter studies, the issue of boundary conditions in general needs to be 
addressed, as discussed above. It would also be useful to study the effects of additional 
interaction forces beyond the lift and drag terms included here. Next, there is the issue of 
numerical convergence and computational effort. Several hundred thousand iterations were often 
required to achieve a fairly modest three to four order-of-magnitude residual reduction. These 
case runs typically required two to four days on a relatively lightly loaded processor, for a 
steady-state simulation using only 330 nodes. Simulations on meshes such as those used in 
Chapter 4 (of the order of 80000 nodes) would clearly require extremely long computing times. 
In order to be used for simulations of platelet deposition in the presence of RBCs it would also 
be necessary to somehow model transport of both particulate species and their interactions. And 
if the platelets are allowed to deposit, this would require an unsteady solution of the multiphase 
model, which would very likely be prohibitively time-consuming.  
 In summary, it would appear these very crude preliminary studies raise more questions 
than they answer. The most encouraging result is the rough qualitative agreement between the 
Sinclair and Jackson model and the 20% Hct RBC ghost concentration profiles, which indicates 
that, with suitable parameter adjustment, this model may be capable of simulating RBC behavior 
in tube flow. It is hoped that this preliminary effort and these results will stimulate the 
development of more sophisticated, blood-specific multiphase models, as well as more rigorous 
testing and development of existing models, and that these can be used to eventually develop a 
thrombosis model capable of predicting platelet deposition in realistic medical device 
geometries. 
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6.0 CONCLUSION 
“…I have not failed. I’ve just found 10,000 ways that won’t work.” 
  -Thomas Edison 
6.1 Summary 
 The specific aims of this thesis were to develop and to validate a computational model of 
thrombosis, with the intent of eventually applying it to blood-contacting medical devices. In 
Chapter 1, background on the mechanisms of thrombosis, both arterial and venous, and on the 
state of the art in thrombosis modeling were discussed. Because most cardiovascular devices are 
placed in the arterial circulation, where platelet-mediated thrombi predominate, a model of 
platelet thrombosis, including platelet-surface and platelet-platelet adhesion, platelet activation, 
and agonist generation was developed and its sensitivity to key parameters analyzed in Chapter 
2. This model is based on a single-continuum approximation, with resting and activated platelets 
and their agonists treated as dilute, dissolved species and blood modeled as a Newtonian fluid. 
The effect of thrombus growth on local flow patterns, as well as the embolizing effects of the 
flow on wall-bound aggregates, are neglected. Thus, there is no mechanical mechanism for 
limiting thrombus growth. Chapter 3 presented the results of using this model to simulate platelet 
deposition onto type I collagen from fully-developed parallel-plate Poiseuille flow. Encouraging 
results were obtained for both the “training” cases, in which the model parameters were 
estimated, and the “validation” cases, in which the model was extended to additional shear rates, 
perfusion times, and anticoagulation conditions. In general, good agreement in both the 
magnitude and shape of the predicted deposition curves was obtained. Especially encouraging 
was the model’s ability to predict the different deposition curves measured in the presence of 
partial and complete thrombin inhibition without needing any parameter adjustment. However, 
for the case with the highest wall shear rate (1500 s-1) and sodium citrate as the anticoagulant, the 
shape of the deposition curve could not be reproduced. 
 In Chapter 4, the validation studies were extended to cases of axisymmetric, disturbed 
flow, again over a collagen substrate. First, a tubular expansion case with no agonist effects was 
tested to probe the capabilities of the transport-related portions of the model. For these cases, the 
simulations were unable to accurately predict platelet deposition over the entire length of the 
tube, either in the presence or absence of RBCs. Typically, good agreement could be obtained in 
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the upstream recirculation zone, but not in the downstream, fully developed region, where the 
model predicts diffusion-limited behavior, but the experimental data appear reaction-limited. 
Surprisingly, the model’s predictions in the absence of RBCs were poorer than those in the 
presence of RBCs at 20% Hct. Additionally, one set of parameters that gave an acceptable fit to 
both hematocrit levels could not be found; the platelet-surface reaction rate constants had to be 
treated as lumped parameters governing both RBC-enhanced transport and platelet deposition, 
which is contrary to our original intent. A further complication was the lack of grid independence 
observed for these cases, with deposition levels continually decreasing as the near-wall grid was 
refined. A second set of disturbed-flow test cases, in which non-anticoagulated baboon blood 
was perfused through a stenotic tube, was used to see if the agonist generation portions of the 
model would give it better predictive capabilities than the steady-state one-species model of 
Wootton (104), which had been previously applied to these experimental data. Unfortunately, the 
additional complexity of our model was not an asset, as our predictions were no better than those 
of Wootton. Furthermore, the computing time required for these cases approached greater than 
one month, calling into question the utility of our model’s extra equations and unsteady 
formulation. For both models, platelet deposition was greatly under-predicted downstream of the 
stenosis, again likely due to deficiencies in the modeling of platelet transport. Thus, the key 
conclusion of these investigations was that the single-continuum model is inadequate for 
accurately simulating platelet transport in both the presence and absence of RBCs.  
 This led to the preliminary work presented in Chapter 5, in which attempts were made to 
simulate fully-developed tube flow of an RBC-free platelet suspension and of RBC ghost cells at 
20% Hct using a multiphase flow model. These studies were hampered by the complexity of the 
model equations and associated computational costs, as well as the difficulty of obtaining 
converged solutions. Consequently it was impractical to perform parameter sensitivity studies. 
Although one model showed reasonable qualitative agreement with the experimentally measured 
RBC ghost concentration profile, more work in this area is clearly called for before the utility of 
such a model for blood-related applications can be established. 
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6.2 Contributions of the Thesis 
 The primary contribution of this thesis is the development of a thrombosis model which 
combines platelet transport, activation, and deposition, along with transport and generation of 
platelet-activating agonists. No previous work predicting agonist concentrations and platelet 
deposition in disturbed flow with comparisons to experimental results has been performed. 
Although we did not test our model on a wide range of biomaterials, it has been applied to a 
broader array of experimental deposition results, for both Poiseuille and disturbed flow, than any 
previous model. Furthermore, extensive sensitivity studies were carried out, and the model was 
compared to a simpler one developed by other investigators, providing guidance to those 
interested in developing improved thrombosis models. Our results for disturbed flow also 
emphatically illustrate the failure of the single-continuum mass transfer model, the basis for 
nearly all prior work in this area, to accurately model platelet transport. Finally, we applied 
multiphase flow modeling to blood flow simulations, going beyond previous efforts in this area, 
at least in terms of the complexity of the model applied.  
6.3 Directions for Future Work 
 The results of the simulations in Chapters 4 and 5 clearly demonstrate that the main 
barrier to developing a useful, design-oriented thrombosis model is the lack of an accurate means 
of simulating platelet transport, both in the presence and absence of RBCs. Ideally, a model 
should be developed which is tailored specifically to the unique properties of blood, and this 
model should subsequently be validated against experimental data. Such a model would have to 
be capable of simulating both the dilute suspension behavior of platelets in RBC-free 
suspensions and the RBC-induced near-wall excess platelet concentrations caused by RBC 
migration to the tube axis. Given advances in computing power and the numerical difficulties 
encountered in the Eulerian model we employed, direct Lagrangian simulations of platelets and 
RBCs on a single-cell basis may be the best way to accomplish this, as interaction forces can be 
included easily, and complex derivations of solid-phase constitutive equations are unnecessary.  
 Given an accurate transport model, there are several additional improvements to the 
present thrombus deposition model that should be investigated. Chief among these is the lack of 
interaction between the flow field and the thrombus, i.e. flow disturbances due to thrombus 
growth and platelet embolization due to fluid forces. Incorporating these elements into the model 
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is necessary if one desires to predict thrombus stability. This is important from a design 
perspective because platelet deposition in and of itself may not be a deleterious event, as long as 
the thrombus which develops eventually stabilizes without occluding critical flow paths and 
passivates the device surface. Again, such simulations are better suited to a discrete-cell platelet 
model, since thrombus morphology would not have to be estimated, and embolization of single 
platelets or aggregates could be simulated much more easily than in an Eulerian framework.  
 An additional mechanical event that deserves consideration in future models is shear-
induced platelet activation, as this event is relevant to cardiovascular devices such as 
replacement heart valves and rotary blood pumps. Since the level of activation appears to depend 
on stress level and exposure time, a Lagrangian approach is likely required, again emphasizing 
the value of a discrete-cell model. However, before such work can begin, the correlation between 
shear magnitude, exposure time, and level of activation needs to be rigorously experimentally 
quantified.  
 Given the sensitivity of the model to agonist generation, investigations of more 
sophisticated agonist generation and platelet activation source terms should also be performed. 
Since much more sophisticated coagulation cascade models have already been developed, the 
accuracy of the thrombin generation functions could be improved by utilizing these, with the 
downside of a large increase in computational complexity. Experimental validation of the 
model’s prediction of agonist concentrations would also greatly aid in improving the agonist 
generation and synergism models.  
 In addition to refining the agonist generation functions, it would be desirable to improve 
the entire model by performing a rigorous sensitivity and uncertainty study on most, if not all, of 
its parameters, as discussed in Chapter 4. This might allow the model to be simplified by 
eliminating some unnecessary parameters. Coupling such a sensitivity analysis with an 
optimization-based parameter estimation algorithm would automate the parameter fitting process 
and eliminate the haphazard trial-and-error algorithm used for the cases presented herein. It may 
also be helpful to investigate dimensionless relationships between the parameters, as this might 
allow correlations to be developed that would further simplify the process of re-fitting the model 
when new cases are attempted. 
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 Finally, only a single biomaterial, the highly thrombogenic type I collagen, has been 
studied in this dissertation. Once the aforementioned modeling issues are addressed, simulations 
of surfaces more relevant to medical devices should be performed. Since the kinetics of platelet-
surface interaction for these surfaces will be different from those for collagen, these studies may 
reveal additional deficiencies in the model. It would also be desirable to have a way of predicting 
surface reactivity based on surface composition a priori, rather than needing to estimate it based 
on simulations. This would require further experimental work on platelet-surface interactions. 
 To summarize, then, there is much work to be done before computational thrombosis 
models will be mature enough to be used for device design. Hopefully this dissertation has 
contributed to a better understanding of the issues that need to be addressed, and has provided 
information that will aid in the development of such a mature model one day. 
  
APPENDIX 
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CFD Code Validation 
 
 
 
 This appendix gives results of two test cases used to validate the CFD solver. These cases 
were taken from the work of Demirdzic et al. (163), who published benchmark numerical 
solutions for several problems designed for non-orthogonal grids. The test cases we chose are for 
lid-driven cavity flow in a cavity with walls inclined 45º to the horizontal. Figure 60 shows the 
geometry and velocity boundary conditions; each side of the cavity has a length L = 1 cm. The 
dashed lines are the horizontal and vertical centerlines. Density ρ = 1 g cm-3, and viscosity µ = 
0.01 or 0.001 g cm-1 s-1 to give Reynolds numbers based on side length and lid velocity of 100 or 
1000, respectively. Zero normal derivatives of pressure were specified at all walls; additionally, 
p = 0 dynes cm-2 was set in the lower left-hand corner. 
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Figure 60. Geometry and velocity BCs for CFD validation cases 
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 Steady-state solutions were obtained at both Reynolds numbers and compared to the 
benchmark results obtained by Demirdzic et al. (163) on their finest grid, which contained 960 × 
960 (921600) quadrilateral control volumes. We used five levels of grid refinement: 403, 1631, 
6532, 26345, and 50181 nodes. Solutions were considered converged when the normalized RMS 
residuals for the x- and y-momentum equations and for mass loss (obtained from the pressure 
correction equation) were all less than 10-10. For the convection terms in the momentum 
equations, we used the second-order upwind scheme because of its high accuracy. This scheme 
was also used to obtain all the single-phase CFD results shown in the dissertation. It was not 
used for mass transfer or multiphase flow simulations because it can create non-physical 
negative species concentrations and solid-phase volume fractions. For simulations where strict 
positivity was required, the first-order-accurate PSI fluctuation-splitting scheme (135) was used.  
 Figure 61 shows streamlines at Re = 100 and 1000 for the solutions obtained on the 
50181 node grid. At Re = 100, a large vortex fills most of the cavity, similar to lid-driven flow 
with orthogonal walls. However, due to the skewed walls, two smaller, counter-rotating vortices 
develop in the lower left-hand corner. At Re = 1000, the vortex created by the motion of the lid is 
squeezed into the upper right-hand corner, and a second large vortex fills the central region of 
the cavity. Again, two smaller vortices can be seen in the lower left-hand corner.  
 Figure 62 compares our predictions of ux along the vertical centerline to the benchmark 
solution of Demirdzic et al. At Re = 100, our predictions are essentially grid-independent and 
identical to the benchmark solution, even on the very coarse 403 node grid. At Re = 1000, the 
results on the coarsest grid are quite different from the benchmark case, but agreement is 
excellent at all other levels of grid refinement. 
 Figure 63 is a comparison of our CFD solution for uy along the horizontal centerline and 
the benchmark numerical results of Demirdzic et al. The results are basically identical to those 
observed for ux, with good agreement for all grids at Re = 100 and poor agreement only on the 
403 node grid at Re = 1000.  
 For the Re = 1000 case, Demirdzic et al. observed grid independence only once an 80 × 
80 control-volume grid was used (coarser grids employed in that study contained 10 ×10, 20 × 
20 and 40 × 40 control volumes). Thus, our solutions appear to attain grid independence more 
rapidly than the benchmark solutions, since we observed grid-independent behavior at 1631 
nodes, corresponding roughly to Demirdzic’s 40 × 40 quadrilateral grid. However, this may be 
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partially due to the convergence tolerance used, as Demirdzic et al. considered their solutions 
converged once values of the dependent variables stopped changing in the sixth decimal place, 
which they state typically corresponded to a six to eight order-of-magnitude reduction in the 
residuals (163). This tolerance is slightly lower than our 10 order-of-magnitude residual 
reduction tolerance. Nevertheless, given this strong grid independence and the excellent 
agreement of our CFD predictions with the numerical benchmark cases, we assumed the CFD 
code could be considered validated. 
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Figure 61. Streamline plots: CFD validation cases 
(A) Re = 100. (B) Re = 1000. 
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Figure 62. Velocity ux along vertical centerline: CFD validation cases 
(A) Re = 100. (B) Re = 1000. 
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Figure 63. Velocity uy along horizontal centerline: CFD validation cases 
(A) Re = 100. (B) Re = 1000. 
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